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    Chronic kidney disease is a world-wide health problem. In the Netherlands, in 2005, 
approximately 13,000 people had end-stage renal disease of whom 45% were treated with 
chronic renal replacement therapy (either with haemodialysis or peritoneal dialysis) and 55% 
had received a renal transplant [1]. The number of people with end-stage renal disease is 
rising with 4-5% annually [1]. Earlier stages of chronic kidney disease are even more 
prevalent. 
    Patients with end-stage renal disease have a high mortality, mainly due to cardiovascular 
disease, which is 10 to 30 times higher compared to the general population [2]. More recently, 
it has been shown that earlier stages of chronic kidney disease are also associated with an 
increased total and cardiovascular mortality [3–5]. The causes of cardiovascular disease are 
diverse in chronic kidney disease, including many well known (traditional) cardiovascular 
risk factors like older age, male sex, hypertension, higher low-density lipoprotein cholesterol 
and lower high-density lipoprotein cholesterol plasma levels, diabetes mellitus, smoking, 
physical inactivity, family history of cardiovascular disease and left ventricular hypertrophy 
[6]. Most of these traditional risk factors have a high prevalence in chronic kidney disease [7]. 
However, risk equations based on people without chronic kidney disease have been shown to 
underestimate the actual cardiovascular risk in patients with chronic kidney disease [8–10]. 
Therefore, it is conceivable that other, non-traditional cardiovascular risk factors, like 
hyperhomocysteinaemia, endothelial dysfunction, low-grade inflammation and higher blood 
levels of advanced glycation end-products, are involved in the pathogenesis of cardiovascular 
disease in chronic kidney disease. In this thesis, studies are presented which aimed to 
elucidate the relationship between renal function and these non-traditional cardiovascular risk 
factors. 
    Homocysteine is an amino acid which may lead to cardiovascular disease through various 
proposed mechanisms, which include increasing oxidative stress, smooth muscle cell 
proliferation, coagulation and platelet activation, and decreasing endothelial function, 
gluthathione peroxidase activity and the vasodilator response to nitric oxide. 
Homocysteinaemia is a continuous independent risk factor for ischaemic heart disease and 
stroke in the general population [11]. Many determinants of the plasma homocysteine 
concentration have been identified. Nutritional deficiency of B-vitamins (e.g. folic acid, 
pyridoxine, cobalamin), genetic polymorphisms (e.g. C677T transition of 5,10-
methylenetetrahydrofolate reductase, 844ins68 variant of cystathionine β-synthase, A2756G 
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transition of methionine synthase), drugs (e.g. anticonvulsants, methotrexate, penicillamine), 
certain diseases (e.g. hypothyroidism), older age and male sex have been associated with 
hyperhomocysteinaemia, while malnutrition and hyperthyroidism have been associated with a 
lower plasma homocysteine concentration [12]. Plasma homocysteine concentration is also 
and strongly related to glomerular filtration rate [13]. Hyperhomocysteinaemia occurs in 85 to 
100% of patients with end-stage renal disease [14–16]. The cause of hyperhomocysteinaemia 
in chronic kidney disease, especially the role of the kidney, is not completely understood. In 
Chapter 2,  homocysteine  metabolism  (Figure)  in  chronic  kidney  disease  is  discussed. In 
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Figure. An overview of homocysteine metabolism. A concise overview of homocysteine metabolism, with open arrows 
indicating metabolic fluxes, ovals indicating enzymes and italics indicating vitamins. Homocysteine is the transmethylation 
(TM) product of the essential sulphur-containing amino acid methionine, with S-adenosylmethionine (AdoMet) and S-
adenosylhomocysteine (AdoHcy) as intermediates. Homocysteine can be either remethylated to methionine or degraded by 
transsulphuration (TS). In the folate-dependent remethylation reaction, which is catalyzed by methionine synthase (MS) and 
uses cobalamin as a cofactor, 5-methyltetrahydrofolate (5-MTHF) donates a methyl group to homocysteine. Subsequently, 
tetrahydrofolate (THF) receives a methylene group from the serine/glycine couple, a reaction that uses pyridoxine as a co-
factor. Tetrahydrofolate can also be generated by reduction of supplemented synthetic folic acid to dihydrofolate (DHF) and 
subsequently to THF. Next, 5,10-methylenetetrahydrofolate (5,10-MeTHF) is reduced to 5-MTHF, requiring the enzyme 
methylenetetrahydrofolate reductase (MTHFR). Another folate-independent remethylation reaction, which is quantitatively 
unimportant in humans in physiological conditions [17], uses betaine as a methyl group donor, generating dimethylglycine 
(DMG). In the irreversible, catabolic (transsulphuration) pathway, the rate-limiting reaction is catalyzed by cystathionine β-
synthase (CBS) and requires the active form of pyridoxine as a cofactor. 
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Chapter 3, whole body homocysteine metabolism is studied in end-stage renal disease 
patients, using a stable isotope labelled methionine tracer infusion technique, to test the 
hypothesis that one-carbon fluxes (methionine transmethylation, homocysteine remethylation 
and homocysteine transsulphuration) and metabolic homocysteine clearance are decreased in 
end-stage renal disease patients compared to healthy individuals. In addition, we explored the 
relationship of one-carbon flux rates with blood levels of the homocysteine precursors S-
adenosylmethionine and S-adenosylhomocysteine. In Chapter 4 and Chapter 5, the effect of 
folic acid treatment on homocysteine metabolism is described in end-stage renal disease and 
healthy individuals, respectively, to investigate whether one-carbon flux rates and metabolic 
homocysteine clearance and blood levels of homocysteine can be increased. In healthy 
individuals the effect of folic acid on S-adenosylmethionine and S-adenosylhomocysteine was 
also studied. 
    In atherogenesis, endothelial dysfunction and (low-grade) inflammation are important and 
interrelated early steps [18]. There is evidence that a decreased renal function is associated 
with endothelial dysfunction and inflammatory activity [19,20]. In Chapter 6, the relation 
between impaired renal function and plasma concentrations of biochemical markers of 
endothelial dysfunction and/or of inflammatory activity is described in a cross-sectional study 
of non-diabetic patients with a wide range in renal function.  
    Evidence accumulates that atherosclerosis may be an inflammatory disease, in which 
immune mechanisms interact with metabolic risk factors [21]. A high blood concentration of 
advanced glycation end-products, a heterogeneous group of compounds derived from the non-
enzymatic reaction between glucose or other reducing sugars and proteins, has been suggested 
to be one of these metabolic factors [22,23]. Advanced glycation end-products may be 
involved in atherogenesis by acting with specific receptors for advanced glycation end-
products [24] and accumulation in the vascular matrix [22]. There are limited data indicating 
that plasma levels of advanced glycation end-products are increased in chronic kidney 
disease, especially in end-stage renal disease [25,26]. In Chapter 7, the relations between on 
the one hand the plasma level of advanced glycation end-product-peptides (incomplete 
metabolites of advanced glycation end-products) and on the other hand renal function and 
biochemical markers of endothelial dysfunction and inflammatory activity are investigated in 
the same population as in Chapter 6. 
    Several biochemical markers of endothelial dysfunction and inflammatory activity have 
been shown to be independent risk factors for cardiovascular morbidity and mortality in 
patients without chronic kidney disease [27–31]. It is unknown, whether the elevated 
Introduction 
 5
cardiovascular risk in chronic kidney disease is (partially) attributable to endothelial 
dysfunction and inflammation. In Chapter 8, we investigated whether endothelial dysfunction 
and inflammatory activity are related to mildly impaired renal function in a population-based 
study. Furthermore, in a prospective follow-up of the same population, it was investigated 
whether endothelial dysfunction and inflammatory activity contributed to cardiovascular and 
all-cause mortality associated with a lower glomerular filtration rate.  
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    Of the many amino acid abnormalities that are present in chronic renal failure, 
hyperhomocysteinemia has drawn increasing attention because of its proposed role in the 
development and/or progression of atherothrombotic disease. Renal function is a major 
determinant of fasting plasma homocysteine level, and the inverse relationship between the 
glomerular filtration rate and plasma homocysteine level is present throughout the whole 
range of renal function. Although this suggests an active renal homocysteine metabolism, no 
important urinary excretion or active homocysteine extraction has been demonstrated in the 
human kidney. Analysis of plasma concentrations of the various cofactors and substrates of 
homocysteine metabolism, and the effects of different therapies indicate that an abnormal 
folate metabolism may be the cause of hyperhomocysteinemia in uremia. This is further 
supported by the finding that homocysteine remethylation, as assessed by stable isotope 
techniques, is impaired in dialysis patients. It is unclear whether decreased remethylation is 
also responsible for other abnormalities of homocysteine metabolism in renal failure such as 
the exaggerated rise and the impaired decline of plasma homocysteine concentration after 
methionine or homocysteine loading. More studies are necessary to pinpoint the precise 
mechanisms that lead to hyperhomocysteinemia in renal failure. This should lead to optimal 
treatment and, ultimately, to the prevention of cardiovascular complications in this vulnerable 
patient group. 
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    Chronic renal failure has consistently been associated with abnormalities in plasma and 
intracellular amino acid concentrations. Some of these changes are likely to be caused, at least 
partially, by a defective synthesis, degradation or clearance by the kidneys themselves. For 
example, normal kidneys produce serine and arginine [1] and low levels of these amino acids 
are usually found in subjects with renal failure [2]. Additional factors that may influence 
amino acid levels are related to malnutrition, or to the uremic state per se, in which uremic 
toxins could affect enzyme activities, impair membrane transport or alter protein-binding.  
    Methionine is an essential sulfur amino acid derived from food or from the breakdown of 
endogenous protein. The biochemical pathway in which it is converted into homocysteine is 
called transmethylation. In this pathway, methionine first forms S-adenosylmethionine 
(AdoMet), which donates its activated methyl group to a variety of acceptors to form S-
adenosylhomocysteine (AdoHcy). AdoHcy is subsequently hydrolyzed to homocysteine. In 
humans, methionine is the only precursor for homocysteine. Homocysteine can either be 
remethylated to methionine or be transsulfurated to cysteine. In remethylation, homocysteine 
receives a methyl group from 5-methyltetrahydrofolate or from betaine. Cobalamin is a 
necessary cofactor in the folate-dependent remethylation. The two reactions in 
transsulfuration, from homocysteine to cystathionine and from cystathionine to cysteine, 
require pyridoxal phosphate as the cofactor. Cysteine can be incorporated into protein and 
used for the synthesis of compounds such as taurine and glutathione, or be metabolized and 
excreted as sulfate. Key regulators of this metabolism are AdoMet, which activates 
homocysteine transsulfuration and inhibits its remethylation, and AdoHcy, which inhibits 
methionine transmethylation.  
    Renal function is an important determinant of the plasma homocysteine concentration. 
Various methods to estimate glomerular filtration rate (GFR), such as serum creatinine, 
creatinine clearance, plasma iohexol clearance, 51Cr-EDTA clearance or plasma cystatin C, 
have unequivocally shown that declining renal function is associated with higher plasma 
homocysteine levels. This relationship is strongest when methods of assessing GFR that are 
more precise than serum creatinine are used. It has also been shown that the increase in 
plasma homocysteine with age is likely to be caused, at least partly, by the age-related decline 
in renal function [3]. The inverse relationship between plasma homocysteine and GFR seems 
to be independent of the primary renal disease and is present throughout the whole range of 
renal function, extending from normal to end-stage renal failure (ESRD), but remarkably also 
from normal to the hyperfiltering state in diabetic subjects [4]. Patients with end-stage renal 
disease usually exhibit plasma total homocysteine levels that are at least three times the upper 
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normal value, which is 12 to 15 µmo1/L in most laboratories. As in healthy subjects, about 
75% of homocysteine in plasma in uremic patients is protein-bound. The free fraction consists 
of homocysteine-cysteine mixed disulfide, homocystine (that is, the oxidized dimer of 
homocysteine) and, to a minor degree, of reduced homocysteine. The plasma concentration of 
the latter does not seem to be increased in renal failure [5].  
    Hyperhomocysteinemia is not the only abnormal finding in renal patients when plasma 
concentrations of the various substances involved in methionine-homocysteine metabolism 
are considered. In contrast to the hypermethioninemia found in classical homocystinuria, 
caused by cystathionine β-synthase deficiency, methionine levels in renal failure are usually 
reported to be normal, whereas the metabolites of transsulfuration, that is, cystathionine and 
cysteine, are invariably elevated. Plasma concentrations of the intermediates of 
transmethylation, AdoMet and AdoHcy, are increased in hemodialysis patients, but AdoHcy 
more so than AdoMet, which results in a lower AdoMet to AdoHcy ratio compared to that in 
control subjects [6]. A similar pattern is found in erythrocytes: homocysteine and AdoHcy 
concentrations are increased and the AdoMet to AdoHcy ratio is reduced. In dialysis patients, 
the high intracellular AdoHcy levels are probably the result rather than the cause of the 
hyperhomocysteinemia [7]. Serum folate, vitamin B12 and vitamin B6 1evels are usually 
normal in renal patients, whereas serine, an amino acid required in both transsulfuration and 
the folate cycle, is low. Serum levels of betaine and its demethylated product dimethylglycine 
seem to be normal in subjects with renal failure [8].  
    Several observations support the view that high plasma homocysteine levels in general are 
more likely the consequence than the cause of renal dysfunction. First, renal insufficiency is 
not a clinical feature of patients with classical homocystinuria, and these patients have very 
high plasma homocysteine levels of sometimes more than 200 µmol/L [9]. Second, higher 
plasma homocysteine levels are not associated with a more rapid decline of renal function 
[10]. 
    Basically, two options are available to explain hyperhomocysteinemia in chronic renal 
failure. The first is a defective clearance or metabolism by the kidneys themselves, and the 
second is a systemic impairment in whole body homocysteine metabolism. These possibilities 
do not necessarily exclude each other. As urinary homocysteine excretion in humans is only 
minimal, that is, 3 to 10 µmo1/day [11] or 0.3% of creatinine clearance [12], loss of this 
excretion does not explain the hyperhomocysteinemia found in renal failure. In addition, the 
decline in the filtered homocysteine load in renal insufficiency is offset by an increase in 
fractional clearance [13], a common observation with amino acids. The hypothesis that 
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hyperhomocysteinemia in renal failure is caused by the loss of an active homocysteine 
catabolism in tubular cells is attractive in view of the large quantities of homocysteine that the 
tubules can derive from the glomerular ultrafiltrate [about 540 µmol/day, that is, 3 µmol/L 
(free homocysteine concentration) X 180 L/day (normal GFR)] or from the peritubular 
capillaries as well [about 2700 µmol/day, that is, 3 µmol/L x 900 L/day (normal ERPF)]. The 
presence of such renal metabolism can be studied in vivo by the renal arteriovenous 
difference technique. In postabsorptive rats, the total homocysteine concentration in the renal 
vein has been shown to be substantially (~20%) lower compared to that in the aorta [14]. In 
the absence of a sizeable urinary excretion, this indirectly proves that renal homocysteine 
catabolism does exist. The magnitude of the arteriovenous difference suggests uptake and 
conversion of the filtered homocysteine fraction only. In contrast to these findings, we did not 
find a significant renal arteriovenous difference in either free or total plasma homocysteine 
concentration in fasting humans with a normal renal function [1]. This discrepancy between 
the two species might relate to differences in the plasma free homocysteine fraction and the 
homocysteine metabolizing capacity of renal tissue. In rats, 75% of plasma homocysteine is in 
the free form and thus filterable, whereas in humans this fraction is only 25%. Furthermore, 
rat kidneys exhibit higher enzyme activities of cystathionine β-synthase and cystathioninase 
compared to human kidneys [15], which probably explains why homocysteine can readily be 
degraded to cysteine in the rat kidney [16]. Whether homocysteine metabolism occurs in the 
human kidney in non-fasting or uremic conditions remains to be investigated, but so far there 
is no evidence that loss of tubular homocysteine disposal is the cause of 
hyperhomocysteinemia in humans with renal failure.  
    Is hyperhomocysteinemia in renal failure then caused by a defective extrarenal or systemic 
homocysteine metabolism? Contributing factors in this scenario may be deficiencies of 
vitamins and/or substrates, genetic defects, and an altered total body homocysteine turnover. 
The role of vitamins and substrates can be studied by measuring their plasma (or intracellular) 
levels and by investigating the plasma homocysteine response after supplementation. Plasma 
levels of folate, cobalamin and pyridoxine status are generally adequate in renal failure 
patients, but apparently are insufficient to prevent hyperhomocysteinemia. Interestingly, the 
relation between these vitamin levels and plasma homocysteine is maintained in ESRD 
patients, but at a higher homocysteine level compared with subjects with normal renal 
function [17]. Of the three vitamins, folate is the strongest determinant of plasma 
homocysteine level in renal patients. This is also reflected by the results of several treatment 
regimens that have been investigated, which show that only folic-acid-containing therapy is 
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able to lower plasma homocysteine concentration in renal failure patients. Cobalamin is 
effective only when vitamin B12 levels are low, whereas vitamin B6 has no significant effect 
on fasting plasma homocysteine. Serine deficiency would be a plausible candidate to explain 
hyperhomocysteinemia as plasma levels of serine, which is necessary both in transsulfuration 
and in the folate cycle, are low in renal failure. The results of serine supplementation in a 
small study, however, were disappointing [18]. A betaine-dependent remethylation defect also 
seems unlikely because plasma betaine levels are normal in renal failure and treatment with 
betaine alone or added to folic acid is not effective [19].  
    An important genetic determinant of plasma homocysteine level in the general population 
is the C677T mutation in the gene encoding for 5,10-methylenetetrahydrofolate reductase, 
which in its homozygous form is associated with higher homocysteine levels, especially in 
low folate states. In ESRD, the prevalence of the homozygous (TT) state is similar to that in 
the general population, about 10%. ESRD patients with the TT-variant have higher plasma 
homocysteine levels than wild-type or heterozygous patients, but in the latter groups, plasma 
homocysteine is still much higher compared to subjects with normal renal function. Until 
now, no specific genetic defects have been linked to hyperhomocysteinemia in renal disease. 
The third possibility, an altered whole body homocysteine handling, has been studied by oral 
methionine and homocysteine loading and by stable isotope techniques. Oral methionine 
loading, which is thought to stress the transsulfuration pathway, has been performed in 
subjects with chronic renal failure, renal transplant recipients and hemodialysis patients 
[13,20,21]. All studies have shown an exaggerated increase in plasma homocysteine level 
after the methionine load, which suggests a transsulfuration defect. In the hemodialysis 
patients, however, the postmethionine loading plasma homocysteine was significantly related 
to serum folate and not to vitamin B6. In addition, folate therapy lowered both fasting and 
postmethionine-loading plasma homocysteine concentration, implying not only that folate-
dependent remethylation is impaired in renal failure, but also that the remethylation and 
transsulfuration pathways are linked. After oral homocysteine loading, renal failure subjects 
exhibit a three- to fourfold increase in plasma homocysteine half-life compared to healthy 
controls [22]. This decreased plasma clearance did not significantly improve after folic acid 
therapy, although plasma homocysteine level was lower after treatment. Similar observations 
were made in dialysis patients after methionine loading [21]. The nature of this folate-
resistant reduction in plasma homocysteine clearance in renal failure remains to be elucidated, 
but may relate to an impaired cellular uptake or intracellular catabolism of an acute 
homocysteine load. To quantitatively assess whole body transmethylation, remethylation and 
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transsulfuration rates in humans, stable isotope techniques can be applied. We have performed 
primed, continuous infusions of [2H3-methyl-l-13C]methionine in fasting hemodialysis 
patients and healthy control subjects [23]. This tracer methionine has a 2H3-methyl and a 13C-
carboxyl label, which are removed during transmethylation and oxidation (via 
transsulfuration), respectively. From the enrichments of the different isotopomers at steady 
state, the fluxes through the various pathways can be calculated. We found that remethylation 
and transmethylation were proportionally decreased in the dialysis patients, whereas 
transsulfuration was non-significantly decreased [23]. The latter showed an association with 
the vitamin B6 status. The results strongly point to a defective total body homocysteine 
remethylation as the cause of hyperhomocysteinemia in renal failure. The pathogenesis of this 
impairment is not known, but may relate to direct inhibitory effects of uremic toxins or to an 
altered folate metabolism in uremia [24]. The influence of vitamin treatment on remethylation 
(and other) rates is currently under investigation.  
    In conclusion, several lines of evidence suggest that hyperhomocysteinemia in renal failure 
is due to impaired folate-dependent remethylation. At the same time, it should be stressed that 
this view may be too simplistic, as the regulation of the different pathways in methionine- 
homocysteine metabolism is not yet fully understood and probably is much more 
sophisticated and interrelated than presently assumed. Further studies on whole body and 
organ-specific abnormalities in homocysteine and folate metabolism and their regulatory 
factors are necessary to gain further insight in the pathogenesis of hyperhomocysteinemia in 
renal failure. This should lead to an optimal treatment and, hopefully, ultimately to a 
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    Hyperhomocysteinemia is a risk factor for cardiovascular disease and occurs frequently in 
end-stage renal disease (ESRD), but its pathogenesis is poorly understood. We aimed to 
evaluate one-carbon flux rates of methionine and homocysteine (Hcy) in ESRD patients and 
healthy controls. Transmethylation (TM), remethylation (RM) and transsulfuration (TS), as 
well as Hcy clearance by TS (i.e., TS/plasma total Hcy concentration) and by RM (i.e., 
RM/plasma total Hcy concentration) were evaluated in relation to body composition, 
vitamins, and S-adenosylhomocysteine (AdoHcy) and S-adenosylmethionine (AdoMet) 
levels. After a fixed protein diet for three days, primed-continuous infusion of [2H3-methyl-1-
13C]methionine was performed in the postabsorptive state in 12 hemodialysis patients and 16 
healthy volunteers. Hcy clearance by TS (–80% , P < 0.001) and by RM (–77% , P < 0.001) in 
ESRD patients were decreased as compared with healthy controls. The absolute flux rates of 
TM (–27%, P < 0.01) and RM (–28%, P = 0.02) were lower in the ESRD patients. After 
adjustment for age, TS was not significantly reduced. Whole blood AdoHcy was significantly 
elevated in ESRD and was a significant determinant of TM (standardized β = –1.24, P = 
0.01), and RM (standardized β = –1.43, P = 0.03). In conclusion, patients with ESRD have 
impaired Hcy clearance by TS and RM. Elevated whole blood AdoHcy levels are associated 
with impaired RM and TM flux rates in these patients, and AdoHcy may be a key regulatory 
compound in one-carbon flux. 




    Hyperhomocysteinemia is an independent cardiovascular risk factor in patients with end-
stage renal disease (ESRD), with a prevalence reported as high as 85–100% [1]. Treatment 
regimens containing folic acid decrease plasma homocysteine (Hcy) concentration in ESRD 
patients [2–4], but only a small proportion of treated patients attain circulating Hcy levels in 
the normal range. The persistence of hyperhomocysteinemia in ESRD patients with 
supraphysiological folate levels is poorly understood. Elucidation of the regulation of the 
methionine-Hcy metabolism is necessary to understand the pathophysiology of 
hyperhomocysteinemia in patients with chronic renal failure and to develop more effective 
therapies. 
    In the one-carbon cycle (Figure 1), Hcy is the transmethylation (TM) product of the 
essential sulfur-containing amino acid methionine, with S-adenosylmethionine (AdoMet) and 
S-adenosylhomocysteine (AdoHcy) as intermediates. Hcy can be either remethylated to 
methionine or degraded by transsulfuration (TS). There are two remethylation (RM) reactions 
in which Hcy is involved. In one reaction, methionine synthase converts Hcy into methionine 
with 5-methyltetrahydrofolate as methyl donor and reduced vitamin B12 as a cofactor; 5-
methyltetrahydrofolate is generated by a reaction catalyzed by the enzyme 5,10-
methylenetetrahydrofolate reductase. In the other RM reaction, betaine is used as methyl 
donor. In the irreversible catabolic (TS) pathway, the rate-limiting reaction is catalyzed by 
cystathionine β-synthase, requiring the active form of vitamin B6 as a cofactor. 
    Patients with chronic renal failure have a substantially decreased plasma disappearance rate 
of Hcy after Hcy loading [5]. Diminished renal function (i.e., glomerular filtration rate) is 
strongly correlated with elevated plasma Hcy levels over a wide range of glomerular filtration 
capacity [6], suggesting a central role for the kidney in Hcy metabolism. As urinary Hcy 
excretion is negligible [7,8], loss of renal TS capacity has been hypothesized as a cause of 
hyperhomocysteinemia in renal failure [9,10]. However, no net renal extraction of Hcy occurs 
[11], which does not exclude Hcy metabolism in the kidney with a zero balance. 
Alternatively, whole body Hcy metabolism may be impaired in ESRD. In a previous pilot 
study, we have reported that the in vivo flux rates of RM and TM were diminished in patients 
with ESRD compared to healthy controls on the same protein intake, whereas TS was not 
significantly different [12]. The latter finding could have been due to the small number of 
individuals studied. It was argued by Hoffer [13] that the TS rate is not an adequate index of 
the whole  body Hcy  disposal capacity, i.e., the metabolic Hcy clearance by TS. Therefore, in  
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                          TM  
      5,10-MeTHF      vitamin B12    MS                BHMT           Methyl group 
                     RM 
   MTHFr            5-MTHF               Betaine       AdoHcy  
 
        Homocysteine 
        vitamin B6    CBS     TS 
  Cystathionine 
        vitamin B6                                 
  Cysteine            Carbon dioxide 
Figure 1. Pathways of homocysteine metabolism. Schematic overview of homocysteine metabolism, with open arrows 
indicating metabolic rates, ovals indicating enzymes, and italics indicating vitamins. RM, remethylation; TM, 
transmethylation; TS, transsulfuration; MTHFr, 5,10-methylenetetrahydrofolate reductase; MS, methionine synthase; BHMT, 
betaine-homocysteine methyltransferase; CBS, cystathionine β-synthase; AdoMet, S-adenosylmethionine; AdoHcy, S-
adenosylhomocysteine; DMG, dimethylglycine; DHF, dihydrofolate; THF, tetrahydrofolate; 5,10-MeTHF, 5,10-
methylenetetrahydrofolate; 5-MTHF, 5-methyltetrahydrofolate. 
 
addition to TS, we calculated Hcy clearance as TS divided by the plasma total Hcy (tHcy) 
concentration. 
    Impaired regulation of one-carbon cycling, possibly through accumulation of uremic 
toxins, may be an explanation for abnormalities in RM and TM rates in ESRD patients. In 
patients with chronic renal failure, plasma AdoHcy and AdoMet levels are elevated [14], but 
methionine levels are not increased [15]. Whether and how these metabolite changes are 
related to tissue one-carbon fluxes has hitherto not been studied. From single-enzyme 
kinetics, the following interactions can be deduced [16,17]. 1) In TS, increased levels of 
AdoMet and AdoHcy are activators of cystathionine β-synthase. 2) In RM, AdoMet and 
AdoHcy are inhibitors of betaine-Hcy methyltransferase, and AdoHcy inhibits MS, whereas 
AdoMet inhibits 5,10-methylenetetrahydrofolate reductase, and both methyltransferases are 
inhibited by their metabolic product, methionine. 3) In TM, AdoHcy inhibits the activity of 
most methyltransferases. From these data, elevated intracellular levels of AdoMet and 
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AdoHcy are expected to be associated with diminished RM (and TM) flux rates, whereas TS 
flux is expected to be stimulated by methionine ingestion and the subsequent elevations of 
AdoMet and AdoHcy by adenosyltransferase activity. However, little is known about the in 
vivo regulation of one-carbon metabolism by AdoMet and AdoHcy in healthy humans and in 
patients with chronic renal failure.  
    In view of these considerations, the aims of the present study were to test the hypothesis 
that in vivo one-carbon fluxes (TM, RM and TS) and the Hcy clearance by RM and TS are 
decreased in ESRD patients compared to healthy individuals and to explore the relationships 
of these fluxes with plasma Hcy and blood AdoMet and AdoHcy levels. 
 
 
MATERIALS AND METHODS 
 
Subjects 
    For the present study, eight ESRD patients on maintenance hemodialysis treatment and 10 
healthy controls, with an age > 18 years, were included. The patients were on chronic 
standard bicarbonate hemodialysis (thrice weekly for at least six mo) and received a 
multivitamin tablet (once daily) containing 2 mg vitamin B6, 2 mg thiamine, 2 mg riboflavin, 
15 mg nicotinamide, and 70 mg ascorbic acid. Five ESRD patients received a tablet (once 
weekly) containing 1 mg folic acid. The healthy controls did not use any medication or 
vitamin supplements. To enhance the power of the study to measure a clinically relevant 
difference in methionine-Hcy metabolism, data from a previous study in four ESRD patients 
and six healthy controls were combined with those of the present study group. The results of 
these 10 individuals have been published previously [12]. The total study group thus consisted 
of 12 ESRD patients and 16 healthy individuals. The study protocol was approved by the 
ethics committee of the VU University Medical Center, and written informed consent was 
obtained from all individuals. 
  
Experimental protocol  
    The experimental protocol has been described earlier [12]. 
    Fat-free mass. Body weight (BW) was measured on a balance scale (accuracy 50 g), and 
four skinfolds were measured using a caliper (Holtain, accuracy 0.1 mm). Fat-free mass 
(FFM) was calculated from skinfold measurements according to Durnin and Womersley [18]. 
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This method has been shown to be a reliable method of quantifying body composition in 
healthy individuals as well as ESRD patients [19,20]. 
    Stable isotopes. All subjects were kept on a fixed diet containing 1.0 g of protein.kg BW–1. 
day–1 for 3 days before the study. The experiments were conducted after an overnight fast. 
Fasting was continued throughout the infusion period. Only drinking of small amounts of tap 
water was allowed. The hemodialysis patients were studied 1 day before a regular midweek 
dialysis session. All subjects were kept in bed during the study period. A priming bolus of 
NaH13CO3 (99% 13C, ARC Laboratories, Apeldoorn, The Netherlands) was administered, 
followed by a primed constant infusion of L-[2H3-methyl-1-13C]methionine (95% dilabeled; 
99% 1-13C; 99% 2H1, Isotec, Miamisburg, OH), according to the infusion protocol described 
previously [12]. 
    Sample analysis. Plasma total (free plus protein bound) Hcy was measured with the use of a 
microparticle enzyme immunoassay method based on fluorescence polarization (IMX 
analyzer; Abbott, Chicago, IL). AdoMet and AdoHcy were measured using stable-isotope 
dilution tandem mass spectrometry [21]. AdoHcy and AdoMet levels were not determined in 
the 10 individuals described in the previous study [12]. Serum folate and vitamin B12 
concentrations were measured in plasma and whole blood with radioassay (ICN, Costa Mesa, 
CA) and serum vitamin B6 with the use of fluorescence HPLC [22]. The methionine 
concentration in the infusate was measured with the use of an amino acid analyzer equipped 
with a high-pressure analytical column packed with Utrapac 8 resin (Pharmacia Biotech, 
Cambridge, UK). Isotopic enrichments of methionine in plasma were measured in the 
acetyl-3,5-bis(trifluoromethyl)benzyl derivative with the use of gas chromatography-mass 
spectrometry (GCMS), as previously described [23]. Enrichments [in mole percent excess 
(MPE)] were calculated on the basis of the relative abundance of the (m + 0), (m + 1) and (m 
+ 4) methionine species [24], and calibration curves obtained from weighed amounts of tracer 
(m + 1 and m + 4) and tracee methionine were used to correct for minor instrument variation 
[18]. The 13C-enrichment of CO2 in breath samples was measured on a dual-inlet isotope 
radio mass spectrometer (VG OPTIMA, Fisons Instruments, Middlewich, Cheshire, UK) and 
expressed in atom percent excess (APE; %), as previously described [12]. 
    Gene polymorphisms. The polymorphisms of 5,10-methylenetetrahydrofolate reductase 
(C677T transition), cystathionine β-synthase (844ins68 variant) and methionine synthase 
(A2756G transition) were assessed in DNA obtained from the buffy coat of EDTA blood as 
described by Tsai et al. [25], who demonstrated that healthy individuals who were 
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heterozygous for these mutations had plasma tHcy levels that were not different from those in 
the wild-type subjects. 
 
Calculations 
    The features of the [2H3-methyl-1-13C]methionine plateau model have been previously 
summarized [24,26]. In the isotopic steady-state, whole body fluxes of TM, TS and RM can 
be estimated from enrichments at plateau from the five plasma samples obtained during the 
tracer infusion between 3.5 and 5 h. The RM flux is calculated from the difference between 
the whole body methionine-methyl flux rate (Qm) and the methionine-COOH flux rate (Qc), 
because the 2H3-methyl label is split from the methionine tracer during TM, whereas 13C is 
retained in the COOH moiety of Hcy 
 
RM = Qm – Qc     (1)  
 
    From the infusion rate of the tracer and with correction for isotopic enrichment of the 
tracer, Qm can be calculated from the enrichments of methionine (m + 4) and Qc from the sum 
of the enrichments of methionine (m + 4) and (m + 1). RM then follows from substitution in 
Eq. 1 [12,24]. 
    The rate of TS flux from Hcy equals the methionine oxidation flux and is calculated from 
the 13CO2 (the COOH end-product of Hcy oxidation) excretion in breath air and the 
methionine (m + 1) enrichment in plasma and tracer infusion rate as follows 
 
TS = V13CO2 *  (1/[13C]methionine enrichment in plasma 
– 1/[13C]methionine enrichment in tracer infusate)         (2) 
 
in which V13CO2 equals the whole body CO2 production (in µmol/h) * breath air 13CO2 
enrichment * 0.72, where 0.72 is the bicarbonate retention factor [27]. As methionine is the 
only precursor of Hcy, the disappearance of Hcy (RM + TS) equals Hcy appearance, thus 
 
TM = RM + TS     (3) 
 
    CO2 production was measured during 30 min with a ventilated hood and using an indirect 
calorimeter (2900 Metabolic Measurement Cart, SensorMedics, Yorba Linda, CA). Internal 
calibration for CO2 and volume was conducted before each infusion. Gas volumes were 
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automatically corrected for temperature and air pressure. The flux rates for RM, TS and TM 
were expressed as micromoles per hour per kilogram BW and per kilogram FFM. Metabolic 
Hcy clearance by TS and by RM was calculated by dividing the flux rates (TS and RM, 
respectively) by plasma tHcy concentration and is expressed in liters per kilogram per hour. 
 
Statistical analysis 
    Values are expressed as mean ± SD or as median (range) if data were skewed. Differences 
between patients and controls were tested with unpaired Student’s t-tests, Mann-Whitney 
tests, and Fisher’s exact tests as appropriate. Pearson’s correlation coefficients were 
calculated, with log-transformed data in case of a skewed distribution of a variable. The 
distribution of genetic polymorphisms (wild-type or heterozygote mutant = 0; homozygote 
mutant = 1) was analyzed with the χ2 test. Multivariate regression analysis was performed to 
analyze ESRD (absent = 0; present = 1), sex, age, and vitamin status (plasma concentrations) 
as determinants of FFM-adjusted flux rates and Hcy clearance. All regression coefficients (β) 





    The median (range) time on dialysis of the 12 ESRD patients was 17 (10–140) mo. 
Baseline characteristics are presented in Table 1. Patients with ESRD had significantly higher 
plasma levels of tHcy and folate, and a significantly higher mean age compared with the 16 
healthy controls. 
 
Whole body flux rates of RM, TM, TS, and Hcy clearance in ESRD patients and 
controls  
    CO2 production was similar in patients (2.79 ± 0.21 ml.kg–1.min–1) and controls (2.72 ± 
0.15 ml.kg–1.min–1). Patients with ESRD had a RM rate that was 28% lower than the controls 
[95% confidence interval (CI) –50 to –5%,  P = 0.02],   whereas TM was 27% lower  (95% CI 
–43 to –11%, P < 0.01) and TS was 26% lower (95% CI –45 to –7%, P < 0.01). Hcy clearance 
by RM was 77% lower (95% CI –100 to –55%, P < 0.001) and Hcy clearance by TS was 80% 
lower (95% CI –100 to –52%, P < 0.001) in ESRD patients as compared with controls (Table 
2). 
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1, ADPKD* M 69 81 75 CT -/- AG 43.6 17.8 11 182 
2, HUS* F 51 82 62 CC -/- AG 63.2 17.4 93 403 
3, CGN* F 31 61 48 CT -/- AA 49.4 14.3 32 193 
4, CGN* F 25 54 42 CC -/+ AG 57.0 14.2 16 201 
5, ADPKD M 63 75 62 CT -/- AG 37.9 21.2 53 464 
6, FSGS F 52 109 68 CC -/- AA 27.5 14.9 47 431 
7, RAS M 53 74 60 CC -/- AA 16.6 28.0 14 385 
8, PRO M 69 78 66 TT -/- GG 19.6 45.0† 42 213 
9, HN M 79 67 58 CT -/- AG 28.1 45.0† 89 302 
10, MPGN M 60 59 54 CT -/- AG 16.6 45.0† 61 336 
11, HN M 24 63 55 CT -/+ AG 14.8 45.0† 48 573 
12, PRO M 70 76 64 CT -/- AA 26.7 15.2† 47 218 







54 ± 18 
 
 
73 ± 14 
 
 

























1* M 41 68 62 CC -/- GG 7.0 16.1 44 290 
2* M 20 70 60 CT -/- AG 5.6 28.7 81 368 
3* M 22 78 66 TT -/- AG 14.1 11.7 35 186 
4* M 50 84 69 CT -/+ AA 7.7 14.1 58 332 
5* F 21 75 60 CC -/- AA 10.2 12.3 70 124 
6* F 53 63 47 CT -/- AG 12.0 23.0 27 197 
7 M 35 74 65 CC -/- AA 9.6 12.9 26 208 
8 F 22 62 44 CC -/- AA 5.6 16.2 28 274 
9 F 23 64 47 CC -/- AA 10.6 7.3 20 260 
10 M 22 73 61 CC -/+ AA 8.9 17.2 29 216 
11 F 19 60 40 CT -/- AA 7.0 18.7 38 175 
12 M 20 69 57 CC -/- AG 6.1 14.6 44 214 
13 F 19 66 46 CC -/- AA 7.1 15.4 55 181 
14 F 47 57 43 CT -/+ AA 7.4 10.4 20 313 
15 M 64 108 90 CC -/- AA 8.6 15.1 24 227 
16 F 46 63 46 CT -/- AA 7.4 17.5 8 218 







32 ± 16 
 
 
71 ± 12 
 
 
























P value‡ 0.21 <0.01 0.65 0.50 1.00 1.00 1.00 <0.001 0.02 0.38 0.07 
M, male; F female; BW, body weight; FFM, fat-free mass; MTHFr, 5,10-methylenetetrahydrofolate reductase; CBS, cystathionine β-
synthase; MS, methionine synthase; CC, wildtype; CT, heterozygous for C677T; TT, homozygous for C677T; -/-, wildtype; -/+, heterozygous 
for 844ins68; +/+, homozygous for 844ins68; AA, wildtype; AG, heterozygous for A2756G; GG, homozygous for A2756G; tHcy, total plasma 
homocysteine; Vit, vitamin; ESRD, end-stage renal disease; ADPKD, autosomal dominant polycystic kidney disease; HUS, hemolytic 
uremic syndrome; CGN, chronic glomerulonephritis; FSGS, focal and segmental glomerulosclerosis; RAS, renal artery stenosis; PRO, 
postrenal obstruction; HN, hypertensive nephropathy; MPGN, membranoproliferative glomerulonephritis. *Data from previous study group 
presented by Van Guldener et al. [12]; FFM and genotype analysis for CBS and MS are added. †Patients with additional use of 1 mg folic 
acid once weekly; the upper limit of the folate assay was 45 nmol/l. ‡Comparison of the group patients with ESRD with the group of healthy 
controls. 
 
    RM and TM rates were positively correlated, both within the patient group (r = 0.84, P < 
0.001) and within the control group (r = 0.89, P < 0.001). Correlations between RM and TS 
and between TM and TS were not significant in either group (data not shown). 
    After adjustment for sex and age, RM (–18%; 95% CI –45 to +9%, P = 0.19), TM (–15%; 
95% CI –33 to +2%, P = 0.09), and TS (–10%; 95% CI –30 to +9%, P = 0.29) were no longer 
significantly decreased in the ESRD group,  but Hcy clearance by RM  (–65%; 95% CI –97 to 
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 BW   FFM BW FFM BW FFM BW FFM BW   FFM 
ESRD patients 
1* 2.1   2.3 0.05 0.05 1.7 1.9 0.04 0.04 3.9   4.2 
2* 2.8   3.8 0.04 0.06 3.0 4.0 0.05 0.06 5.8   7.8 
3* 2.6   3.3 0.05 0.07 3.0 3.9 0.06 0.08 5.6   7.2 
4* 2.9   3.7 0.05 0.06 2.4 3.1 0.04 0.05 5.3   6.8 
5 3.1   3.7 0.08 0.10 2.3 2.8 0.06 0.07 5.4   6.5 
6 2.3   3.7 0.08 0.13 1.4 2.3 0.05 0.08 3.7   5.9 
7 5.3   6.5 0.32 0.39 2.4 3.0 0.15 0.18 7.7   9.5 
8 3.4   4.0 0.17 0.20 1.5 1.8 0.08 0.09 4.8   5.7 
9 3.9   4.5 0.14 0.16 1.8 2.1 0.06 0.07 5.6   6.5 
10 2.7   3.0 0.16 0.18 1.6 1.7 0.10 0.11 4.2   4.6 
11 4.1   4.7 0.28 0.32 2.7 3.1 0.18 0.21 6.8   7.8 
12 2.3   2.8 0.09 0.10 2.4 2.9 0.09 0.11 4.7   5.6 
Mean ± SD 3.1 ± 0.9 3.8 ± 1.1 0.13 ± 0.09 0.15 ± 0.11 2.2 ± 0.6 2.7 ± 0.8 0.08 ± 0.04 0.10 ± 0.05 5.3 ± 1.2 6.5 ± 1.5 
Healthy controls 
1* 4.0   4.4 0.57 0.63 3.2 3.5 0.46 0.50 7.2   7.9 
2* 5.2   6.1 0.93 1.09 3.0 3.5 0.54 0.63 8.2   9.6 
3* 3.9   4.6 0.28 0.33 2.8 3.3 0.20 0.23 6.7   7.9 
4* 3.0   3.6 0.39 0.47 3.2 3.9 0.42 0.50 6.2   7.5 
5* 3.1   3.9 0.30 0.38 3.0 3.8 0.29 0.37 6.0   7.5 
6* 3.3   4.4 0.27 0.37 2.8 3.7 0.23 0.31 6.2   8.3 
7 3.7   4.2 0.39 0.44 2.0 2.2 0.21 0.23 5.7   6.4 
8 3.2   4.5 0.57 0.81 3.4 4.9 0.61 0.87 6.6   9.4 
9 5.4   7.3 0.51 0.69 2.3 3.1 0.22 0.29 7.7 10.5 
10 4.7   5.6 0.53 0.63 3.4 4.0 0.38 0.45 8.0   9.6 
11 4.4   6.6 0.63 0.95 3.1 4.6 0.44 0.66 7.5 11.2 
12 3.9   4.7 0.64 0.78 4.6 5.5 0.75 0.91 8.5 10.3 
13 7.0 10.1 0.99 1.42 2.8 4.1 0.40 0.58 9.8 14.2 
14 2.9   3.9 0.40 0.52 3.2 4.2 0.43 0.57 6.1   8.1 
15 5.7   6.9 0.66 0.80 1.9 2.3 0.22 0.27 7.6   9.2 
16 2.5   3.4 0.34 0.46 1.5 2.1 0.20 0.28 4.0   5.5 
Mean ± SD 4.1 ± 1.2 5.3 ± 1.8 0.52 ± 0.21 0.67 ± 0.30 2.9 ± 0.7 3.7 ± 0.9 0.37 ± 0.16 0.48 ± 0.21 7.0 ± 1.4 8.9 ± 2.1 
P value† 0.02 0.02 < 0.001 < 0.001 0.01 < 0.01 < 0.001 < 0.001 < 0.01 < 0.01 
RM, remethylation; TS, transsulfuration; TM, transmethylation; tHcy, plasma total homocysteine. *Data for BW from previous study by Van 
Guldener et al. [12]; corrections for FFM are added. †Comparison of patients with ESRD with healthy controls. 
 
–32%, P < 0.001) and Hcy clearance by TS (–65%; 95% CI –97 to –33%, P < 0.001) were 
still  significantly  decreased.  Age  itself  was  a  significant  determinant  of  TS  (β  =  –0.51, 
P = 0.01) and TM (β = –0.45, P = 0.03), but not of RM (β = –0.29, P = 0.21), Hcy clearance 
by RM (β = –0.25, P = 0.14) and Hcy clearance by TS (β = –0.29, P = 0.08). Plasma tHcy, the 
other component of the equation for Hcy clearance by TS and RM, was not significantly 
determined by age (β = –0.04, P = 0.80). 
    Because ESRD status and age were strongly associated, analyses adjusted for age may to 
some extent result in overadjustment. We therefore repeated the multivariate analysis in two 
age-matched subgroups, which consisted of 8 ESRD patients (patients 2, 3, 4, 5, 6, 7, 10, and 
11; mean age 44.9 ± 15.7 yr) and 8 healthy controls (patients 1, 3, 4, 6, 9, 14, 15, and 16; 
mean age 43.3 ± 14.4 years). After adjustment for sex and age, the ESRD group had a 23% 
lower RM (95% CI –44 to –3%, P = 0.03), a 19% lower TM (95% CI –38 to –1%, P = 0.048), 
a 72% lower Hcy clearance by RM (95% CI –96% to –49%, P < 0.001), and a 72% lower Hcy 
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clearance by TS (95% CI –100 to –41%, P < 0.001) compared with the healthy controls, but 
TS was not significantly different (–8%; 95% CI –33 to +17%, P = 0.51). 
    Separate addition of serum levels of vitamins to the statistical models did not change the 
results (data not shown). 
 
Determinants of plasma tHcy 
    Plasma tHcy was about four-fold higher in the ESRD group than in the healthy controls. 
    Multivariate analysis, with forced entry of the covariates sex and age, showed that patients 
with ESRD had a 322% higher plasma tHcy (95% CI 209 to 436%, P < 0.001). To test the 
possibility that this relation was mediated by one-carbon flux rates, plasma and whole blood 
levels of AdoMet and AdoHcy (and their ratio), and vitamins, these individual variables were 
sequentially added to the multivariate model. This did not materially change the relationship 
between ESRD status and plasma tHcy. After adjustment for age and sex, RM (β = –0.37, P = 
0.07) and TM (β = –0.42, P = 0.08) were associated with plasma tHcy with borderline 
significance, and TS (β = –0.08, P = 0.75) was not. Plasma levels of AdoMet (β = 0.78, P < 
0.001), AdoHcy (β = 0.74, P < 0.001), and their ratio (β = -0.69, P = 0.001) were related to 
plasma tHcy, as were whole blood levels of AdoHcy (β = 0.63, P < 0.01) and the 
AdoMet/Hcy ratio (β = –0.55, P = 0.01), but whole blood levels of AdoMet were not 
significantly related to plasma tHcy (β = –0.15, P = 0.46). Of the vitamins, serum folate was 
significantly related to plasma tHcy (β = –0.38, P = 0.01), but vitamin B6 (β = –0.12, P = 
0.63) and vitamin B12 (β = –0.16, P = 0.24) were not. 
 
Blood AdoMet and AdoHcy and their relationship to flux rates and Hcy clearance 
    Table 3 shows the levels of AdoMet, AdoHcy, and their ratio in whole blood and plasma 
for patients with ESRD and healthy controls. After adjustment for sex and age, plasma levels 
of AdoMet (β = 0.87, P < 0.001) and AdoHcy (β = 0.97, P < 0.001) were significantly higher 
in the ESRD patients compared with the healthy controls, and the AdoMet/AdoHcy ratio was 
lower (β = –1.00, P < 0.001). In whole blood, the same results were found for AdoHcy (β = 
0.95, P < 0.001) and the AdoMet/AdoHcy ratio (β = –1.01, P < 0.001), but AdoMet levels of 
the ESRD patients were not significantly different (β = –0.59, P = 0.08) from the healthy 
controls. 
    After adjustment for sex and age, whole blood levels of AdoHcy were a significant 
determinant of RM (β = –1.43, P = 0.03), TM (β = –1.24, P = 0.01) (Figure 2), but not of TS 
(β = –0.37, P = 0.48),  Hcy clearance by RM  (β = –0.55, P = 0.23),  and Hcy clearance by TS 
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Table 3. Plasma and whole blood levels of S-adenosylmethionine and S-adenosylhomocysteine in the postabsorptive state 
AdoMet, S-adenosylmethionine; AdoHcy, S-adenosylhomocysteine; NA, not available. *Comparison of patients with ESRD 
with healthy controls. 
 
(β = 0.02, P = 0.97) in the whole group. The whole blood levels of AdoMet were significantly 
associated with TS (β = 0.40, P = 0.049), but not with RM (β = –0.06, P = 0.85), TM (β = 
0.14, P = 0.57), Hcy clearance by RM (β = 0.02, P = 0.92), or Hcy clearance by TS (β = 0.25, 
P = 0.20).  The whole blood AdoMet/AdoHcy ratio was significantly associated with TM (β = 
0.51, P = 0.02), and less with RM (β = 1.27, P = 0.07) and TS (β = 0.68, P = 0.15). The whole 
blood AdoMet/AdoHcy ratio was not a significant determinant of Hcy clearance by RM (β = 
0.49,  P = 0.27) and Hcy clearance by TS (β = 0.22, P = 0.63). Plasma levels of AdoMet, 
AdoHcy or the AdoMet/AdoHcy ratio were not significantly associated with one-carbon 
fluxes or Hcy clearance (data not shown). 
    Data were insufficient to test whether the relationship between ESRD status on the one 
hand and one-carbon fluxes and Hcy clearances on the other were mediated by AdoMet, 
AdoHcy, or their ratio. 





 Plasma Whole blood Plasma Whole blood Plasma Whole blood Hematocrit 
ESRD patients 
5 NA NA NA NA NA NA 0.38 
6 268 1435 252 262 1.1 5.5 0.41 
7 190 1195 139 124 1.4 9.6 0.34 
8 390 1260 562 407 0.7 3.1 0.32 
9 304 1610 325 230 0.9 7.0 0.36 
10 247 1150 410 294 0.6 3.9 0.38 
11 240 1120 437 374 0.6 3.0 0.32 
12 346 1350 465 305 0.7 4.4 0.37 














0.36 ± 0.03 
 
Healthy controls 
7 70 NA 11 NA 6.4 NA 0.41 
8 61 1335 10 77 5.9 17.3 0.36 
9 74 1095 13 53 5.7 20.7 0.35 
10 83 1760 13 70 6.6 25.1 0.42 
11 102 1580 13 62 7.9 25.4 0.37 
12 87 1615 11 66 8.3 24.7 0.38 
13 88 1360 12 58 7.1 23.4 0.33 
14 91 1630 9 63 10.4 26.1 0.37 
15 89 1660 13 57 6.7 29.0 0.42 
16 81 1220 12 88 6.8 13.9 0.37 














0.38 ± 0.03 
 
P value* < 0.001 0.06 < 0.001 < 0.001 < 0.001 < 0.001 0.20 
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Figure 2. Relation between whole blood S-AdoHcy levels and 1-carbon flux rates in 7 patients with end-stage renal 
disease (■) and 9 healthy controls (о). Whole blood S-AdoHcy is expressed as the natural logarithm (ln) of the 
concentration (in nmol/l), and RM and TM fluxes are expressed per kg fat-free mass. The correlation coefficient (r) in A 
(RM) for the whole group is –0.61 (P < 0.01); –0.68 (P = 0.09) for end-stage renal disease; and –0.65 (P = 0.11) for controls. 
In B, r for whole group TM is –0.75 (P < 0.001); –0.71 (P = 0.03) for end-stage renal disease; and –0.66 (P = 0.06) for 





    Our study shows that in ESRD patients, metabolic Hcy clearance by TS and RM is severely 
reduced and indicates that absolute RM and TM rates are reduced to a much lesser extent, 
whereas the TS rate is unchanged. We also found evidence for an inverse relationship 
between whole blood AdoHcy concentration and TM and RM rates. 
    In steady-state conditions in weight-maintaining adults, TS rate reflects oxidation of 
methionine from dietary intake, because methionine is the only precursor of Hcy, and TS is 
the only way of Hcy disposal (methionine catabolism by transamination is negligible in 
humans) [28]. In the design of our study, protein intake was the same in ESRD patients and 
healthy controls. It is thus not surprising that in the present study TS rate (after adjustment for 
age and gender) was similar for ESRD patients and controls. This is in agreement with 
observations in our previous study [12].  
    As an explanation of the elevated plasma tHcy concentrations in ESRD patients, the 
concept of decreased metabolic Hcy clearance has been put forward [13]. In this concept, any 
block in Hcy transsulfuration has to be followed by an increase in plasma tHcy in order to 
maintain a constant (diet-dependent) methionine oxidation. The initial rise in Hcy is followed 















































by an accumulation of its precursors AdoHcy and AdoMet, which are activators of 
cystathionine β-synthase [16,29], the rate limiting enzyme in the TS pathway. The rise in the 
concentration of these compounds in ESRD may stimulate TS to such an extent that it 
equilibrates with methionine intake. We and others [14] found elevated AdoMet and AdoHcy 
levels in ESRD patients, and we also found that whole blood levels of AdoMet were 
positively related to TS. Thus in the steady state, the absolute TS rate reflects oxidation of 
ingested methionine, but the ratio of TS and plasma tHcy (i.e., Hcy clearance by TS) reflects 
the degree of the impairment of TS to metabolize its substrate. Expressed in this way, Hcy 
clearance was decreased by 80% in ESRD patients, which is in good agreement with the 
reduction in plasma Hcy clearance by 75% reported after oral Hcy loading in patients with 
chronic renal failure [5]. From our study, the cause of this metabolic block cannot be 
determined. 
    The interpretation of the whole body RM rate in ESRD patients is somewhat difficult as 
these patients were older than the control individuals. After correction for age, there was no 
significant difference in RM, but because age and renal function are strongly related there 
might have been some overcorrection. To prevent such a statistical effect, we also performed 
an age-matched subgroup analysis and, by doing so, found a significantly lower RM in the 
renal patients. However, even in the presence of a normal absolute RM flux, an elevated 
plasma tHcy level would be indicative of a metabolic RM block under the metabolic 
clearance concept. Substantial hyperhomocysteinemia is common in ESRD [1] and was 
present in all patients participating in our study. This is evidence for a substantial metabolic 
block in Hcy clearance by RM in the majority of the ESRD population. Treatment regimens 
containing folic acid decrease plasma tHcy concentration in ESRD patients [2–4], which 
indicates that this block is modifiable. 
    TM was diminished in ESRD patients, despite accumulation of the methyl group donor 
AdoMet. However, in accordance with Loehrer and co-workers [14], we found that the ratio 
of AdoMet to AdoHcy in plasma was eight times lower in ESRD patients than in healthy 
individuals. From in vitro studies, the AdoMet/AdoHcy ratio is known to have a regulatory 
function in the enzymatic TM reactions [16]. The metabolic consequence of diminished 
whole body TM flux in ESRD patients is impaired capacity to provide methyl groups in 
tissues. This may explain the impaired DNA methylation in hyperhomocysteinemic ESRD 
patients as recently reported [30]. Less requirement for creatine biosynthesis, and therefore 
methyl donation, due to diminished muscle mass in ESRD patients has been suggested to 
result in a smaller need for TM (and RM) by Hoffer [13]. However, in our study we expressed 
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TM per kilogram FFM, which was similar in healthy controls and ESRD patients. Whether 
reducing tissue AdoHcy accumulation can increase methylation flux rates in patients with 
ESRD and will improve DNA methylation merits further study. 
    This is the first study in humans that shows that the whole body flux rates of RM and TM 
are negatively related to the whole blood AdoHcy level. The inverse relation between 
AdoHcy levels and RM rate may be explained by inhibitory effects of AdoHcy on methionine 
synthase activity in the tissues and most other acceptor methyltransferases, as suggested by 
Finkelstein [16]. Also, in our study design, protein intake was fixed and TS unchanged, 
implying that RM and TM are linearly related with each other (see Eq. 3). Therefore, RM and 
TM showed the same trend in their relationships with AdoHcy. The whole blood 
AdoMet/AdoHcy ratio showed only a weak relationship with TM and none with RM, and 
plasma AdoHcy was not related to RM and TM flux. This suggests that the intracellular 
AdoHcy concentration, reflected by its whole blood levels, is a possible regulator of methyl 
group flux from methionine demethylation and folate-dependent RM in humans. Plasma tHcy 
was not significantly associated with RM or TM in our ESRD and healthy control individuals. 
Taken together, these findings indicate that in humans, and particularly when renal function is 
impaired, AdoHcy may be a key intracellular regulator of one-carbon flux. 
    The limitations of the study need to be addressed. First, in retrospect, the present study had 
a power of 80% to detect a difference of 27% in TS and TM and 38% in RM, but, despite 
inclusion of data from our previous stable-isotope study [12], the number of subjects was too 
small to quantify the impact of AdoHcy and AdoMet on the relationship between ESRD and 
flux rates. The conclusions regarding relationships have to be interpreted with caution, as we 
cannot exclude that other factors associated with ESRD (e.g., uremic compounds) interact 
with enzyme function in methionine and Hcy metabolism. 
    Second, the validity of the stable-isotope model as a reflection of intracellular methyl group 
metabolism merits discussion. Isotope retention in the body’s bicarbonate pool is a recognized 
cause of underestimation of catabolism when 13CO2 enrichment in breath air is used, and 
therefore TS flux was corrected with the bicarbonate retention factor [31]. Also, RM, TM, and 
TS fluxes are underestimated to some extent when plasma enrichments are used in the 
calculations, due to tracer dilution in the intracellular compartment. Young and co-workers 
[24] assumed, from measurements of dilution of other indispensable amino acids, that use of 
plasma values underestimates RM and TM in postabsorptive adults by ~20%. In labeled 
methionine studies in humans, enrichment in plasma Hcy, a surrogate measure of intracellular 
methionine enrichment, was 90% of tracer methionine enrichment in plasma after 9 h [32]. 
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Lower values for plasma enrichment of Hcy (the precursor for RM) compared with 
methionine have been found in studies using priming of the methionine pool [33,34], because, 
in the absence of priming of the Hcy pool, plasma enrichment rises much more slowly than 
when priming is used. There are no known pathways for Hcy production apart from TM, 
rendering additional dilution of intracellular Hcy unlikely and underpinning the validity of the 
use of [13C]methionine enrichment for methionine and Hcy flux estimation. With the use of 
our study protocol, plasma methionine enrichment reaches plateau in primed steady-state 
protocols within 6 h, even in ESRD patients [23], in whom hyperhomocysteinemia coexists 
with normal methionine levels [15]. With these considerations, we do not expect the 
underestimation of TM and RM in ESRD patients and healthy controls to be much different 
from 10–20% under the conditions of our study. 
    Third, with respect to the role of selection bias on interpretation of the study data, the effect 
of age and vitamin supplementation must be addressed. There was a difference of ~22 yr in 
mean age between the ESRD patients and healthy controls in our study, and multiple 
regression analysis showed a significant negative relationship between their age and TS and 
TM rates. With the same stable-isotope infusion technique, others have reported similar flux 
rates in whole body methionine and Hcy metabolism in healthy elderly (n = 12; age 74 ± 2 yr) 
and young individuals (n = 8; age 27 ± 6 yr) on the same protein intake [31,35]. In post hoc 
analysis, ESRD patients had a significantly lower TM and RM than age-matched controls, but 
TS was similar. The patient-control difference in TS rate between the post hoc analysis (–8%) 
and the overall analysis (–27%) cannot be easily explained entirely by age alone. A difference 
in vitamin intake is another potential bias. Five ESRD patients received low-dose folic acid 
supplementation (1 mg once weekly). Compared with the other seven ESRD patients, these 
supplemented patients had significantly lower plasma tHcy levels (21.2 ± 6.0 versus 42.2 ± 
16.3 µmol/l, P = 0.02), but similar rates of RM (3.8 ± 0.9 vs. 3.8 ± 1.3 µmol.kg FFM–1.h–1, P = 
0.92) and the other fluxes (data not shown). When plasma folate levels were used in 
multivariate analysis, to correct for confounding by folic acid substitution, no significant 
changes in outcome were found. No conclusions on whether or to which extent folic acid 
supplementation may increase the rate of the folate-dependent RM pathway in ESRD can be 
drawn from the data of the present study. 
    In summary, this study shows that one-carbon metabolism in patients with ESRD is 
characterized by impaired in vivo metabolic Hcy clearance by TS and RM. Elevated levels of 
AdoHcy, AdoMet, or both stimulate TS until the flux rate equals methionine intake from the 
diet. Our data suggest that the absolute rates of RM and TM are diminished and are negatively 
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related to whole blood AdoHcy levels. We hypothesize that the elevated intracellular 
concentration of AdoHcy in ESRD mediates the impairment in RM and TM flux rates. Given 
the persistence of hyperhomocysteinemia in ESRD patients supplemented with high doses of 
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    Background. The pathogenesis of hyperhomocysteinemia in end-stage renal disease 
(ESRD) is unclear. Folic acid lowers, but does not normalize, the plasma homocysteine level 
in patients with ESRD, but its effect on whole body metabolism of homocysteine is unknown. 
    Methods. We studied the effect of 3 weeks of oral treatment with 5 mg folic acid per day on 
homocysteine metabolism in six chronic hemodialysis patients and six healthy controls. 
Primed, continuous infusions with [2H3-methyl-1-13C] methionine were used to determine 
flux rates of methionine transmethylation, homocysteine remethylation, and homocysteine 
transsulfuration. Metabolic homocysteine clearance was defined as the ratio of 
transsulfuration and plasma homocysteine level. 
    Results. Folic acid treatment lowered plasma homocysteine significantly by 48% (95% CI 8 
to 88) in the ESRD group, but plasma homocysteine remained higher than baseline values in 
the control group. In ESRD patients, homocysteine remethylation and methionine 
transmethylation rate increased by 32% (95% CI 5 to 58) and 20% (95% CI 8 to 32), 
respectively (i.e., levels that were similar to the baseline values of the control group). 
Transsulfuration rate and metabolic homocysteine clearance were not significantly altered by 
folic acid treatment in both the ESRD and the control group. 
    Conclusions. In ESRD patients, folic acid treatment lowers, but does not normalize plasma 
homocysteine, whereas homocysteine remethylation and methionine transmethylation 
increase to levels found in untreated healthy controls. These findings indicate a persistent, 
folate-independent, defect in metabolic homocysteine clearance in ESRD. 




    Hyperhomocysteinemia is associated with cardiovascular disease [1], and is a prevalent risk 
factor for cardiovascular disease in patients with chronic renal insufficiency [2]. 
Hyperhomocysteinemia occurs in 85 to 100% of patients with end-stage renal disease (ESRD) 
[3]. The pathophysiological explanation for the strong inverse relationship between renal 
function and plasma homocysteine level is controversial and focuses on whether the defect in 
homocysteine clearance is located in the kidneys themselves or should be sought extrarenally 
[4,5]. We have studied whole body metabolism of homocysteine in patients with ESRD by 
applying stable isotope methods [6]. In this model, primed, continuous infusions with 
bilabeled methionine were used to determine flux rates of methionine transmethylation to 
homocysteine, homocysteine remethylation to methionine and homocysteine transsulfuration 
to cysteine (Figure 1). We found that transmethylation and remethylation were reduced in 
hyperhomocysteinemic ESRD patients compared to healthy individuals. Transsulfuration was 
similar, reflecting the same protein (methionine) intake in both groups. The metabolic 
clearance of homocysteine by transsulfuration, which is expressed by the ratio of 
transsulfuration and plasma homocysteine [7], however, was severely impaired in ESRD 
patients when compared to healthy individuals [8]. 
    Several homocysteine-lowering treatments have been tested in ESRD patients [9]. There is 
consensus that folic acid is the cornerstone of any homocysteine-lowering regimen in this 



















treatment with folic acid in dialysis patients have shown that normalization of plasma 
homocysteine is seldom reached, which has led some authors to suggest that this folic acid 
resistance is the result of an altered folate metabolism in renal failure [10]. These claims have 
so far not been sustained by studies using active folate compounds instead of folic acid or 
intravenous administration of folinic acid [11–13]. In addition, it is not clear from these 
studies whether folic acid in ESRD patients is capable of restoring whole body homocysteine 
metabolism to normal values.  
    In this study, we aimed to elucidate the apparent folate resistance in ESRD by investigating 
the effect of folic acid administration on plasma homocysteine and whole body methionine 
and homocysteine conversion rates in ESRD patients using the tracer infusion technique with 





    Six hemodialysis patients and six healthy control individuals were studied. Renal diagnoses 
were chronic glomerulonephritis in two, polycystic disease in two, hypertensive renovascular 
disease in one and focal glomerulosclerosis in one. All patients had been on chronic standard 
bicarbonate hemodialysis thrice weekly for at least 6 months. They received one multivitamin 
tablet per day containing 2 mg vitamin B6, but no folic acid or vitamin B12. Table 1 shows 
other baseline characteristics. 
 
Table 1. Baseline characteristics in six patients with end-stage renal disease (ESRD) and six healthy controls 
Characteristic Control ESRD 
Sex, male/female 3 / 3 3 / 3 
Age, years 50 ± 9 49 ± 17 
Time on dialysis, months  22 ± 9 
Body weight, kg 76 ± 21 76 ± 19 
Fat free mass, kg 62 ± 19 59 ± 12 
Homocysteine, µmol/L 8.1 ± 1.4 38.7 ± 14.8* 
Folate, nmol/L 15 (10–18) 18 (14–28) 
Vitamin B6, nmol/L 24 (8–58) 21 (11–53) 
Vitamin B12, pmol/L 290 (218–332) 293 (182–464) 
Values are presented as mean ± SD for variables with a normal distribution or median (range) for variables with a skewed 
distribution. *P < 0.01. 
 
    The study protocol was approved by the ethics committee of the VU University Medical 
Center, and all participants gave their written informed consent. 
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Experimental protocol 
    The study protocol has been described in detail elsewhere [6]. Briefly, the participants were 
kept on a stable protein diet of 1.0 g/kg/day. In the hemodialysis patients, the experiments 
were executed the day between two regular midweek dialysis sessions. All individuals 
remained fasting and recumbent during the test. After baseline samples were taken, a priming 
bolus of 5.9 µmol NaH13CO3 (99% [13C]) (ARC Laboratories, Apeldoorn, The Netherlands) 
was administered, followed by a primed (3.5 µmol/kg) constant infusion of 
L-[2H3-methyl-1-13C]methionine (95% doubly labeled) (99% [1-13C]; 99% [2H1]) (Isotec, 
Miamisburg, OH, USA) at a rate of 2.2 µmol/kg/hour for 6 hours (5 hours in control 
individuals). Plateau enrichment levels were calculated as the mean of the final five 20-
minute interval samples of the infusion period. Body weight was measured on a balance scale 
(accuracy 50 g), and four skinfolds were measured using a caliper (Holtain) (accuracy 0.1 
mm). Fat-free mass was calculated from skinfold measurements according to Durnin and 
Womersley [14]. Measurement of skinfold thicknesses has shown to be a reliable method to 
quantify body composition in healthy individuals and ESRD patients [15].  
 
Intervention 




    Plasma total (free plus protein bound) homocysteine was measured with the use of a 
microparticle enzyme immunoassay method based on fluorescence polarization (IMX 
analyzer) (Abbott, Chicago, USA). Serum folate and vitamin B12 concentrations were 
measured by radioassay (ICN, Costa Mesa, CA, USA), and serum vitamin B6 with the use of 
fluorescence high-performance liquid chromatography (HPLC) [16]. The methionine 
concentration in the infusate was measured with an amino acid analyzer equipped with a high 
pressure analytical column packed with Utrapac 8 resin (Pharmacia Biotech, Cambridge, 
UK). Isotopic enrichments of methionine in plasma was measured in the acetyl-3,5-
bis(trifluoromethyl)benzyl derivative with the use of gas chromatography mass spectrometry 
(GCMS), as previously described [17]. Enrichments [in mole percent enrichment (MPE)] 
were calculated on the basis of the abundance relative of the (m + 0), (m + 1), and (m + 4) 
methionine species [18], and calibration curves obtained from weighed amounts of tracer (m 
+ 1 and m + 4) and tracee methionine were used to correct for minor instrument variation 
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[17]. The 13C-enrichment of carbon dioxide in breath samples was measured on a dual-inlet 
isotope ratio mass spectrometer (VG OPTIMA) (Fisons Instruments, Middlewich, Cheshire, 
UK) and expressed in atom percent excess (APE) (%). 
 
Calculations 
    Doubly labeled methionine (L-[2H3-methyl-1-13C]methionine) was used as a tracer, 
according to the method described by Storch et al. [18]. This stable isotope has a molecular 
weight of m + 4 relative to natural methionine (m). The 2H3-methyl label is removed from 
methionine during transmethylation and thus 2H3-methyl-1-13C]methionine is converted to [1-
13C]homocysteine. Remethylation will result in the generation of m + 1 methionine, because 
the 13C atom of the carboxyl moiety of homocysteine remains intact. In contrast, during 
transsulfuration the carboxyl moiety of [1-13C]homocysteine loses its 13C atom. When α-
ketobutyrate is oxidized in the Krebs cycle, the label ultimately appears as 13CO2 in breath air. 
The m + 4 methionine tracer is diluted by methionine entering the pool via the diet, from 
homocysteine remethylation, and by free methionine entering from protein breakdown in the 
tissues. In steady state, the rate of appearance of methionine from these sources equals the rate 
of disappearance (i.e., protein synthesis and transmethylation). In this model, it is assumed 
that the intracellular and intravascular compartments are in rapid and complete isotopic 
equilibrium. 
    From the enrichments of methionine (m + 4 and m + 1 ), the whole body methionine-
methyl rate of appearance and disappearance (Qm) and methionine-carboxyl rate of 
appearance and disappearance (Qc) are calculated as follows: 
 
Qm = I * (Etr / E4 -1) 
Qc = I * (Etr / (E1 + E4) -1) 
 
in which I is the tracer infusion rate, Etr the enrichment of the tracer in the infusate, and E1 
and E4 are the plasma plateau enrichments of [m + 1]methionine and [m + 4]methionine, 
respectively. 
    As the rate of appearance equals the rate of disappearance, it follows for Qm: 
 
        Qm = appearance = D + B + RM = disappearance = S + TM 
 
and for Qc : 
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        Qc = appearance = D + B = disappearance = S + TS 
 
in which D is methionine intake via the diet (which is zero during the infusion), B is 
methionine release from protein breakdown, RM is homocysteine remethylation, S is 
methionine incorporation in protein synthesis, TM is methionine transmethylation and TS is 
homocysteine transsulfuration. It follows that: 
 
RM = Qm - Qc. 
 
    Transsulfuration rate is calculated from 13CO2 excretion in breath air as follows: 
 
TS = V13CO2*(1/[13C]methionine enrichment in plasma - 1/ 
         [13C]methionine enrichment in tracer infusate). 
 
    As methionine is the only precursor of homocysteine, homocysteine disappearance (RM + 
TS) equals homocysteine appearance (TM); thus: 
 
TM = RM + TS. 
 
    The flux rates for transmethylation, remethylation, and transsulfuration were expressed in 
µmol/kg fat-free mass/hour. Metabolic homocysteine clearance was calculated with the 
formula: TS/plasma homocysteine level, and expressed in L/kg fat-free mass/hour. 
 
Statistical methods 
    Values are expressed as mean ± standard deviation (SD) or as median with range if data 
were skewed. Differences between mean values before and after treatment within groups were 
tested with the paired t test. For comparisons between groups, the independent t test was used. 





    All individuals completed the study protocol. 
    Baseline plasma homocysteine level was significantly elevated in the dialysis patients. 
Before treatment, remethylation, transmethylation and transsulfuration rates were not 
significantly different between ESRD and control individuals, whereas metabolic 
homocysteine clearance was significantly lower in ESRD patients (0.09 ± 0.05 vs. 0.41 ± 0.14 
L/kg FFM/hour) (P < 0.01).  
    After treatment, plasma folate concentration increased in all participants. Plasma 
homocysteine concentration decreased by 48% (95% CI 8 to 88) in the dialysis patients and 
by 20% (95% CI –1 to +40) in the control group (Table 2). After folic acid treatment, plasma 
homocysteine concentration was still significantly higher in the dialysis patients compared to 
the baseline concentration in the control group. In the dialysis patients, there was a significant 
increase in both the remethylation and transmethylation rate (Table 2). Remethylation 
increased by 32% (95% CI 5 to 58) and transmethylation by 20% (95% CI 8 to 32). In the 
control group, remethylation and transmethylation increased non-significantly by 35% (95% 
CI –14 to +84) and by 11% (95% CI –3 to +25), respectively. In both groups, transsulfuration 
rate and metabolic homocysteine clearance were not significantly altered by folic acid 
treatment (Table 2). The remethylation and transmethylation rates after folic acid treatment in 
the dialysis patients were similar to the baseline levels in the control individuals (both P = 
0.91) (Figure 2).  
 
Table 2. Plasma homocysteine concentrations, one carbon flux rates, and metabolic homocysteine clearance before and after 
folic acid treatment in six patients with end-stage renal disease (ESRD) and six healthy controls 
 ESRD ___________________________________ 
Control 
____________________________________ 
Characteristic Baseline After folic acid Baseline After folic acid 
Plasma homocysteine µmol/L 38.7 ± 14.8 20.2 ± 4.1* 8.1 ± 1.4 6.5 ± 1.0‡ 
Remethylation µmol/kg fat-free mass/hour 3.9 ± 1.4 5.1 ± 2.1* 5.0 ± 1.7 6.7 ± 1.1 
Transmethylation µmol/kg fat-free mass/hour 6.7 ± 1.7 8.0 ± 1.9† 8.1 ± 1.7 9.0 ± 1.8 
Transsulfuration µmol/kg fat-free mass/hour 2.8 ± 0.7 2.9 ± 1.0 3.2 ± 0.9 2.7 ± 1.1 
Metabolic homocysteine clearance L/kg fat-free mass/hour 0.09 ± 0.05 0.15 ± 0.05 0.41 ± 0.14 0.43 ± 0.18 
Values are mean ± SD. *P < 0.05; †P < 0.01; and ‡P = 0.055 compared to baseline. 
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Figure 2. Individual changes in remethylation and transmethylation rate in end-stage renal disease (ESRD) patients 





    The main findings of this study are that oral treatment with folic acid in ESRD patients (1) 
lowers, but does not normalize plasma homocysteine concentration, (2) increases whole body 
homocysteine remethylation and methionine transmethylation rate to normal values, and (3) 
































































































    At first glance, one would expect that the net effect of an increase in both remethylation 
and transmethylation is an unchanged plasma homocysteine level, as the increase in 
homocysteine removal by remethylation is offset by a similar increase in homocysteine 
production through transmethylation of methionine. This would leave the decrease in plasma 
homocysteine unexplained. One possible explanation is that transmethylation is not directly 
determined in the stable isotope model we used, but calculated as the sum of remethylation 
and transsulfuration. In steady state, any change in remethylation would be paralleled by the 
same change in transmethylation if transsulfuration is unchanged, as in our study. One 
important condition that must be met before this calculation can be applied is the presence of 
a steady state. From earlier studies, we have established that, after 2 weeks of folic acid 
treatment in hemodialysis patients, plasma homocysteine levels are stable [19]. Because the 
participants were prescribed a fixed dietary protein (methionine) intake, steady-state 
conditions were likely to be present in our study. However, it is possible that in the initial 
phase of the folic acid treatment, some of the homocysteine remethylates to methionine 
without increasing transmethylation (possibly by intracellular storage and/or insertion in 
proteins). After reaching saturation of this process, plasma homocysteine does not decrease 
further, because increased remethylation is now balanced by an increase in transmethylation. 
    Another explanation may be that folic acid not only stimulates remethylation, but also 
improves the metabolic homocysteine clearance. An improved metabolic homocysteine 
clearance would allow the daily methionine disposal by transsulfuration to take place at a 
lower plasma homocysteine concentration. In our study, there was an increase in metabolic 
homocysteine clearance which, however, was not significant, but this could have been due to 
a type 2 error. Folic acid is not known to have a direct effect on transsulfuration from single 
enzyme kinetics, but the increase in remethylation could increase levels of methionine and its 
adenosylated product S-adenosylmethionine. S-adenosylmethionine is a stimulator of β-
cystathionine synthase, the rate limiting enzyme of transsulfuration [20].  
    Our findings may help to explain the cause of hyperhomocysteinemia in ESRD patients. 
From our pilot study, we have suggested a major role of impaired homocysteine 
remethylation in the development of hyperhomocysteinemia in chronic renal failure [5]. 
Although in the present study, baseline remethylation and transmethylation rates in the 
dialysis patients were not significantly different from controls (possibly a type 2 error), we 
have demonstrated differences in remethylation rates in a larger study [8]. The present study 
shows that the remethylation rates in dialysis patients on 5 mg folic acid per day are virtually 
the same as in comparable healthy subjects not on folic acid, whereas plasma homocysteine 
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levels are still elevated. Therefore, hyperhomocysteinemia in ESRD patients can only be 
partially explained by a decreased total body remethylation. An other factor that may play a 
role is the metabolic homocysteine clearance, which is decreased by ~80% in ESRD [8]. For 
normalization of plasma homocysteine, restoration of homocysteine clearance (by 
transsulfuration) seems to be required. Stimulation of the transsulfuration in ESRD patients 
with vitamin B6 has been disappointing as it did not result in a significant decrease of fasting 
plasma homocysteine [21]. Vitamin B6 seems to have some effect on plasma homocysteine in 
renal patients only when the transsulfuration pathway is further stressed by methionine 
loading [22]. Interestingly, we have shown earlier that folic acid is also capable of lowering 
plasma homocysteine after methionine loading [23] and in the present study, we observed an 
increase, although not significant, in homocysteine clearance. Together, these observations 
suggest that folic acid may have a direct or indirect effect on homocysteine transsulfuration; 
nevertheless, such an effect, even if it exists, is clearly insufficient to normalize plasma 
homocysteine. Methods that further improve homocysteine clearance by transsulfuration (or 
by increased extraction during dialysis) are probably necessary to normalize plasma 
homocysteine in ESRD patients. 
    Folic acid treatment in ESRD patients was paralleled by an increase in methionine 
transmethylation in our study. Transmethylation of methionine provides methyl groups to the 
majority of methyl group acceptors in the body, such as DNA. Recently, Ingrosso et al. [24] 
have shown that DNA in leukocytes of ESRD patients is hypomethylated and that this could 
be restored by folate treatment. The authors suggested that this effect is mediated by an 
improved transmethylation. The present study shows that folic acid is indeed capable of 
increasing transmethylation flux in dialysis patients. We conclude that folic acid treatment in 
ESRD patients results in an increase of homocysteine remethylation and methionine 
transmethylation rate to normal levels and an unaltered transsulfuration rate. These changes in 
fluxes are accompanied by a lower, but still elevated plasma homocysteine concentration. 
Studies aimed at amelioration of hyperhomocysteinemia in ESRD by stimulation of 
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    Folic acid treatment decreases plasma total homocysteine concentration in healthy subjects, 
but the effects on homocysteine metabolism are unknown. In the present study, we 
investigated the effect of 3 weeks of oral treatment with 5 mg folic acid on one-carbon flux 
rates in 12 healthy subjects, using in vivo stable isotope methods. In addition, we determined 
the effect of folic acid on blood concentrations of amino acids which may have regulatory 
roles in homocysteine metabolism, i.e. homocysteine, AdoMet (S-adenosylmethionine), 
AdoHcy (S-adenosylhomocysteine), serine and glycine. Primed, continuous infusions with 
[2H3-methyl-1-13C]methionine were used to determine flux rates of methionine 
transmethylation, homocysteine remethylation and homocysteine transsulphuration. 
Metabolic homocysteine clearance was defined as the ratio of transsulphuration and plasma 
homocysteine level. Folic acid treatment increased homocysteine remethylation rate by 59% 
[95% CI (confidence interval) 13 to 97, P = 0.02] and methionine transmethylation rate by 
20%  (95% CI 3 to 41,  P = 0.03).   Plasma total homocysteine concentration  (–18%;  95% CI  
–28 to –9, P < 0.01) and serine/glycine ratio (–20%; 95% CI –63 to –6, P < 0.01) decreased 
significantly, and AdoMet/AdoHcy ratio (11%; 95% CI 1 to 20, P = 0.02) increased 
significantly. Changes in one-carbon flux rates did not correlate significantly with changes in 
plasma concentration of these amino acids. In conclusion, folic acid treatment lowered plasma 
homocysteine concentration and increased whole-body remethylation and transmethylation 
flux in healthy subjects. 
 







    Homocysteinaemia is a continuous independent risk factor for cardiovascular disease [1]. 
Blood concentrations of folate and pyridoxine (vitamin B6) and of cobalamin (vitamin B12) 
are determinants of homocysteinaemia, even in the normal range of the plasma homocysteine 
concentrations [2,3]. In turn, the nutritional status for folate and pyridoxine (vitamin B6) is 
inversely associated with the risk of coronary heart disease [4,5]  
    Homocysteine metabolism is complex (Figure 1), with a central role for folate, a compound 
name for a range of biochemical forms of this B-vitamin. Conceivably, the steady-state 
plasma homocysteine concentration is only partly determined by the rate of homocysteine 
remethylation. Rather, remethylation, transmethylation and transsulphuration act in concert on 
homocysteine homeostasis. Remethylation, transmethylation and transsulphuration have been 
thought to be regulated by the concentrations of the B vitamins involved and the (genetically 
determined) activity of specific enzymes, but also by the concentration of intermediate 
metabolites in homocysteine metabolism. For example, single enzyme kinetic studies have 
provided evidence that AdoMet (S-adenosylmethionine) stimulates homocysteine 
transsulphuration by activating cystathionine β-synthase and inhibits methionine 
remethylation by inhibiting methylenetetrahydrofolate reductase [7]. In contrast, AdoHcy (S-
adenosylhomocysteine) stimulates both homocysteine transsulphuration and remethylation by 
activating cystathionine ß-synthase and methionine synthase [7]. The ratio of AdoMet to 
AdoHcy determines the activity of the methyltransferases involved in methionine 
transmethylation [7]. 
    Folic acid (pteroylglutamic acid) has been the cornerstone of most homocysteine-lowering 
regimens [8], and has been shown to lower plasma homocysteine even in healthy, folate-
replete, normohomocysteinaemic subjects [9]. However, its homocysteine-lowering 
mechanism is not entirely clear. By conversion into 5-methyltetrahydrofolate, folic acid is 
thought to stimulate remethylation. However, it is unknown how exactly the homocysteine-
lowering effect of folic acid is quantitatively related to folic-acid-induced changes in whole-
body remethylation. It is arguable that this may not be a simple linear relationship, because 
plasma total homocysteine concentrations are an indirect reflection of actual homocysteine 
concentrations in a wide array of different intracellular compartments. In addition, increased 
intracellular AdoMet concentrations, in response to folic-acid-stimulated remethylation, may 
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Figure. 1. An overview of homocysteine metabolism. A concise overview of homocysteine metabolism, with open arrows 
indicating metabolic fluxes, ovals indicating enzymes and italics indicating vitamins. Homocysteine is the transmethylation 
(TM) product of the essential sulphur-containing amino acid methionine, with AdoMet and AdoHcy as intermediates. 
Homocysteine can be either remethylated to methionine or degraded by transsulphuration (TS). In the folate-dependent 
remethylation reaction, which is catalysed by methionine synthase (MS) and uses vitamin B12 as a cofactor, 5-
methyltetrahydrofolate (5-MTHF) donates a methyl group to homocysteine. Subsequently, tetrahydrofolate (THF) receives a 
methylene group from the serine/glycine couple, a reaction that uses vitamin B6 as a co-factor. Tetrahydrofolate can also be 
generated by reduction of supplemented synthetic folic acid to dihydrofolate (DHF) and subsequently to THF. Next, 5,10-
methylenetetrahydrofolate (5,10-MeTHF) is reduced to 5-MTHF, requiring the enzyme methylenetetrahydrofolate reductase 
(MTHFR). Another folate-independent remethylation reaction, which is quantitatively unimportant in humans in 
physiological conditions [6], uses betaine as a methyl group donor, generating dimethylglycine (DMG). In the irreversible, 
catabolic (transsulphuration) pathway, the rate-limiting reaction is catalysed by cystathionine β-synthase (CBS) and requires 
the active form of vitamin B6 as a cofactor. 
 
    The aim of the present study was to quantify folic-acid-induced changes in whole-body 
one-carbon flux rates in healthy subjects, using stable isotope methods [11,12]. In addition, 
we determined the effect of folic acid on plasma concentrations of homocysteine, AdoMet, 
AdoHcy, serine and glycine, which may have regulatory roles in homocysteine metabolism. 








    Twelve healthy adults (five active smokers) were studied. Baseline characteristics are given 
in Table 1. Subjects who used vitamin supplements or drank more than two units of alcohol a 
day were not included. None of the participants used any medication. 
 
Table 1. Baseline characteristics 
Sex (male/female) 6/6 
Age (years) 29 (19–64) 
Body mass index (kg/m2) 22 (19–30) 
Body weight (kg) 65 (57–108) 
Fat-free mass (kg) 52 (40–90) 
Serum creatinine (µmol/l) 89 (62–105) 
Genotype  
    5,10-Methylenetetrahydrofolate reductase 8 CC, 4 CT and 0 TT 
    Cystathionine β-synthase 9 -/-, 3 -/+ and 0 +/+ 
    Methionine synthase 10 AA, 1 AG and 1 GG 
Values of continuous variables are presented as medians (range). CC denotes wild-type; CT, heterozygous for C677T; TT, 
homozygous for C677T; -/-, wild-type; -/+, heterozygous for 844ins68; +/+, homozygous for 844ins68; AA, wild-type; AG, 
heterozygous for A2756G; GG, homozygous for A2756G. 
 
    The study protocol was approved by the Ethics Committee of the VU University Medical 
Center, and all participants gave their written informed consent. 
 
Experimental protocol 
    Subjects were instructed to use oral supplements of folic acid for 21 days (one tablet 
containing 5mg of folic acid daily at 18:00 hours). Stable isotope infusion was performed at 
baseline and after 3 weeks of folic acid treatment, where the last folic acid tablet was taken 
the day before the second measurement. The study protocol concerning the stable isotope 
infusion has been described in detail elsewhere [11]. Briefly, the participants were kept on a 
stable protein diet of 1.0 g · kg–1 of body weight · day–1 for 3 days prior to the experiment. All 
subjects remained fasting and recumbent during the test. At 08:00 hours, two intravenous 
catheters were placed in a dorsal hand vein, one for infusion of substances and one, in the 
contralateral hand, for sampling. Arterialized blood samples were drawn from the dorsal hand 
vein after the hand was inserted in a heated box [13]. Blood was collected in heparinized glass 
tubes, immediately placed on ice and centrifuged for 10 min at 1000 g at –4ºC within 15 min. 
Plasma was stored at –30ºC until analysed. Samples of end-tidal expired breath air were 
collected in a 15 ml Venoject® tube by instructing the subjects to exhale through a straw. 
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During the last 3 s of expiration, the straw was withdrawn from the tube, which was 
immediately closed by the investigator. After baseline samples were taken, a priming bolus of 
5.9 µmol NaH13CO3 (99% [13C]; ARC Laboratories, Apeldoorn, The Netherlands) was 
administered, followed by a primed (3.5 µmol/kg of body weight) constant infusion of 
L-[2H3-methyl-1-13C]methionine (95% doubly labeled; 99% [1-13C]; 99% [2H1]; Isotec, 
Miamisburg, OH, U.S.A.) at a rate of 2.2 µmol kg–1 of body weight hr–1 for 5 h. Plateau-
enrichment concentrations were calculated as the mean of the final five 20-min interval 
samples of the infusion period. Body weight was measured on a balance scale (accuracy 50 
g), and four skinfolds were measured using a calliper (Holtain; accuracy 0.1 mm). FFM (fat-




    Plasma total (free plus protein bound) homocysteine was measured with the use of a 
microparticle enzyme immunoassay method based on fluorescence polarization (IMX 
analyser; Abbott, Chicago, IL, U.S.A.). Intra- and inter-assay CVs (coefficients of variation) 
were 2.1 and 5.1% respectively. Serine (inter-assay CV, 3%) and glycine (inter-assay CV, 
3%) analyses were performed by HPLC after precolumn derivatization with 
orthophtalaldehyde. AdoMet and AdoHcy were measured in plasma and whole blood using 
stable-isotope dilution tandem MS [15]. The intra-assay CVs for AdoMet and AdoHcy were 
4.2 and 4.0% respectively, and the inter-assay CVs for AdoMet and AdoHcy were 7.6 and 
5.9% respectively. Serum creatinine was measured by means of modified Jaffé method. 
Serum folate (intra- and inter-assay CVs, 4 and 5% respectively) and vitamin B12 (intra- and 
inter-assay CVs, 4 and 5% respectively) were measured by radioassay (ICN, Costa Mesa, CA, 
U.S.A.), and serum vitamin B6 (inter-assay CV 7%) with the use of fluorescence HPLC [16]. 
The methionine concentration in the infusate was measured with an amino acid analyser 
equipped with a high-pressure analytical column packed with Ultrapac 8 resin (Pharmacia 
Biotech, Cambridge, U.K.). Isotopic enrichments of methionine in plasma was measured in 
the acetyl-3,5-bis(trifluoromethyl)benzyl derivative with the use of GC-MS, as previously 
described [17]. Enrichments, expressed in MPE (mole percent enrichment), were calculated 
on the basis of the abundance relative of the (m + 0), (m + 1) and (m + 4) methionine species 
[18], and calibration curves obtained from weighed amounts of tracer (m + 1 and m + 4) and 
tracee methionine were used to correct for minor instrument variation [17]. The 
[13C]-enrichment of CO2 in breath samples was measured on a dual-inlet isotope ratio mass 





spectrometer (VG OPTIMA; Fisons Instruments, Middlewich, Cheshire, U.K.) and expressed 
in APE (atom percent excess). 
 
Gene polymorphisms 
    The polymorphisms of 5,10-methylenetetrahydrofolate reductase (C677T transition), 
cystathionine β-synthase (844ins68 variant) and methionine synthase (A2756G transition) 
were assessed in DNA obtained from the buffy coat of EDTA-collected blood as described by 
Tsai et al. [19]. 
  
Calculations 
    L-[2H3-methyl-1-13C]methionine was used as a tracer, according to the method described 
by Storch et al. [18]. This stable isotope has a molecular weight of m + 4 relative to natural 
methionine (m). The 2H3-methyl label is removed from methionine during transmethylation 
and thus [2H3-methyl-1-13C]methionine is converted into [1-13C]homocysteine. Remethylation 
will result in the generation of m + 1 methionine, because the [13C] atom of the carboxyl 
moiety of homocysteine remains intact. In contrast, during transsulphuration, the carboxyl 
moiety of [1-13C]homocysteine loses its [13C] atom. When α-ketobutyrate is oxidised in the 
Krebs cycle, the label ultimately appears as 13CO2 in breath air. The m + 4 methionine tracer 
is diluted by methionine entering the pool via the diet, from homocysteine folate-dependent 
remethylation and by free methionine entering from protein breakdown in the tissues. In the 
steady state, the rate of appearance of methionine from these sources equals the rate of 
disappearance (i.e. protein synthesis and transmethylation). In this model, it is assumed that 
the intracellular and intravascular compartments are in rapid and complete isotopic 
equilibrium. 
    From the plasma enrichments of methionine, the whole-body methionine-methyl rate of 
appearance and disappearance (Qm) and methionine-carboxyl rate of appearance and 
disappearance (Qc) are calculated as follows:  
 
       Qm = I x (Etr / E4 - 1) 
   Qc = I x [Etr / (E1 + E4) - 1] 
 
where I is the tracer infusion rate, Etr the enrichment of the tracer in the infusate, and E1 and 
E4 are the plasma plateau enrichments of m + 1 and m + 4 methionine respectively. 




  Qm = appearance = D + B + RM = disappearance = S + TM 
 
and for Qc: 
        Qc   = appearance = D + B = disappearance = S + TS 
where D is methionine intake via the diet (which is zero during the infusion protocol), B is 
methionine release from protein breakdown, RM is homocysteine remethylation, S is 
methionine incorporation in protein synthesis, TM is methionine transmethylation, and TS is 
homocysteine transsulphuration. It follows that: 
 
   RM = Qm - Qc. 
 
The transsulphuration rate is calculated from 13CO2 excretion in breath air as follows: 
 
    TS = V13CO2 x (1/[13C]methionine enrichment in plasma 
          - 1/[13C]methionine enrichment in tracer infusate). 
 
Note that we made the assumption that, in healthy subjects, the transamination pathway is 
negligible [20]. However, if the transamination pathway is significant, 13CO2 from the 
[13C]carboxyl-labelled tracer would arise via AdoMet-independent pathways, leading to 
overestimation of transsulphuration and transmethylation in our model. Nevertheless, the 
estimate of total methionine oxidation would not be affected. 
    As methionine is the only precursor of homocysteine, homocysteine disappearance (RM + 
TS) equals homocysteine appearance (TM), thus TM = RM + TS. 
    The flux rates for remethylation, transmethylation and transsulphuration were expressed as 
µmol · h–1 · kg–1 body weight and µmol · h–1 · kg–1 of FFM. Because the metabolic 
homocysteine clearance by transsulphuration reflects homocysteine disposal capacity in the 
steady state [21], we also calculated homocysteine clearance by transsulphuration with the 
formula: [TS (as expressed per kg of FFM) x FFM]/total plasma homocysteine. 
 
Statistical methods 
    Data were analysed using SPSS version 11.5.0 (SPSS Inc, Chicago, IL, U.S.A.). CIs 
(confidence intervals) were calculated by CIA version 2.0.0 (Medical Statistics Computing, 
Southampton, U.K.). The plateau isotopic-enrichment levels were analysed by visual 





inspection and ANOVA. Values are expressed as medians (range). Differences between 
medians are expressed as relative changes from baseline in percentages with 95% CIs. 
Differences between values before and after treatment were tested with the Wilcoxon signed-
ranks test. Differences between subgroups were tested with the Mann-Whitney test. Pearson’s 
test was used for correlation analyses. For calculation of correlations with flux rates, the flux 






    All 12 subjects completed the study protocol. Plateau plasma methionine and breath air 
13CO2 enrichments were obtained in all individuals. Plateau was reached after 220 min. 
Conditions for MS measurements were similar before and after folic acid treatment (isotopic 
enrichment ranged between 1–2 MPE for [1-13C]methionine and between 5 to 10 MPE for 
[2H3-methyl-1-13C]methionine, and breath air 13CO2 was > 0.002 APE in each subject). 
    The effects of treatment with folic acid on blood concentrations of vitamins and amino 
acids are shown in Table 2. In summary, all subjects showed an increase in the serum folate 
concentration (284%; 95% CI 136 to 629). Compared to baseline, plasma total homocysteine 
decreased by 18% (95% CI –28 to –9%). The ratio of AdoMet and AdoHcy in  plasma  
increased  significantly  by  11%  (95% CI  1 to 20),   which  was not the case in whole blood. 
 
Table 2. Effects of folic acid treatment (5 mg/day) on vitamins and amino acids involved in methionine and homocysteine 
metabolism in 12 healthy subjects 
 At baseline After folic acid P value 
Serum folate (nmol/l) 14.6 (7.3–18.7) 42.0 (14.1–180.0)       < 0.01 
Serum vitamin B6 (nmol/l) 29 (8–58) 24 (12–55)          0.92 
Serum vitamin B12 (pmol/l) 223 (175–332) 215 (168–424)          0.48 
Plasma total homocysteine (µmol/l) 7.4 (5.6–10.6) 6.4 (4.5–8.2)       < 0.01 
Plasma serine (µmol/l) 90 (75–112) 88 (71–120)          0.06 
Plasma glycine (µmol/l) 184 (52–241)  199 (74–279)          0.03 
Plasma serine/lycine ratio 0.51 (0.37–1.73) 0.47 (0.32–1.20)       < 0.01 
S-adenosylmethionine 
     In plasma (nmol/l) 








         0.70 
         0.25 
S-adenosylhomocysteine 
     In plasma (nmol/l) 






 53 (39–97) 
 
         0.28 
         0.29 
S-adenosylmethionine/ S-adenosylhomocysteine ratio 
     In plasma 








         0.02 
         0.42 




Changes in plasma and whole-blood concentrations of AdoMet and AdoHcy separately did 
not reach significance. In plasma, glycine increased significantly by 10% (95% CI 2 to 22) 
and serine showed a decrease that did not reach the level of significance (–7%; 95% CI –12 to 
+1). The serine/glycine ratio decreased significantly by 20% (95% CI –63 to –6). 
    After folic acid treatment, there was a significant increase in (for FFM corrected) 
remethylation rate (59%; 95% CI 13 to 97) and transmethylation rate (20%; 95% CI 3 to 41). 
Changes in transsulphuration rate (–9%; 95% CI –27 to +11) and metabolic homocysteine 
clearance by transsulphuration (8%; 95% CI –18 to +35) were not significant (Table 3). There 
were no significant differences in changes in flux rates and homocysteine clearance between 
men and women, and smokers and non-smokers (results not shown). 
 
Table 3. Effects of folic acid treatment (5 mg/day) on one-carbon flux rates of methionine and homocysteine metabolism in 
12 healthy subjects in the postabsorptive state 
 At baseline After folic acid P-value 
Remethylation  
     Expressed in body weight (µmol · kg–1 BW · h–1) 








         0.02 
         0.02 
Transmethylation 
     Expressed in body weight (µmol · kg–1 BW · h–1) 








         0.02 
         0.03 
Transsulphuration 
     Expressed in body weight (µmol · kg–1 BW · h–1) 








         0.27 
         0.24 
Homocysteine clearance by transsulfuration 
     Expressed in body weight (l · kg–1 of BW · h–1) 








         0.48 
         0.58 
Methionine methyl flux 
     Expressed in body weight (µmol · kg–1 BW · h–1) 








         0.64 
         0.64 
Methionine carboxyl flux 
     Expressed in body weight (µmol · kg–1 BW · h–1) 








       < 0.01 
       < 0.01 
Values are presented as medians (range). BW denotes body weight; FFM, fat-free mass. P values were determined using the 
Wilcoxon signed-ranks test. 
 
    Figure 2 shows the effect of folic acid supplementation on remethylation and 
transmethylation rates of subjects. The two subjects with the highest baseline remethylation 
rates showed decreases in both remethylation rate as well as transmethylation rate, yet 
exhibited a decrease in plasma total homocysteine. These two subjects were homozygous 
wild-type for the C677T transition of the methylenetetrahydrofolate reductase gene, the 
844ins68 variant of the cystathionine β-synthase gene, as well as the A2756G transition of the 
methionine synthase gene,  and  had  baseline  concentrations  of folate and increases of folate 
concentrations that were comparable with the concentrations in the other ten subjects (results 
not shown). 






Figure 2. Individual changes in remethylation and transmethylation after treatment with folic acid (5 mg/day). 
 
    Changes in remethylation rate did not correlate significantly with changes in plasma total 
homocysteine concentration (r = –0.38; 95% CI –0.74 to +0.14, P = 0.22). No significant 
correlations  could  be  demonstrated  between  changes  in any  of the  one-carbon fluxes  and 
changes in blood concentrations of total homocysteine, AdoMet, AdoHcy, serine, glycine, or 





    The results of the present study show that, in healthy subjects, treatment with folic acid 
increased rates of whole-body homocysteine remethylation and methionine transmethylation, 
and decreased plasma total homocysteine concentration. Folic acid supplementation did not 
significantly change homocysteine transsulphuration or metabolic homocysteine clearance. In 
addition, the present study shows that folic acid increased the plasma AdoMet/AdoHcy ratio 
and decreased the serine/glycine ratio. 
    The 18% decrease in plasma homocysteine concentration after folic acid treatment was 



























































Homocysteine Lowering Trialists’ Collaboration in the subgroup of patients with baseline 
plasma homocysteine concentrations < 8.9 µmol/l [8]. 
    We did not find a significant relationship between changes of plasma homocysteine 
concentration and remethylation rate. Moreover, two subjects demonstrated a decrease in the 
plasma homocysteine concentration as well as in the remethylation rate. In one subject, this 
might be explained by the simultaneous increase of homocysteine clearance, which might 
have accounted for the decrease in plasma homocysteine concentration. In the other subject, a 
statistical, rather than a biological, explanation for the combined decrease in remethylation 
rate and plasma homocysteine concentration seems more likely (regression to the mean). In 
this regard, it should be stressed that our study was not designed (and thus not powered) to 
examine relationships between the one-carbon fluxes and plasma concentrations of the 
various compounds, but rather to examine their mean changes after folic acid 
supplementation. 
    It is possible that in the initial phase of folic acid treatment, an increase in homocysteine 
remethylation rate lowered the plasma homocysteine concentration (for example by 
intracellular storage and/or insertion of methionine in proteins). A secondary increase in 
methionine transmethylation rate could balance the increased remethylation rate at a lower 
plasma homocysteine concentration. The transsulphuration rate was unchanged after folic 
acid treatment. In weight-maintaining adults, the transsulphuration rate reflects oxidation of 
methionine from dietary intake, because methionine is the only precursor of homocysteine, 
and transsulphuration is the only way of homocysteine disposal (methionine transamination is 
negligible in normal subjects [20]). In the design of our present study, protein intake was kept 
constant, and it is thus not surprising that transsulphuration rate was not affected by folic acid 
treatment. However, it has to be kept in mind that our results reflect the status of methionine 
and homocysteine metabolism reached after 3 weeks of folic acid treatment, which, inherent 
to the stable isotope model, do not necessarily reflect previous (possibly transient) changes in 
flux rates and metabolite concentrations.  
    Dose-response effects of supplemented folic acid on folate and homocysteine 
concentrations in blood have shown to flatten at intakes of 400 µg/day [22,23], a dose that 
could be reached with food fortification [24]. However, the quantitative effects of folic acid 
supplementation on methyl flux rates are unknown. Therefore, it is not clear whether a similar 
threshold exists for changes in methyl flux rates. Thus we applied a high dose of folic acid 
with the intention to stimulate remethylation flux maximally. It is not known whether a lower 
folic acid dose (e.g. 400 µg) induces similar changes in one-carbon fluxes as in our present 





study. Therefore studies on homocysteine metabolism at the internationally recommended 
daily folic acid intake of 200 µg [25,26] to 400 µg [27] are warranted. 
    In our present study, methionine transmethylation was increased by folic acid 
supplementation. An increase in transmethylation may play a crucial role in any beneficial 
effect of folic acid intervention. There are indications that hypomethylation, as reflected by 
DNA methylation status, is important in the pathogenesis of atherosclerosis [28,29]. In 
addition, patients with manifest vascular disease had low plasma AdoMet/AdoHcy ratios in 
conjunction with DNA hypomethylation [30]. Hypomethylation can be reversed by folic acid 
treatment, as was demonstrated in end-stage renal disease patients by Ingrosso et al. [31]. 
However, our study suggests that changes in transmethylation rate may not accurately be 
reflected by changes in plasma homocysteine concentration in healthy subjects. Thus the 
degree of homocysteine concentration reduction may not be a good predictor of clinical 
benefit of folic-acid-based interventions [32]. 
    Folic acid therapy lowered the serine/glycine ratio in the present study. Serine is, by 
conversion into glycine, a major donor of one-carbon units used in the folate-dependent 
remethylation of homocysteine to methionine [33]. The observed decrease in the 
serine/glycine ratio is consistent with the use of serine as a one-carbon donor [6]. Glycine 
itself is needed for several biosynthetic pathways, including creatine, porphyrins, purines, bile 
acids and glutathione [34]. It can be hypothesised that the folic-acid-induced changes in the 
serine/glycine ratio might have affected these biosynthetic pathways, but the exact 
implications of these findings are unknown. 
    Taken together, our data show that oral folic acid administration lowers plasma 
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    Background. Patients with end-stage renal disease (ESRD) as well as those with mild renal 
insufficiency are at increased risk for the development of cardiovascular disease, which 
cannot be attributed entirely to traditional risk factors. Endothelial dysfunction and chronic 
inflammatory activity, two important phenomena in atherogenesis, can be found in ESRD. At 
present, it is unclear whether endothelial dysfunction and chronic inflammatory activity are 
related to renal function in the pre-dialysis stage. 
    Methods. In a cross-sectional, single-centre study, four groups of twenty subjects with renal 
function ranging from a normal, calculated creatinine clearance (> 90 ml/min) to a pre-
dialysis situation (< 31 ml/min) were investigated. We measured markers of endothelial 
function [von Willebrand factor (vWf), soluble intercellular adhesion molecule-1 (sICAM-1), 
soluble vascular-cell adhesion molecule-1 (sVCAM-1), tissue-type plasminogen activator 
(tPA), plasminogen activator inhibitor-1 (PAI-1) and E-selectin (ES)], and markers of 
inflammatory activity [secretory phospholipase A2 (sPLA2) and C-reactive protein (CRP)]. 
Using these markers, composite endothelial function and inflammatory activity scores were 
constructed.  
    Results. Creatinine clearance correlated with the endothelial function score (r = –0.43, P < 
0.001), the inflammatory activity score (r = –0.53, P < 0.05), vWf (r = –0.54, P < 0.001), 
sVCAM-1 (r = –0.50, P < 0.001), sPLA2 (r = –0.28, P < 0.05), homocysteine (r = –0.61, P < 
0.001), age (r = –0.54, P < 0.001) and blood pressure (r = –0.44, P < 0.001). In multivariate 
analyses, creatinine clearance was an independent determinant of the endothelial function 
score (β = –0.34, P < 0.01), plasma vWf (β = –0.37, P < 0.05) and sICAM-1 (β = –0.33, P < 
0.05). The relationship of creatinine clearance with sVCAM-1 and endothelial function score 
was not significant when plasma homocysteine was added to the model. Creatinine clearance 
was also a determinant of the inflammatory activity score (β = –0.31, P = 0.025) and sPLA2 (β 
= –0.32, P < 0.05), although this was no longer significant after correction for systolic blood 
pressure. 
    Conclusions. Renal dysfunction is associated with markers of endothelial dysfunction and 
inflammatory activity. Plasma homocysteine may be an intermediate factor in the relationship 
between endothelial dysfunction and renal function, while blood pressure may modulate the 
association between inflammatory activity and renal function. 




    Patients with end-stage renal disease (ESRD) are at high risk of developing cardiovascular 
disease (CVD), which limits their life expectancy considerably [1]. Prospective studies in 
patients with milder degrees of renal impairment have also shown that a reduced glomerular 
filtration rate (defined as elevated serum creatinine level or reduced creatinine clearance) is 
associated with an increased (cardiovascular) mortality and morbidity [2,3]. This excess risk 
cannot be attributed totally to established cardiovascular risk factors. Therefore, the nature of 
the link between renal function and CVD remains to be explained. 
    On the one hand, renal insufficiency may be part of a generalized (subclinical) 
atherothrombotic process. On the other, it is conceivable that a reduction in renal function 
creates a atherogenic milieu, e.g. by the retention of vasotoxic substances or by metabolic 
changes that may lead to increased oxidative stress or an enhanced (low-grade) inflammatory 
state. Such changes may cause endothelial dysfunction, which is an important first step in 
atherogenesis [4].  
    Endothelial dysfunction, characterized by increased plasma concentrations of endothelium-
derived proteins or reduced endothelium-dependent vasodilatation, has been demonstrated in 
ESRD patients [5]. However, it is unknown whether this is the result of the lost kidney 
function or merely reflects the high prevalence of established vascular disease in ESRD 
patients. In patients with pre-dialysis renal failure, endothelium-dependent vasodilatation is 
also reduced [6]. In addition, some biochemical markers of endothelial dysfunction, such as 
von Willebrand factor (vWf) and soluble vascular cell adhesion molecule-1 (sVCAM-1), may 
be increased [6]. It remains unclear, however, whether renal function per se is related to this 
endothelial dysfunction.  
    Plasma levels of pro-inflammatory response markers, such as C-reactive protein (CRP), 
interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α), are also increased in pre-dialysis 
renal patients [6]. However, the relationship between inflammatory activity and creatinine 
clearance or endothelial function is not well defined in this population. We hypothesised that 
renal insufficiency per se contributes to endothelial dysfunction and inflammatory activity, 
and as such may be causally related to CVD.  
    In view of these considerations, we investigated, in individuals with a wide range of 
creatinine clearance, whether impaired renal function was associated with changes in plasma 




SUBJECTS AND METHODS 
 
Subjects 
    The protocol was approved by the Ethics Committee of the VU University Medical Centre, 
and all patients gave their informed consent. Individuals were recruited from the outpatient 
clinics of the Departments of Nephrology and Internal Medicine of the VU University 
Medical Centre. Exclusion criteria were age younger than 18 years or older than 75 years, 
haemodialysis, peritoneal dialysis, renal transplantation, diabetes mellitus (ADA criteria), 
inflammatory diseases, WHO performance > 2, other severe disease (malignancy or liver 
disease) or use of folic acid, immunosuppressive drugs, penicillamine or anticonvulsant drugs. 
 
Study design 
    Eighty subjects were included in this cross-sectional, single-centre study. Consecutive 
patients were included until four groups of 20 subjects were formed, with a creatinine 
clearance (calculated with the formula of Cockcroft and Gault as a surrogate marker for the 
glomerular filtration rate) of ≥ 91 ml/min, 61 to 90 ml/min, 31 to 60 ml/min and < 31 ml/min. 
This was performed to ensure a balanced representation throughout the whole spectrum of 
renal function. After correcting the creatinine clearance for body surface area, the group was 
divided into quartiles. The first quartile (with the highest creatinine clearance) served as the 
control group. In 65 (81%) of the 80 individuals, a renal disease was diagnosed: hypertensive 
nephrosclerosis in 20, polycystic kidney disease in 15, primary glomerular disease in 14, 
urolithiasis in four, vasculitis in four, chronic pyelonephritis in two, Alport syndrome in two 
and other renal diseases in four. Most of the 15 (19%) patients without renal disease were 
evaluated for chronic fatigue or treated for thyroidal illness. Of these 15 patients without renal 
disease, 10 were included in the control group and five in the group with a creatinine 
clearance between 61 and 90 ml/min. For each patient, data were collected with regard to age, 
cardiovascular medication (antihypertensive medication, platelet aggregation inhibitors and 
lipid-lowering drugs), smoking status (having smoked in the past year), presence of CVD 
(history of myocardial infarction, angina pectoris, stroke or peripheral arterial occlusive 
disease), body mass index, and systolic and diastolic blood pressure (the mean of three 
measurements during one visit, performed with a mercury sphygmomanometer at the left arm, 
with the individual seated). The presence of hypertension was defined as a blood pressure > 
140 mmHg, > 90 mmHg and/or use of antihypertensive medication. Hypercholesterolaemia 
was defined as a serum total cholesterol level > 6.5 mmol/l and/or the use of lipid-lowering 
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medication. Blood samples were taken in the fasting state. Plasma was separated and frozen 
immediately at –20oC for homocysteine and at –70oC for markers of endothelial function and 
inflammation, until analysis. 
 
Measurement of markers of endothelial function and inflammatory activity 
    We determined vWf, soluble intercellular adhesion molecule-1 (sICAM-1), sVCAM-1, 
soluble E-selectin (ES), tissue-type plasminogen activator (tPA) and plasminogen activator 
inhibitor-1 (PAI-1) as markers of endothelial function. Plasma vWf antigen was measured by 
an enzyme-linked immunosorbent assay (ELISA), with rabbit anti-vWf antigen as a capturing 
antibody and a peroxidase-conjugated rabbit anti-vWf antigen as a detecting antibody (Dako, 
Copenhagen, Denmark). The concentration of vWf was expressed as a percentage of the 
antigen concentration in normal pooled plasma, which is defined as 100%. The intra- and 
interassay variations were 2.3 and 3.8%, respectively. sICAM-1 and sVCAM-1 were assayed 
by ELISA methods (Diaclone, Besancon, France) with intra- and interassay coefficients of 
variation of 4.0 and 8.6% for sICAM-1 and 4.0 and 8.6% for sVCAM-1, respectively. 
Commercially available ELISA kits were used for the measurement of ES (R&D Systems, 
Minneapolis, MN), tPA antigen (Imulyse tPA, Biopool, Umeå, Sweden), and PAI-1 (Innotest 
PAI-1, Innogenetics, Zwijndrecht, Belgium). 
    Plasma concentrations of CRP and secretory phospholipase A2 (sPLA2) were measured as 
markers of inflammatory activity. CRP was measured with a highly sensitive in-house 
ELISA, with rabbit anti-CRP (Dako, Copenhagen, Denmark) as a capturing and tagging 
antibody, with intra- and interassay coefficients of variation of 3.8 and 4.7%, respectively. 
Antigen concentration of sPLA2 were measured with an ELISA with two different 
monoclonal antibodies against human sPLA2 (Oklahoma Medical Research Foundation, 
Oklahoma City, OK), which were used as coating and capturing antibodies, respectively. All 
markers were measured in duplicate. 
 
Other measurements 
    Plasma total (free plus protein-bound) homocysteine (tHcy) was measured by HPLC with 
fluorescence detection. Intra- and interassay coefficients of variation were 2.1 and 5.1% 
respectively. Plasma total cholesterol and serum creatinine were measured with standard 
laboratory methods, as were urinary levels of creatinine and protein. Serum folate and vitamin 





    Variables were tested for normality and log-transformed if necessary. ANOVA was used to 
test differences between groups. When significant differences were found, pairwise 
comparisons were made using the Student’s t-test. Pearson’s test was used to assess 
correlation coefficients. Multiple linear regression analysis was performed to investigate the 
relationship between all markers of endothelial function and inflammatory activity as 
dependent factors, and creatinine clearance and other factors (tHcy, plasma total cholesterol 
and blood pressure) as independent variables, with forced entry of age, gender, smoking and 
prior CVD. 
    To explore further the association between creatinine clearance and endothelial function 
and inflammatory activity, we created mean SD scores for markers of endothelial function and 
inflammatory activity. This approach was used to reduce the influences of biological 
variability of separate measurements, and to reduce the number of associations to be 
investigated, as has been described by O’Brien [7]. The method has been used before by our 
group for evaluating markers of endothelial dysfunction, but has not been validated because 
of the lack of a gold standard for endothelial dysfunction [8]. For every individual, each 
variable was expressed as the SD of the difference from the population mean. The mean 
scores were calculated as the mean of these SDs. The endothelial function score was 
calculated as (vWf + sVCAM-1 + sICAM-1 + ES + PAI-1 + tPA)/6, and the inflammatory 
activity score as (CRP + sPLA2)/2. Because sICAM-1 probably is a marker not only of 
endothelial function but also of inflammatory activity, we recalculated the inflammatory 
activity score also after addition of sICAM-1. Thus, high scores reflect high levels of 
endothelial dysfunction and inflammatory activity, respectively. A P value < 0.05 was 





    Table 1 shows baseline characteristics of the participants. There were no significant 
differences with regard to gender, body mass index, presence of hypercholesterolaemia, prior 
CVD, serum cholesterol, vitamin B12 and folic acid, and use of acetylsalicylic acid or a statin, 
among the four groups. Patients in the control group had a significantly lower mean age, 
blood pressure (both systolic and diastolic), plasma level of homocysteine and urinary 
excretion  of  protein  compared  to the  patients  in the  other  three groups.  Otherwise, in the 
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control group, the prevalence of hypertension was significantly lower than that in the other 
three groups, as was the use of angiotensin converting enzyme inhibitors and angiotensin II 
receptor antagonists. The prevalence of active smokers was higher in the control group. In one 
male subject, a very high plasma homocysteine level was found (94.6 µmol/l). This was 
shown to be caused by a vitamin B12 deficiency (serum level 65 pmol/l) due to pernicious 
anaemia. This subject was excluded from the analyses when plasma homocysteine was 
considered as a variable. In all other participants, vitamin B12 status was normal. 
 
Table 1. Baseline characteristics 
Variables Q1 (Control) n = 20 Q2 n = 20 Q3 n = 20 Q4 n = 20 
Creatinine clearance 
(ml/min/1.73 m2) 
100.3 ± 21.7 (83–163) 67.3 ± 8.6 (54–79) 40.0 ± 7.6 (28–52) 16.3 ± 5.4 (8–27) 
Gender 
(male/female) 
8/12 9/11 11/9 12/8 
Age 
(years) 
36.9 ± 8.6 (25–53) 54.3 ± 8.7 (40–66)* 49.5 ± 12.5 (23–68)* 55.1 ± 12.2 (31–73)* 
Body mass index 
(kg/m2) 
25.1 ± 3.4 (20.2–31.5) 26.3 ± 3.1 (21.7–32.6) 24.6 ± 3.9 (18.4–35.9) 24.0 ± 3.8 (18.4–33.2)† 
Systolic blood pressure 
(mmHg) 
120.6 ± 13.1 (102–149) 133.8 ± 17.3 (114–171)* 131.8 ± 19.6 (97–177)* 137.7 ± 10.9 (113–161)* 
Diastolic blood pressure 
(mmHg) 
69.3 ± 9.3 (58–93) 78.5 ± 8.0 (69-95)* 78.0 ± 9.5 (54–97)* 81.5 ± 6.9 (71–100)* 
Hypertension 
(Yes/No) 
5/15 15/5* 19/1* 20/0*† 
ACEI or AII antagonist 
(Yes/No) 
4/16 6/14 13/7*† 10/10* 
Proteinuria 
(g/day) 
0.096 (0.050–6.996) 0.145 (0.050–0.706) 0.825 (0.056–4.578)*† 1.337 (0.149–6.672)*† 
Smoker 
(Yes/No) 
14/6 7/13* 5/15* 6/14* 
Serum folate 
(nmol/l) 
13.3 (3.8–40.4) 16.8 (5.5–53.8) 12.4 (6.5–48.1) 13.5 (9.1–20.4) 
Serum vitamin B12 
(pmol/l) 
309 (176–531) 286 (65–1009) 274 (140–395) 215 (140–611) 
Plasma total homocysteine 
(µmol/l) 
8.2 (5.3–17.0) 8.9 (5.3–94.6) 20.6 (6.8–66.4)*† 23.1 (13.7–32.2)*† 
Plasma total cholesterol 
(mmol/l) 
5.2 ± 1.4 (2.9–7.7) 5.4 ± 0.7 (4.0–6.7) 5.8 ± 1.6 (3.7–9.8) 5.5 ± 1.2 (2.0–6.7) 
Hypercholesterolaemia 
(Yes/No) 
3/17 4/16 10/10*† 7/13 
Statin 
(Yes/No) 
0/20 4/16* 4/16* 5/15* 
Prior cardiovascular disease 
(Yes/No) 
1/19 5/15 3/17 5/15 
Acetylsalicylic acid 
(Yes/No) 
1/19 4/16 4/16 2/18 
Values are presented as mean ± SD (range) or median (range) for variables with a skewed distribution. Q, quartile; ACEI, 
angiotensin-converting enzyme inhibitor; AII antagonist, angiotensin II receptor antagonist. *P < 0.05 compared with Q 1; †P 
< 0.05 compared with Q 2. 
 




Table 2. Biochemical markers of endothelial function and inflammatory activity 
Variables Q1 (Control) n = 20 Q2 n = 20 Q3 n = 20 Q4 n = 20 
vWf 
(%) 
91 (42–232] 111 (57–250)* 159 (90–390)*† 173 (94–298)*† 
sICAM-1 
(ng/ml) 
470 (225–1281] 562 (202–913) 539 (394–1088) 658 (358–1302) 
sVCAM-1 
(ng/ml) 
1126 ± 338 (613–1983) 1080 ± 249 (673–1516) 1556 ± 444 (754–2376)*† 1796 ± 594 (1164–3469)*†
sES 
(ng/ml) 
45 ± 21 (10–96) 48 ± 26 (20–129) 49 ± 28 (19–144) 80 ± 109 (11–516) 
PAI-1 
(ng/ml) 
22 (6–224) 48 (7–196)* 29 (4–82)† 42 (3–124) 
tPA 
(ng/ml) 
9.2 ± 4.5 (4.0–22.2) 12.4 ± 3.8 (4.8–18.0)* 9.5 ± 5.4 (2.2–22.6) 10.4 ± 4.6 (3.8–17.9) 
CRP 
(mg/l) 
1.7 ± 2.5 (0.1–10.4) 2.3 ± 1.5 (0.3–10.4) 4.5 ± 11.1 (0.6–51.0) 5.0 ± 4.1 (0.3–14.4)*† 
sPLA2 
(µg/l) 
1.1 ± 3.9 (0.0–16.5) 1.9 ± 4.4 (0.0–16.4) 3.2 ± 9.5 (0.0–41.8) 6.7 ± 7.1 (0.0–23.7)*† 
Values are presented as mean ± SD (range) or median (range) for variables with a skewed distribution. Q, quartile. *P < 0.05 
compared with Q1; †P < 0.05 compared with Q2. 
 
    Table 3 shows the correlations of creatinine clearance with markers of endothelial function, 
inflammatory activity and conventional risk factors for CVD. 
 
Table 3. Relation of creatinine clearance with markers of endothelial function and inflammatory activity, and conventional 
risk factors for cardiovascular disease 
 Creatinine clearance (ml/min/1.73 m2)  
Continuous variables Correlation coefficient P value 
Endothelial function score –0.43  < 0.001 
Inflammatory activity score –0.25  < 0.05 
vWf* –0.54  < 0.001 
sICAM-1* –0.21      0.06 
sVCAM-1 –0.50  < 0.001 
ES –0.19     0.10 
PAI-1* –0.10     0.40 
tPA –0.06     0.61 
CRP –0.19     0.10 
sPLA2 –0.28  < 0.05 
Age –0.54  < 0.001 
Body mass index   0.15     0.19 
Systolic blood pressure –0.36  < 0.01 
Diastolic blood pressure –0.44  < 0.001 
Proteinuria* –0.54  < 0.001 
Serum folate* –0.08     0.54 
Serum vitamin B12*  0.13     0.34 
Plasma total homocysteine * –0.61  < 0.001 
Plasma total cholesterol –0.19     0.08 
Nominal variables Yes No P value 
Male gender 51.7 ± 34.3 60.3 ± 33.1    0.26 
Hypertension 42.8 ± 24.9 93.1 ± 27.6 < 0.001 
Smoker 69.0 ± 38.9 47.3 ± 27.1 < 0.01 
Hypercholesterolaemia 46.3 ± 26.6 60.4 ± 36.0    0.08 
Prior cardiovascular disease 44.5 ± 27.0 58.4 ± 34.8    0.16 
Values are shown as Pearson correlation coefficients for continuous variables and as mean of the creatinine clearance ± SD 
for nominal variables. *Data logarithmically transformed. 
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    Creatinine clearance was significantly related to the endothelial function score, vWf and 
sVCAM-1 (Figure 1). The relationships between creatinine clearance and the inflammatory 
activity score and sPLA2 are shown in Figure 2. One subject showed very high inflammatory 
markers (CRP 51.0 mg/l and sPLA2 41.8 µg/l) without signs or symptoms of disease. When 
this patient was omitted from the analyses, inflammatory activity score (r = –0.43, P < 0.001), 
CRP (r = –0.35, P < 0.01) and sPLA2 (r = –0.34, P < 0.01) correlated even more strongly with 
creatinine clearance. Plasma tHcy correlated negatively with creatinine clearance (r = –0.61, P 
< 0.001), plasma folate (r = –0.34, P < 0.05), and plasma vitamin B12 (r = –0.24, P = 0.07). 
 
A                B 
Figure 1. Relationship between (A) creatinine clearance and endothelial function score and (B) creatinine clearance and von 
Willebrand factor. 
  
A               B 
Figure 2. Relationship between (A) creatinine clearance and inflammatory activity score and (B) creatinine clearance and 
secretory phospholipase A2. 
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    In the multivariate analysis (with forced entry of gender, age, smoking and prior CVD), 
creatinine clearance was a significant determinant of the endothelial function score [β 
(standardised) = –0.34, P < 0.01). After addition of systolic blood pressure to the model, the 
relationship between creatinine clearance and endothelial function score was somewhat 
attenuated (β = –0.27, P < 0.05). Substituting diastolic or mean blood pressure for systolic 
blood pressure did not materially change any of the results. After addition of plasma tHcy to 
the model, creatinine clearance was no longer a significant determinant of the endothelial 
function score (β = –0.05, P = 0.74). Plasma tHcy was independently associated with the 
endothelial function score (β = 0.28, P < 0.05). The presence of an underlying renal disease 
was not a significant determinant of the endothelial function score (β = 0.10, P = 0.41), nor 
were the separately entered diagnoses hypertensive nephrosclerosis (β = –0.17, P = 0.23), 
polycystic kidney disease (β = –0.03, P = 0.81) and primary glomerular disease (β = 0.19, P = 
0.12). 
    When the individual markers of endothelial function were analysed separately, creatinine 
clearance was a significant determinant of vWf, sICAM-1 and sVCAM-1. Addition of 
systolic blood pressure to the model did not influence these relationships. When plasma tHcy 
was added to the model, creatinine clearance remained a significant determinant of vWf (β = 
–0.37, P < 0.05), but the strength of the associations between creatinine clearance and 
sVCAM-1 (β = –0.44, P < 0.01) and sICAM-1 (β = –0.33, P < 0.05) decreased (β = –0.22, P = 
0.17 and β = –0.31, P = 0.07, respectively). Plasma tHcy was associated independently with 
sVCAM-1 (β = 0.37, P < 0.01). The association between creatinine clearance and vWf 




    Creatinine clearance was an independent determinant of the inflammatory activity score (β 
= –0.31, P < 0.05). However, after adjustment for systolic blood pressure, this association was 
no longer significant (β = –0.19, P = 0.14). Systolic blood pressure was independently 
associated with the inflammatory activity score (β = 0.41, P < 0.001). Addition of sICAM-1 to 
the inflammatory activity score did not materially change the results. The presence of an 
underlying renal disease was not a significant determinant of the inflammatory activity score 
(β = 0.04, P = 0.76), nor were the separately entered diagnoses hypertensive nephrosclerosis 
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(β = 0.20, P = 0.21), polycystic kidney disease (β = 0.00, P = 0.97) and primary glomerular 
disease (β = 0.02, P = 0.87). 
    Multivariate analysis of the individual markers of inflammatory activity showed that 
creatinine clearance was an independent determinant of sPLA2 (β = –0.32, P < 0.05). The 
relationship with CRP was borderline significant (β = –0.25, P = 0.07). After adjustment for 
systolic blood pressure, both these associations were no longer significant (β = 0.18, P = 0.16 
and β = –0.17, P = 0.22, respectively). Systolic blood pressure proved to be an independent 






    In this study, impaired renal function was associated with markers of endothelial 
dysfunction and increased inflammatory activity, as assessed by the scores derived from 
several different biochemical markers. The individual markers which showed the strongest 
associations with renal function were vWf, sVCAM-1, sICAM-1, sPLA2 and CRP. We also 
showed, for the first time, that this effect is linear and is present already in patients with mild 
renal insufficiency. 
    The endothelial function score was no longer significantly associated with renal function 
when plasma tHcy was added as a factor in the multivariate model. The same was true for the 
relationship between sVCAM-1 and renal function, and plasma tHcy affected the association 
between endothelial function score and renal function probably by its relationship with 
sVCAM-1. 
    The relationship between renal function and sVCAM-1 has not been extensively 
investigated. In agreement with others, we found that plasma sVCAM-1 was elevated in 
patients with impaired renal function [6]. Urinary excretion of sVCAM-1 is very low in 
healthy persons and may rise in certain types of renal failure [9]. Decreased excretion of 
sVCAM-1 therefore does not explain the elevated plasma sVCAM-1 in individuals with 
reduced creatinine clearance.  
    The adhesion molecule sVCAM-1 is believed to play a crucial role in the development of 
atherosclerosis [10]. In the Hoorn Study it was shown prospectively that, among subjects with 
type 2 diabetes mellitus, the relative risk of cardiovascular mortality was 1.13 (95% 
confidence interval 1.07 to 1.20) per 100 ng/ml increase in sVCAM-1 [11]. 
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    The relationship between creatinine clearance and sVCAM-1 was abolished when plasma 
tHcy was added into the regression model. It is well known that plasma tHcy increases with 
declining renal function [12]. In our study, plasma tHcy was related independently not only to 
creatinine clearance, but also to plasma sVCAM-1 level. The most likely interpretation of this 
finding is that plasma tHcy is an intermediate in this relationship, i.e. that renal insufficiency 
leads to elevated plasma tHcy levels which, in turn, induce endothelial dysfunction reflected 
by elevated sVCAM-1 levels. This is supported by findings in a murine model, in which diet-
induced hyperhomocysteinaemia resulted in enhanced atherosclerosis with increased 
expression of sVCAM-1 in the arterial wall [13]. In addition, a recent in vitro study showed 
that human aortic endothelial cells exhibited an increase of VCAM-1 expression when 
homocysteine was added to the medium [14]. An alternative interpretation is that 
homocysteine causes both renal insufficiency and endothelial dysfunction (i.e. confounds the 
association between creatinine clearance and sVCAM-1), but there is no firm evidence that 
homocysteine can in fact cause renal insufficiency. 
    The inverse relationship between creatinine clearance and plasma vWf level that we found 
was independent of conventional cardiovascular risk factors and plasma homocysteine. 
Thambyrajah et al. also observed elevated plasma vWf concentrations in 80 subjects with 
non-diabetic chronic renal failure [15]. In that study, however, the relationship between 
plasma vWf and renal function could not be defined accurately, probably as a result of the 
smaller range of creatinine clearance (14 to 54 ml/min). In another, smaller study, plasma 
vWf tended to increase with declining renal function [6]. We found that plasma vWf was 
already increased at an early stage of renal insufficiency (creatinine clearance < 91 ml/min). 
This increase in plasma vWf is probably not caused by diminished renal excretion because, in 
healthy persons, urinary vWf levels are undetectable [16]. Although it is possible that the 
metabolism of vWf is altered in renal insufficiency, we speculate that the rise in plasma vWf 
level is the result of endothelial dysfunction caused by renal insufficiency. The clinical 
importance of high plasma vWf levels is underlined by studies that have shown that plasma 
vWf is a predictor of microalbuminuria, CVD and mortality in both diabetic and non-diabetic 
patients [17]. 
    Creatinine clearance was an independent predictor of the inflammatory activity score, but 
this relationship disappeared when adjusted for systolic blood pressure. The relationship 
between the inflammatory markers sPLA2 and CRP, and blood pressure, however, is unclear. 
In the WOSCOP study, CRP significantly correlated with systolic blood pressure, while 
sPLA2 did not [18]. In that study, the predictive value of CRP for coronary events was 
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attenuated when systolic blood pressure was included in the multivariate model, whereas the 
association between sPLA2 and coronary events was not influenced [18]. The precise 
relationship between inflammatory activity and blood pressure deserves further investigation. 
    Renal function has been implicated as an independent cardiovascular risk factor, especially 
in individuals with essential hypertension, heart failure and coronary artery disease [19]. Our 
study may provide a clue why renal function may act as the “Cinderella of cardiovascular risk 
profile” [19]. Reduced glomerular filtration rate may lead to endothelial dysfunction and 
inflammatory activity, that can be detected by measurement of biochemical markers which 
have been shown to predict CVD. The cross-sectional character of our study does not allow 
any conclusion on the causality of these relationships. Furthermore, the pathophysiological 
mechanism by which reduction of glomerular filtration rate leads to dysfunction of the 
endothelium and to increased inflammatory activity cannot be derived from our data and 
remains to be elucidated. Our study population was heterogeneous concerning the underlying 
renal disorders. However, (the type of) renal disease was not a determinant of the markers of 
endothelial function and inflammatory activity. The high prevalence of hypertension in the 
groups with the lowest creatinine clearance is a common finding, for which we chose not to 
match, but to correct with a multivariate analysis. We found a possible role of homocysteine 
in the rise of sVCAM-1, and of blood pressure in the rise of sPLA2. In addition, retention of 
uraemic toxins, e.g. advanced glycation end-products, or oxidative stress may contribute to 
these processes. This hypothesis could be tested in prospective trials with subjects with mild 
to moderate renal insufficiency using interventions which aim to improve endothelial function 
and lower the inflammatory state. It is of note that homocysteine-lowering treatment with 
folic acid did not result in amelioration of endothelium-dependent vasodilatation or plasma 
vWf in patients with predialysis renal failure [20]. In these studies, the effect of folic acid on 
sVCAM-1, however, was not investigated. 
    The clinical relevance of the present study may be that in individuals with even minor 
reductions of creatinine clearance, an aggressive approach should be adopted to prevent 
further decline of renal function, e.g. by intensive treatment of elevated blood pressure and 
proteinuria. Whether patients with mild renal failure should be treated with specific anti-
inflammatory agents is currently unknown. 
    In summary, this cross-sectional study showed that impaired renal function per se was 
associated with endothelial dysfunction and increased inflammatory activity as assessed by 
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    Background. Patients with end-stage renal disease as well as mild renal impairment have an 
increased risk for the development of cardiovascular disease. It has been suggested that 
advanced glycation end-products (AGEs) are involved in atherogenesis, possibly through 
induction of endothelial dysfunction and low-grade inflammation. 
    Methods. In a cross-sectional, single-centre study, we investigated four groups of twenty 
non-diabetic subjects with a creatinine clearance ranging from normal (> 90 ml/min per 1.73 
m2) to < 31 ml/min per 1.73 m2. We measured AGE-peptides, markers of endothelial 
dysfunction (von Willebrand factor, soluble E-selectin, plasminogen activator inhibitor-1, 
tissue-type plasminogen activator, soluble vascular-cell adhesion molecule-1), and markers of 
inflammatory activity (soluble intercellular adhesion molecule-1, C-reactive protein, secretory 
phospholipase A2). We constructed composite endothelial dysfunction and inflammatory 
activity Z-scores using these markers.  
    Results.  AGE-peptides were independently related to  creatinine clearance  (standardized β 
–0.55; 95% confidence interval (CI) –0.77 to –0.34, P < 0.001). AGE-peptides were not 
independently related to the individual markers of endothelial dysfunction and inflammation, 
nor to the composite endothelial dysfunction Z-score (standardized β 0.08; 95% CI –0.14 to 
+0.30, P = 0.48) or the inflammatory activity Z-score (standardized β –0.05; 95% CI –0.25 to 
+0.16, P = 0.66). 
    Conclusions. Plasma concentrations of AGE-peptides are associated with creatinine 
clearance but not with biochemical markers of endothelial dysfunction and inflammatory 
activity in non-diabetic patients over a wide range of renal function. This suggests that the 
atherogenic effects of AGE-peptides in individuals with renal functional impairment are not 
mediated by endothelial dysfunction or inflammatory activity as estimated by the markers 
used. 




    Patients with chronic kidney disease, end-stage renal disease as well as mild renal 
impairment, have an increased risk for the development of cardiovascular disease. Endothelial 
dysfunction and chronic low-grade inflammation may play a major role in atherogenesis and 
evidence accumulates that atherosclerosis may be an inflammatory disease in which immune 
mechanisms interact with metabolic risk factors [1]. A high blood concentration of advanced 
glycation end-products (AGEs), a heterogeneous group of compounds derived from the non-
enzymatic reaction between glucose or other reducing sugars and proteins, has been suggested 
to be one of these metabolic factors [2]. 
    AGEs may be involved in atherogenesis by interacting with specific receptors for AGE, 
which leads to the production of free oxygen radicals and subsequent release of cytokines [3]. 
In addition, AGEs have been found to accumulate in the vascular matrix where they are 
thought to disturb endothelial permeability and induce vessel-wall thickening [2]. 
Accumulation of AGEs in plasma has been described in diabetic and non-diabetic patients 
with end-stage renal disease [4]. Information about the relationship between creatinine 
clearance and AGEs in non-diabetic individuals with predialysis renal dysfunction is scarce 
and mainly derived from patients after kidney transplantation, where blood concentrations of 
AGEs normalized when normalization of renal function was achieved after kidney 
transplantation [5]. 
    Resistance to complete enzymatic degradation of AGE-modified proteins leads to the 
formation of AGE-peptides. Measurement of AGE-peptides can be easily performed by a 
simple analytical procedure using spectrophotometry and spectrofluoroscopy as first 
described by Wróbel et al. [6]. Age-peptides have been shown to be related to renal function 
in diabetic patients with chronic kidney disease [7] and non-diabetic patients after kidney 
transplantation [5]. 
    In the present study, we investigated the relationship between renal function, as estimated 
by the Cockcroft-Gault creatinine clearance, and AGE-peptides in non-diabetic individuals 
with a wide range of renal function. In addition, we aimed to investigate whether AGE-




SUBJECTS AND METHODS 
 
Subjects 
    The study population has been previously described [8]. Briefly, 80 consecutive patients 
were recruited from the outpatient clinics of the Departments of Nephrology and Internal 
Medicine of the VU University Medical Centre. Exclusion criteria were age under 18 years or 
over 75 years, haemodialysis, peritoneal dialysis, renal transplantation, diabetes mellitus 
(ADA criteria), inflammatory diseases, WHO performance greater than 2, severe other 
disease (malignancy or liver disease) or use of folic acid, immunosuppressive drugs, 
penicillamine or anticonvulsant drugs. Patients were included until four groups of 20 subjects 
were formed with a creatinine clearance (calculated with the formula of Cockcroft and Gault) 
of 91 ml/min or higher, 61 to 90 ml/min, 31 to 60 ml/min and less than 31 ml/min per 1.73 
m2. This was done to assure a balanced representation throughout the whole spectrum of renal 
function. After correcting the creatinine clearance for body surface area, the group was 
divided into quartiles. In 65 (81%) of the 80 subjects a renal disease was diagnosed: 
hypertensive nephrosclerosis in 20, polycystic kidney disease in 15, primary glomerular 
disease in 14, urolithiasis in 4, non-active vasculitis in 4, chronic pyelonephritis in 2, Alport 
syndrome in 2 and other renal diseases in 4. Most of the 15 (19%) patients without renal 
disease were evaluated for chronic fatigue or treated for thyroidal illness. Of these 15 patients 
without renal disease 10 were included in the control group and 5 in the group with a 
creatinine clearance between 61 and 90 ml/min. Of each patient, data were collected with 
regard to age, cardiovascular medication (antihypertensive medication, platelet aggregation 
inhibitors and lipid-lowering drugs), smoking status (having smoked in the past year), 
presence of cardiovascular disease (history of myocardial infarction, angina pectoris, stroke or 
peripheral arterial occlusive disease), body mass index, and systolic and diastolic blood 
pressure (the mean of three measurements during one visit, performed with a mercury 
sphygmanometer at the left arm, with the individual seated). The presence of hypertension 
was defined as a systolic blood pressure > 140mmHg, a diastolic blood pressure > 90 mmHg 
and/or use of antihypertensive medication. Hypercholesterolaemia was defined as a serum 
total cholesterol level > 5.0 mmol/l and/or the use of lipid-lowering medication. Blood 
samples were taken in the fasting state. Plasma was immediately separated and frozen at –20 
oC for homocysteine and at –70 oC for AGEs and markers of endothelial dysfunction and 
inflammation, until analysis. 
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    The protocol was approved by the Ethics Committee of the VU University Medical Centre 
and all patients gave their informed consent. 
 
Measurement of advanced glycation end-product-peptides 
    AGE-peptides were measured with a simple analytical procedure as described by Wróbel et 
al. [6] based on simultaneous detection of low-molecular-mass peptides and AGE-peptides 
with a flow system and two detectors connected on-line: spectrophotometrically for peptides 
(absorption at 280 nm) and spectrofluorometrically for AGE-peptides (λex = 247 nm, λem = 
440 nm). Briefly, plasma (40 µL) in microcentrifuge tubes was deproteinized with 
trichloroacetic acid (460 µL, 0.15 mol/l) and lipids were simultaneously extracted with 
chloroform (100 µL). The tubes were shaken vigorously and were centrifuged (10 min x 
12000 g). Twenty µl of the aqueous layer was injected and fluorescence and absorption 
signals were measured. The ratio between fluorescence and absorption signal was calculated. 
AGE-peptide concentrations were determined with a proteinase K digest of AGE-bovine 
serum albumin (BSA) as calibrator (100% AGE-peptide calibrator). AGE-BSA was prepared 
by incubating BSA (50 g/l) with 0.5 mol/l glucose in 0.2 mol/l phosphate buffer (pH 7.4) for 
42 days. After incubation, dialysis against phosphate buffered saline was carried out to 
remove unbound material. The AGE-peptide calibrator was obtained by hydrolysis of AGE-
BSA (50 g/l) with proteinase K: 10 µl of proteinase K solution (8 g/l) was mixed with 90 µl of 
AGE-BSA and incubated for 24 h at 37 °C. In parallel, BSA was incubated with proteinase K 
to obtain a peptide calibrator (0% AGE-peptide calibrator). Mean AGE-peptide levels (± SD) 
in 44 healthy subjects were 10.6% ± 1.7% (of the difference in AGE-peptide concentration 
between the 100% and 0% AGE-peptide calibrator), which is comparable with the AGE-
peptides amounts measured in healthy subjects by Wróbel et al. [6]. Within-day and between-
day coefficients of variation were < 3% at an AGE-peptide concentration corresponding to 
that in healthy subjects. 
 
Other measurements 
    We determined plasma concentrations of von Willebrand factor (vWf), soluble vascular-
cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), tissue-type 
plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) as markers of 
endothelial dysfunction, and soluble intercellular adhesion molecule-1 (sICAM-1), C-reactive 
protein (CRP) and secretory phospholipase A2 (sPLA2) as markers of inflammatory activity. 
All markers were measured in duplicate. In addition, plasma total (free plus protein bound) 
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homocysteine (tHcy) and total cholesterol, serum creatinine, and urinary levels of creatinine 




    All analyses were performed with SPSS, version 11.5 (SPSS Inc, Chicago, IL, U.S.A.). 
Variables are presented as mean ± standard deviation, number with percentage of total, or, in 
case of a skewed distribution, median with interquartile range. Analysis of variance 
(ANOVA) was used to test differences between groups. Pearson’s test was used to asses 
bivariate correlations. To study whether AGE-peptides were related to creatinine clearance, 
body mass index, blood pressure, proteinuria and blood levels of total cholesterol, total 
homocysteine and markers of endothelial dysfunction and inflammatory activity, all 
regression analyses were performed with adjustment for age. In addition, to explore whether 
AGE-peptides were independently related to creatinine clearance, markers of endothelial 
dysfunction and markers of inflammatory activity, regression analyses were performed with 
five additional models. In the first model, multivariate analysis was performed with 
adjustment for age, sex, body mass index, diastolic blood pressure, the presence of 
cardiovascular disease and smoking status. In model 2 to 5, sequential adjustments were 
performed for plasma total cholesterol, plasma total homocysteine, and estimates of 
endothelial dysfunction and inflammatory activity, respectively. When necessary, variables 
were log-transformed for a better fit in linear regression analyses. 
    Because markers of endothelial dysfunction and inflammatory activity show marked intra-
individual (day-to-day) variation and because we measured these markers only once, the 
associations (if any) of endothelial dysfunction and inflammatory activity with other variables 
will tend to be underestimated. Therefore, we created mean standard deviation (Z-)scores for 
markers of endothelial dysfunction and inflammatory activity, and used these in regression 
analyses as described below. For every individual, each variable was expressed as standard 
deviations of difference from the population mean. The mean Z-scores for endothelial 
dysfunction and inflammatory activity were calculated as the mean of these standard 
deviation scores as follows: endothelial dysfunction Z-score = (vWf + sVCAM-1 + sE-
selectin + PAI-1 + tPA)/5, and inflammatory activity Z-score = (CRP + sICAM-1 + sPLA2)/3. 
Thus, high scores reflect high levels of endothelial dysfunction and inflammatory activity, 
respectively. 
    A P-value < 0.05 was considered to reflect statistical significance. 




    Table 1 shows baseline characteristics of the participants according to quartiles of 
creatinine clearance. 
 












(ml/min per 1.73 m2)† 
100 ± 22 67 ± 9 40 ± 8 16 ± 5 < 0.001 
AGE-peptides 
(%) 
10.0 (8.1–11.5) 10.5 (9.5–15.9) 14.7 (10.1–27.7) 32.9 (16.6–37.8) < 0.001 
Male sex 
(N [%]) 
8 [40] 9 [45] 11 [55] 12 [60] 0.59 
Age 
(years) 
37 ± 9 54 ± 9 50 ± 13 55 ± 12 < 0.001 
Current smoker 
(N [%]) 
14 [70] 7 [35] 5 [25] 6 [30] < 0.05 
Prior cardiovascular disease 
(N [%]) 
1 [5] 5 [25] 3 [15] 5 [25] 0.29 
Body mass index 
(kg/m2) 
25.1 ± 3.4 26.3 ± 3.1 24.6 ± 3.9 24.0 ± 3.8 0.22 
Systolic blood pressure 
(mmHg) 
121 ± 13 134 ± 17 132 ± 20 138 ± 11 < 0.01 
Diastolic blood pressure 
(mmHg) 
69 ± 9 78 ± 8 78 ± 9 81 ± 7 < 0.001 
Pulse pressure 
(mmHg) 
51 (46–56) 52 (47–63) 49 (44–65) 57 (52–60) 0.44 
Hypertension 
(N [%])‡ 
5 [25] 15 [75] 19 [95] 20 [100] < 0.001 
Plasma total cholesterol 
(mmol/l) 
5.2 ± 1.4 5.4 ± 0.7 5.8 ± 1.6 5.5 ± 1.2 0.46 
Hypercholesterolaemia 
(N [%])§ 
8 [40] 16 [80] 13 [65] 16 [20] < 0.05 
Plasma total homocysteine 
(µmol/l) 
8.2 (7.2–11.4) 8.9 (6.7–10.9) 20.6 (11.5–25.0) 23.1 (19.1–27.1) < 0.001 
Proteinuria 
(g/day) 
0.096 (0.050–0.378) 0.145 (0.104–0.341) 0.825 (0.287–1.855) 1.337 (0.548–2.096) < 0.001 
Von Willebrand factor 
(%) 
91 (62–118) 111 (88–145) 159 (103–211) 173 (134–211) < 0.001 
Soluble E-selectin 
(ng/ml) 
45 ± 21 48 ± 26 49 ± 28 80 ± 109 0.20 
Plasminogen activator inhibitor-1 
(ng/ml) 
22 (12–34) 48 (28–83) 29 (12–50) 42 (18–62) 0.10 
Tissue-type plasminogen activator 
(ng/ml) 
9.2 ± 4.5 12.4 ± 3.8 9.5 ± 5.4 10.4 ± 4.6 0.13 
Soluble VCAM-1 
(ng/ml) 
1126 ± 338 1080 ± 249 1556 ± 444 1796 ± 594 < 0.001 
Endothelial dysfunction score 
(Z-score)¶ 
-0.41 ± 0.56 -0.02 ± 0.46 0.05 ± 0.56 0.38 ± 0.68 < 0.01 
Soluble ICAM-1 
(ng/ml) 
470 (419–689) 562 (417–669) 539 (477–688) 658 (547–757) 0.17 
C-reactive protein 
(mg/l) 
1.7 ± 2.5 2.3 ± 1.5 4.5 ± 11.1 5.0 ± 4.1 0.26 
Secretory phospholipase A2 
(µg/l) 
1.1 ± 3.9 1.9 ± 4.4 3.2 ± 9.5 6.7 ± 7.1 < 0.05 
Inflammatory activity score 
(Z-score)║ 
-0.26 ± 0.50 -0.20 ± 0.47 0.08 ± 1.23 0.38 ± 0.55 < 0.05 
Values for continuous variables are presented as mean ± SD or median (interquartile range) for variables with a skewed 
distribution. Analysis of variance (ANOVA) was used for calculation of P values for trend. Abbreviations: Q, quartile of 
creatinine clearance; AGE, advanced glycation end-product; VCAM-1, vascular adhesion molecule-1; ICAM-1; intercellular 
adhesion molecule-1. 
*Adapted from a previous description of this study population [8]; †Estimated with the Cockcroft-Gault formula; ‡Systolic 
blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg and/or the use of antihypertensive medication; §Plasma 
total cholesterol concentration > 5.0 mmol/l and/or the use of cholesterol lowering medication; ¶Calculated as the mean of the 
standard deviation scores as follows: (von Willebrand factor + soluble E-selectin + plasminogen activator inhibitor-1 + 
tissue-type plasminogen activator + soluble vascular adhesion molecule-1)/5; ║Calculated as the mean of the standard 
deviation scores as follows: (Soluble intercellular adhesion molecule-1 + C-reactive protein + secretory phospholipase A2)/3. 
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    Figure 1 shows the significant inverse relationship between AGE-peptides and creatinine 
clearance. The age-adjusted relations between AGE-peptides and (potential) risk factors for 
cardiovascular disease are presented in Table 2. Age itself did not significantly correlate with 
AGE-peptides (r = 0.19, P = 0.10). 
    Multivariate analyses (Table 3) showed that, after adjustment for age, sex, body mass 
index, diastolic blood pressure, prior cardiovascular disease and smoking, creatinine clearance 
was independently associated with AGE-peptides. Sequential addition of total cholesterol, 
plasma total homocysteine, endothelial dysfunction score and plasma inflammatory activity 
score did not materially change this relationship. Besides creatinine clearance, none of the 
independent variables was significantly associated with AGE-peptides. When, in models 4 
and 5, adjustment for the separate (instead of the Z-scores) markers for endothelial 
dysfunction and inflammation was performed, the relationship between creatinine clearance 
and AGE-peptides was also not materially affected (data not shown). AGE-peptides were not 
independently related to vWf (standardized β –0.04; 95% CI –0.25 to +0.18, P = 0.74 ), sE-
selectin  (standardized β 0.02; 95% CI –0.17 to +0.21, P = 0.81),  PAI-1  (standardized β 0.15; 

































Figure 1. Relation between the natural logarithm of the plasma concentration of advanced glycation end-product-peptides 
and creatinine clearance (n = 80). Pearson’s correlation coefficient: –0.59 (P < 0.001). 
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95% CI –0.06 to +0.35,  P = 0.16), tPA (standardized β 0.08; 95% CI –0.12 to +0.27, P = 
0.45), sVCAM-1 (standardized β –0.01; 95% CI –0.17 to +0.16, P = 0.95), or the endothelial 
dysfunction Z-score (standardized β 0.08, 95% CI –0.14 to +0.30, P = 0.48). Nor were AGE-
peptides significantly related to sICAM-1 (standardized β 0.05, 95% CI –0.15 to 0.26, P = 
0.62), CRP (standardized β –0.12; 95% CI –0.29 to +0.06, P = 0.23) and sPLA2 (standardized 
β –0.02, 95% CI –0.22 to +0.18, P = 0.84), or to the inflammatory activity Z-score 
(standardized β –0.05; 95% CI –0.25 to 0.16, P = 0.66). 
 
Tabel 2. Relation between advanced glycation end-product-peptides and risk factors for cardiovascular disease 
 Advanced glycation end-product-peptides (%)* P value 
Continuous variables Standardized β (95% confidence interval)  
Creatinine clearance (ml/min per 1.73m2)† -0.70 (-0.92 – -0.48) < 0.001 
Body mass index (kg/m2) -0.08 (-0.30 – 0.14) 0.47 
Systolic blood pressure (mmHg) 0.32 (0.11 – 0.53) < 0.01 
Diastolic blood pressure (mmHg) 0.43 (0.21 – 0.64) < 0.001 
Pulse pressure (mmHg)* 0.12 (-0.11 – 0.35) 0.32 
Plasma total cholesterol (mmol/l) 0.15 (-0.07 – 0.37) 0.20 
Plasma total homocysteine (µmol/l)* 0.42 (0.22 – 0.62) < 0.001 
Proteinuria (g/day)* 0.36 (0.12 – 0.59) < 0.01 
Von Willebrand factor (%)* 0.31 (0.09 – 0.53) < 0.01 
Soluble E-selectin (ng/ml) 0.13 (-0.06 – 0.32) 0.24 
Plasminogen activator inhibitor-1 (ng/ml)* 0.17 (-0.05 – 0.39) 0.15 
Tissue-type plasminogen activator (ng/ml) 0.07 (-0.16 – 0.29) 0.57 
Soluble vascular adhesion molecule-1 (ng/ml) 0.27 (0.11 – 0.44) < 0.05 
Endothelial dysfunction score (Z-score)‡ 0.34 (0.11 – 0.57) < 0.01 
Soluble intercellular adhesion molecule-1 (ng/ml)* 0.24 (0.03 – 0.45) < 0.05 
C-reactive protein (mg/l) 0.01 (-0.21 – 0.23) 0.93 
Secretory phospholipase A2 (µg/l) 0.17 (-0.05 – 0.39) 0.12 
Inflammatory activity score (Z-score)§ 0.18 (-0.13 – 0.30) 0.11 
Linear regression analysis of age-adjusted relations between advanced glycation end-product (AGE)-peptides and continuous 
variables. 
*Data are logarithmically transformed; †Estimated with the Cockcroft-Gault formula; ‡Calculated as the mean of the standard 
deviation scores as follows: (von Willebrand factor + soluble E-selectin + plasminogen activator inhibitor-1 + tissue-type 
plasminogen activator + soluble vascular adhesion molecule-1)/5; §Calculated as the mean of the standard deviation scores as 
follows: (Soluble intercellular adhesion molecule-1 + C-reactive protein + secretory phospholipase A2)/3. 
 
Table 3. Multiple regression analysis of the relation between advanced glycation end-product-peptides and creatinine 
clearance 
  Advanced glycation end-product-peptides*  
Model Creatinine clearance† Standardized β (95% confidence interval) P value 
1 Age, sex, body mass index, diastolic blood 
pressure, prior CVD, current smoking 
-0.55 (-0.77 – -0.34) < 0.001 
2 Model 1 + 
plasma total cholesterol 
-0.56 (-0.77 – -0.34) < 0.001 
3 Model 1 + 
plasma total homocysteine* 
-0.52 (-0.84 – -0.19) < 0.001 
4 Model 1 + 
endothelial dysfunction score (Z-score)‡ 
-0.54 (-0.75 – -0.32) < 0.001 
5 Model 1 + 
inflammatory activity score (Z-score)§ 
-0.56 (-0.78 – -0.35) < 0.001 
Abbreviation: CVD, cardiovascular disease. 
*Data are logarithmically transformed; †Estimated with the Cockcroft-Gault formula; ‡Calculated as the mean of the standard 
deviation scores as follows: (von Willebrand factor + soluble E-selectin + plasminogen activator inhibitor-1 + tissue-type 
plasminogen activator + soluble vascular adhesion molecule-1)/5; §Calculated as the mean of the standard deviation scores as 




    As age, sex, body weight and height are part of the formula for calculation of the body 
surface adjusted creatinine clearance, all models were tested without these variables. This did 
not materially influence our results. For example, in models 4 and 5, the standardized βs of 
the relations between creatinine clearance and AGE-peptides, without adjustment for sex, age, 
and  body  mass  index,  were –0.45  (95% CI  –0.66 to –0.23,  P < 0.001) and –0.46  (95% CI 





    This study shows that plasma concentrations of AGE-peptides were independently related 
to creatinine clearance in non-diabetic individuals over a wide range of renal function. AGE-
peptides were not independently related to endothelial dysfunction and inflammatory activity, 
as estimated by a panel of markers. 
    The relation between renal function on the one hand and AGEs as well as AGE-peptides on 
the other hand has been mainly investigated and demonstrated in patients with diabetes 
mellitus [9], end-stage renal disease [10] and after kidney transplantation [5]. Sharp et al. 
found a positive relationship between serum creatinine and AGE-peptides in 106 healthy 
individuals with an apparently normal renal function (median serum creatinine 90 µmol/l, 
range 42 to 150 µmol/l) [7]. The present study, using a more accurate assessment of renal 
function, confirms this relationship in the full range from normal to predialysis renal function. 
The most likely mechanism for the accumulation of AGEs and AGE-peptides seems to be a 
decreased renal excretion [11], although contribution of a disturbed elimination of AGEs in 
the liver [12] or increased de novo generation of AGEs [13] cannot be excluded. 
    The relation between AGEs (or AGE-modified peptides) and cardiovascular complications 
is still under examination. The widespread belief that AGEs contribute to the development of 
cardiovascular disease [2] was initially based on animal studies that demonstrated properties 
of AGEs to induce vasoconstriction, complement activation, cytokine release, procoagulant 
effects and oxidative stress [3]. Furthermore, in a study in hemodialysis patients, alterations in 
left ventricular geometry were independently related to plasma concentration of the AGE 
pentosidine [14]. Clinical trials with inhibitors of AGE-formation (aminoguanidine) and 
cross-link breakers (ALT-711) have confirmed the potential role of AGEs in the development 
of vascular complications in diabetic patients [15]. So far, however, prospective studies in 
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patients with chronic kidney disease and/or diabetes have not been able to link high AGEs to 
cardiovascular morbidity and mortality [10]. 
    We did not find an independent relationship between blood levels of high serum AGE-
peptides and biomarkers of endothelial dysfunction and inflammatory activity. With respect to 
endothelial dysfunction, in vitro studies have shown that exposure of endothelial cells to 
AGEs enhances vascular expression of VCAM-1 and sE-selectin [16]. In diabetic patients, 
high serum AGEs (the major AGEs Nε-(carboxymethyl)lysine [CML] and Nε-
(carboxyethyl)lysine [CEL]) were associated with high plasma levels of sVCAM-1, vWf and 
soluble thrombomodulin [9]. An association between high serum AGEs and impaired 
endothelium-dependent vasodilatation could be demonstrated in diabetic patients [17], which 
was not the case in end-stage renal disease [18]. 
    With respect to inflammatory activity, expression of the receptor for AGE on peripheral 
blood monocytes has been shown to be associated with plasma levels of CRP and tumour 
necrosis factor alpha in patients with chronic kidney disease [19]. However, as in our study, a 
relationship between blood levels of AGE-peptides and CRP could also not be demonstrated 
in patients with end-stage renal disease [10] and diabetes [9]. 
    This study has some limitations. The use of the AGE-peptides as reflection of AGEs in 
plasma requires some discussion. Several AGEs, such as argpyrimidine and pentosidine, 
exhibit characteristic fluorescence. Based on this, a novel simple analytical procedure to 
measure AGE-peptides with on-line spectrophotometric and spectrofluorometric detection 
was developed [6]. This technique has been validated with an AGE-Elisa [6], and we 
demonstrated a strong correlation of AGE-peptides with the well-characterized non-
fluorescent AGEs CML and CEL, indicating the specificity of this technique for the 
quantification of AGEs [20]. However, the fluorophores as determined in this assay are 
unknown and the exact specificity of the assay needs to be further determined. 
    In addition, due to the limited number of patients and the variety of renal diseases, the 
possibility of a relationship between AGE-peptides and markers of endothelial function and 
inflammatory activity cannot be unequivocally excluded, especially in subgroups. The intra-
individual variability of the markers of endothelial function and inflammatory activity was not 
assessed in our study, but the use of a composite Z-score of these markers should have 
lessened a masking effect (if any) on the associations that were studied. Of course, the cross-




    In conclusion, plasma concentrations of AGE-peptides are associated with creatinine 
clearance but not with biochemical markers of endothelial dysfunction and inflammatory 
activity in non-diabetic patients with a wide range of predialysis renal function. Therefore, the 
supposed atherogenic effect of AGEs seems not to be mediated by endothelial dysfunction or 
chronic low-grade inflammation, as reflected by vWf, sVCAM-1, sE-selectin, PAI-1 and tPA, 
and CRP, sICAM-1 and sPLA2, respectively. Thus, our study does not support the use of 
these biomarkers of endothelial dysfunction and inflammatory activity as intermediary end 
points of AGE-peptide-reducing interventions aiming for cardiovascular risk reduction. 
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    Mildly impaired renal function is associated with cardiovascular morbidity and mortality. 
There are indications that endothelial dysfunction and/or chronic inflammation, which play an 
important role in atherothrombosis, are present in early stages of renal insufficiency. This 
study investigated whether and to which extent endothelial dysfunction and inflammation 
were related to renal function and contributed to renal-function-associated cardiovascular 
mortality in a population-based cohort (n = 613), aged 50 to 75 yr, that was followed with a 
median duration of 12.5 yr. During follow-up, 192 individuals died (67 of cardiovascular 
causes). At baseline, renal function was estimated with serum creatinine, the Cockcroft-Gault 
formula, and the Modification of Diet in Renal Disease equation of glomerular filtration rate 
(eGFR). Endothelial function was estimated by plasma von Willebrand factor, soluble 
vascular cell adhesion molecule-1, and the urinary albumin-creatinine ratio. Inflammatory 
activity was estimated by plasma C-reactive protein and soluble intercellular adhesion 
molecule-1. Renal function was mildly impaired (mean eGFR 68 ± 12 ml/min per 1.73 m2) 
and independently associated with von Willebrand factor [standardized β –0.09; 95% 
confidence interval (CI) –0.18 to –0.002; P < 0.05], soluble vascular cell adhesion molecule-1 
(standardized β –0.14; 95% CI –0.22 to –0.05; P < 0.01) and albumin-creatinine ratio 
(standardized β –0.15; 95% CI –0.23 to –0.08; P < 0.001) but not with markers of 
inflammatory activity. Renal function was inversely associated with cardiovascular and all-
cause mortality. The relative risk of cardiovascular mortality but not all-cause mortality 
associated with renal function decreased from 1.22 to 1.12 per 5 ml/min per 1.73 m2 decrease 
of eGFR after adjustment for markers of endothelial dysfunction. In conclusion, endothelial 
dysfunction was related to renal function and contributed to the excess in cardiovascular 
mortality in this population-based cohort with mild renal insufficiency. 




    Chronic kidney disease is a prevalent health problem, involving more than 10% of the 
general population of the United States [1]. Chronic kidney disease, especially end-stage renal 
disease, is strongly associated with the occurrence of cardiovascular disease [2]. As recently 
demonstrated, even mildly impaired renal function is associated with cardiovascular 
morbidity [3,4] and mortality [3,5]. Although chronic kidney disease is associated with 
several risk factors for cardiovascular disease, such as male gender, older age, 
hyperhomocysteinemia, hypertension, smoking, diabetes, obesity, and pre-existing 
cardiovascular disease, the excess cardiovascular risk in chronic kidney disease is not fully 
explained by this clustering of conventional risk factors. 
    In atherogenesis, endothelial dysfunction and inflammation are important and interrelated 
early steps [6]. Indeed, several biochemical markers of endothelial dysfunction and 
inflammatory activity have been shown to be independent risk factors of cardiovascular 
morbidity and mortality [7–11]. It is unknown whether the excess cardiovascular risk in 
chronic kidney disease is (partially) attributable to endothelial dysfunction and inflammation. 
There is evidence that a decreased glomerular filtration rate (GFR) is associated with 
endothelial dysfunction as well as inflammatory activity [12–14]. However, there is little 
evidence that a low GFR is associated with endothelial dysfunction and inflammation in the 
general population and, if so, whether any such associations can explain the association of a 
low GFR with risk for cardiovascular disease. 
    In view of these considerations, we investigated, in a prospective, population-based study 
(1) whether estimates of GFR were cross-sectionally associated with markers of endothelial 
dysfunction and inflammatory activity at the baseline examination and (2) whether endothelial 




MATERIALS AND METHODS 
 
Participants 
    The study population consisted of an age-, gender-, and glucose tolerance-stratified sample 
of the Hoorn Study, a population-based study of glucose tolerance and other cardiovascular 
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risk factors in a 50- to 75-yr-old general white population conducted from 1989 to 1992, as 
described previously [15]. 
    Briefly, 2484 people (71% of those invited) participated. All participants, except for those 
who had previously diagnosed diabetes and were treated with oral glucose-lowering agents or 
insulin, underwent an oral glucose tolerance test (OGTT) according to the World Health 
Organization guidelines [16]. For reasons of efficiency, participants with a 2-h postload glucose 
≥ 7.5 mmol/L, all participants with type 2 diabetes, and a random sample of participants with a 
2-h postload glucose < 7.5 mmol/l stratified by age and gender were invited within four wk for 
a second visit to investigate glucose intolerance-related complications (709 invited, 631 [89%] 
of whom participated).  
    These participants underwent a second OGTT (except those who already used blood glucose-
lowering agents; n = 67). On the basis of the mean of the two OGTT, glucose tolerance status 
was divided into three categories according to the 1999 World Health Organization criteria: 
Normal glucose metabolism, impaired glucose metabolism, and type 2 diabetes [17]. 
Participants in our study population thus represented a stratified random sample of all 
participants in the initial cohort. 
    The Hoorn Study was approved by the Ethical Committee of the VU University Medical 
Center. Informed consent was obtained from all participants. 
 
Baseline laboratory and clinical assessments 
    C-reactive protein (CRP) and soluble intercellular adhesion molecule-1 (sICAM-1) were 
measured as markers of inflammatory activity, and soluble vascular cell adhesion molecule-1 
(sVCAM-1), von Willebrand factor (vWf), and microalbuminuria were measured as markers 
of endothelial dysfunction. After an overnight fast, blood was drawn from an antecubital vein. 
We measured blood concentrations of vWf, sVCAM-1, CRP, sICAM-1, total (free plus 
bound) homocysteine, glucose, creatinine, albumin, urea nitrogen, and lipids, as described 
elsewhere [10,15]. The urinary albumin-creatinine ratio (ACR) was calculated. 
    Creatinine clearance was estimated (eCC) by the Cockcroft-Gault formula [(140-age) × 
(1.23 × body weight/creatinine), amplified by 0.85 if female] [18]. Glomerular filtration rate 
was estimated (eGFR) by the Modification of Diet in Renal Disease (MDRD) equation [170 ×  
(creatinine)–0.999 × (age)–0.176 × (serum urea nitrogen)–0.170 × (albumin)0.318 × (0.762 if patient is 
female) (1.180 if patient is black)] (MDRD equation is given in traditional units. To convert to 
International System units, multiply creatinine in mg/dl by 88.4, urea in mg/dl by 0.357, and 
albumin in g/dl by 10.) [19]. Estimated CC and eGFR were expressed in ml/min per 1.73 m2 
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body surface area. Blood pressure was measured as the mean of four measurements 
performed on two different occasions, using a random-zero sphygmomanometer under 
standardized conditions. Participants were classified as current cigarette smokers or 
nonsmokers. Body mass index (BMI) and waist-to-hip ratio were calculated as described 
elsewhere [15]. Cardiovascular disease was defined as coronary artery disease, 
cerebrovascular disease, and/or peripheral arterial disease. 
    We excluded individuals for whom no data were available for calculation of the renal 
function estimates (n = 18), leaving 613 individuals available for analysis. From these 
individuals, data on vWf and sVCAM-1 were missing in 21, data on ACR in 23, and data on 
CRP and sICAM-1 in 23. 
 
Follow-up 
    Data on the participants’ vital status on January 1, 2004, were collected from the mortality 
register of the municipality of Hoorn. Of 51 participants who had moved out of town, 
information was obtained from the local municipalities. Of the 613 included participants, one 
was lost to follow-up. For the other 612 participants, we determined whether death had 
occurred during follow-up and, if so, the date when death occurred. For all participants who 
had died, the cause of death was extracted from the medical records of the general practitioner 
and the hospital of Hoorn and classified according to the of the International Classification of 
Diseases, Ninth Revision [20]. Cardiovascular mortality was defined as codes 390 to 459. 
 
Statistical analyses 
    All analyses were performed with the SPSS, version 11.5 (SPSS Inc., Chicago, IL). 
Variables are presented as mean ± standard deviation (SD), number (percentage of the total), 
or, in case of a skewed distribution, the median and the interquartile range. 
    For descriptive purposes, the group was divided in tertiles according to the eGFR. P value 
for trend over tertiles was calculated with univariate analysis of variance (ANOVA) for 
continuous variables and with χ2 test for binary variables. Pearson test was used to assess 
correlation coefficients. 
    To study whether biochemical markers of endothelial dysfunction and inflammatory 
activity were related independently to estimates of renal function, regression analyses were 
performed with three different models. In the first model–because of the stratification 
procedure–multivariate regression analysis was performed with adjustment for age, gender, 
and glucose tolerance status. In the second model, we additionally adjusted for potential 
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confounders, i.e., prior cardiovascular disease, systolic blood pressure, current smoking, 
waist-to-hip ratio, total cholesterol, and homocysteine. Finally, we adjusted the associations 
between renal function and endothelial dysfunction markers for markers of inflammation, and 
vice versa. Variables that did not have a normal distribution of the residuals (vWf, ACR and 
CRP) were transformed into their natural logarithm (ln) for a better fit of the data. Results are 
described as standardized β with 95% confidence intervals (CI). 
    Multivariate Cox regression analyses were performed to assess whether the associations of 
renal function with all-cause mortality and cardiovascular mortality were independent of 
potential confounding or mediating factors. 
    Adjustment for endothelial function was performed by adding each marker of endothelial 
dysfunction separately to the model and by adding vWf, sVCAM-1, and ACR simultaneously. 
Because microalbuminuria has been shown previously to have a heterogeneous association 
with endothelial dysfunction in the Hoorn Study [21,22], we also adjusted for sVCAM-1 and 
vWf only. In an additional analysis, sICAM-1 was added to vWf, sVCAM-1, and ACR, 
because it has been suggested that sICAM-1 may reflect endothelial dysfunction as well as 
inflammatory activity. Adjustment for inflammatory activity was performed by adding CRP 
and sICAM-1 (separately and simultaneously) to the model. 
    Results are described as relative risks (RR; hazard ratios) with 95% CI associated with a 
decrease in eGFR and eCC of 5 ml/min per 1.73 m2 and increase in serum creatinine 





    Table 1 shows the baseline characteristics of the study population according to tertiles of 
eGFR. In the whole study population, eGFR was 68 ± 12 ml/min per 1.73 m2, eCC was 74 ± 
17 ml/min per 1.73 m2, and serum creatinine was 92 ± 19 µmol/L. 
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Table 1. Baseline characteristics of all subjects 
 Tertiles of estimated glomerular filtration rate  
 First (n = 204) 
> 72 ml/min 
per 1.73 m² 
Second (n = 205) 
63 to 72 ml/min 
per 1.73 m² 
Third (n = 204) 
< 63 ml/min 
per 1.73 m² 
P value 
(trend) 
Estimated glomerular filtration rate (ml/min per 1.73 m²) 80 ± 7 68 ± 3 55 ± 8 < 0.001 
Estimated creatinine clearance (ml/min per 1.73 m²) 86 ± 16 74 ± 12 62 ± 14 < 0.001 
Serum creatinine (µmol/L) 82 ± 11 90 ± 12 104 ± 24 < 0.001 
Male gender (n [%]) 133 [65] 109 [53] 135 [66]    0.84 
Age (years) 62 ± 7 63 ± 7 67 ± 6 < 0.001 
Normal glucose metabolism (n [%]) 77 [38] 94 [46] 79 [39]    0.84 
Impaired glucose metabolism (n [%]) 56 [28] 60 [29] 57 [28]    0.91 
Type 2 diabetes (n [%]) 71 [35] 51 [25] 68 [33]    0.75 
Body mass index (kg/m2) 26.7 ± 3.6 26.8 ± 3.5 28.1 ± 4.4 < 0.001 
Waist-to-hip ratio (cm/cm) 0.94 ± 0.09 0.90 ± 0.08 0.92 ± 0.08 < 0.01 
Total cholesterol (mmol/L) 6.5 ± 1.2 6.7 ± 1.2 6.7 ± 1.2    0.06 
High-density lipoprotein cholesterol (mmol/L) 1.3 ± 0.4 1.3 ± 0.3 1.3 ± 0.3    0.98 
Lipid-lowering medication (n [%]) 5 [2] 1 [0] 3 [1]    0.41 
Systolic blood pressure (mmHg) 138 ± 20 136 ± 19 144 ± 19 < 0.01 
Diastolic blood pressure (mmHg) 83 ± 10 82 ± 10 83 ± 10    0.82 
Pulse pressure (mmHg) 55 ± 15 54 ± 13 62 ± 16 < 0.001 
Blood pressure-lowering medication (n [%]) 52 [25] 40 [20] 77 [40] < 0.01 
Hypertension (n [%]) 108 [53] 90 [44] 136 [67] < 0.01 
Current smokers (n [%]) 63 [31] 52 [25] 41 [20] < 0.05 
Prior cardiovascular disease (n [%]) 47 [23] 43 [21] 52 [26]    0.56 
Homocysteine (µmol/l) 11.2 ± 4.2 12.5 ± 5.9 13.9 ± 6.3 < 0.001 
Von Willebrand factor (IU/ml) 110 (88 – 162) 108 (74 – 166) 134 (89 – 188) < 0.05 
Soluble vascular cell adhesion molecule-1 (µg/L) 1304 ± 423 1325 ± 368 1512 ± 515 < 0.001 
Urinary albumin-creatinine ratio (mg/mmol) 0.77 (0.54 – 1.21) 0.87 (0.59 – 1.28) 0.99 (0.65 – 1.72) < 0.05 
C-reactive protein (mg/L) 1.75 (0.88 – 3.44) 1.49 (0.59 – 3.02) 2.13 (1.02 – 4.27)    0.74 
Soluble intercellular adhesion molecule-1 (µg/L) 495 ± 190 462 ± 149 488 ± 146    0.67 
Values for continuous variables are presented as mean ± SD or median (interquartile range). P value for trend was calculated with univariate 
analysis of variance for continuous variables and with χ2 test for dichotomous variables. Hypertension was defined as a blood pressure ≥ 140 
mmHg systolic and/or ≥ 90 mmHg diastolic and/or the current use of blood pressure-lowering medication. 
 
Relationship between renal function and endothelial function 
    Table 2 shows that eGFR was independently associated with vWf, sVCAM-1, and ACR in 
all models (see also Figure 1, A through C). 
 
Table 2. Relation of renal function with markers of endothelial function 




   Stand. β (95% CI) Stand. β (95% CI) Stand. β (95% CI) 
1 Estimated GFR  –0.11* –0.20 to –0.02 –0.23‡ –0.32 to– 0.15 –0.20‡ –0.28 to –0.12 
 Estimated CC –0.02 –0.15 to 0.10 –0.15† –0.24 to –0.05 –0.13† –0.23 to –0.02 
 
Age, gender, glucose tolerance 
status 
Serum creatinine 0.07 0.00 to 0.14 0.25‡ 0.17 to 0.34 0.27‡ 0.19 to 0.35 
       
2 Estimated GFR –0.10* –0.19 to –0.001 –0.18‡ –0.27 to –0.10 –0.14† –0.22 to –0.06 
 Estimated CC –0.05 –0.18 to 0.07 –0.16† –0.28 to –0.05 –0.17† –0.28 to –0.06 
 
Model 1 + prior CVD, 
systolic BP, current smoking, 
BMI, total cholesterol, Hcy Serum creatinine 0.05 0.00 to 0.15 0.18‡ 0.09 to 0.27 0.17‡ 0.09 to 0.25 
       
3 Estimated GFR –0.09* –0.18 to 0.002 –0.14† –0.22 to –0.05 –0.15‡ –0.23 to –0.08 
 Estimated CC –0.05 –0.17 to 0.08 –0.11* –0.22 to –0.01 –0.18† –0.29 to –0.07 
 
Model 2 + C-reactive protein, 
soluble intercellular adhesion 
molecule-1 Serum creatinine 0.04 –0.03 to 0.11 0.11* 0.02 to 0.19 0.18‡ 0.10 to 0.25 
Von Willebrand factor, urinary albumin-creatinine ratio and C-reactive protein were transformed to natural logarithm (ln). Stand., 
standardized; CI, confidence interval; GFR, glomerular filtration rate; CC, creatinine clearance; CVD, cardiovascular disease; BP, blood 
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Figure 1. Relations between estimated glomerular filtration rate and markers of endothelial dysfunction (von Willebrand 
factor [A], soluble vascular cell adhesion molecule-1 [B], urinary albumin-creatinine ratio [C]) and inflammatory activity (C-
reactive protein [D], soluble intercellular adhesion molecule-1 [E]). r, correlation coefficient. 
A B 
C 
r = –0.12 
P < 0.01
r = –0.23 
P < 0.001
r = –0.27 
P < 0.01
D 
r = –0.01 
P = 0.77
E 
r = –0.05 
P = 0.23
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Relationship between renal function and inflammatory activity 
    None of the inflammatory markers was related independently to any of the estimates of 
renal function (Table 3 and Figures 1, D and E). In model 1, a significant positive association 
was found between CRP and eCC, which, however, was not present after adjustment for BMI 
(standardized β 0.03; 95% CI -0.07 to 0.14; P = 0.58), one of the dependent variables in 
models 2 and 3. Body mass index was higher in participants with a higher eGFR (Table 1) 
and strongly positively associated with CRP (model 3: 0.20; 95% CI 0.11 to 0.28; P < 0.001). 
 
Table 3. Relation of renal function with markers of inflammatory activity 
Model  C-reactive protein Soluble intercellular 
adhesion molecule-1 
   Stand. β (95% CI) Stand. β (95% CI) 
1 Estimated GFR 0.00 –0.07 to 0.08 –0.02 –0.10 to 0.07 
 Estimated CC  0.14* 0.04 to 0.25 –0.03 –0.12 to 0.07 
 
Age, gender, glucose tolerance status 
Serum creatinine 0.03 –0.07 to 0.12 0.07 –0.01 to 0.16 
      
2 Estimated GFR 0.04 –0.05 to 0.13 0.02 –0.08 to 0.11 
 Estimated CC  0.04 –0.06 to 0.15 –0.03 –0.15 to 0.09 
 
Model 1 + prior cardiovascular disease, 
systolic blood pressure, current smoking, 
BMI, total cholesterol, homocysteine Serum creatinine –0.01 –0.09 to 0.08 0.01 –0.08 to 0.11 
      
3 Estimated GFR 0.07 –0.03 to 0.16 0.06 –0.03 to 0.15 
 Estimated CC  0.07 –0.06 to 0.20 0.02  –0.14 to 0.10 
 
Model 2 + von Willebrand factor, 
soluble vascular cell adhesion molecule-1, 
urinary albumin-creatinine ratio Serum creatinine –0.04 –0.12 to 0.05 –0.03 –0.12 to 0.06 
C-reactive protein, von Willebrand factor and urinary albumin-creatinine ratio were transformed to natural logarithm (ln). 
Stand., standardized; CI, confidence interval; GFR, glomerular filtration rate; CC, creatinine clearance; BMI, body mass 
index. *P < 0.01. 
     
Renal function, endothelial dysfunction and inflammatory activity in relation to 
cardiovascular and all-cause mortality 
    Median duration of follow-up was 12.5 yr (interquartile range 9.9 to 13.2). During follow-up, 192 of 
613 individuals died (67 of cardiovascular disease and 31 of unknown causes). Renal function, 
whether expressed as eGFR, eCC, or serum creatinine, was inversely associated with risk of 
cardiovascular and all-cause mortality. After adjustment for age, gender, glucose tolerance, systolic 
blood pressure and previous cardiovascular disease, the RR (95% CI) of cardiovascular and all-cause 
mortality associated with a decrease of 5 ml/min per 1.73 m2 of eGFR were 1.22 (1.09 to 1.36) and 
1.12 (1.05 to 1.20), respectively (Tables 4 and 5). The relationship between eGFR and cardiovascular 
mortality is shown in Figure 2. The association was stronger for eGFR than for eCC or serum 
creatinine (Table 4). 
    When vWf, sVCAM-1, and ACR were added individually to the model, the RR for 
cardiovascular mortality associated with renal function decreased from 1.22 to 1.21, 1.16 and 
1.17, respectively (Table 4, models 3 through 5). When the three markers were added 
simultaneously, the RR decreased from 1.22 to 1.12 (Table 4, model 6). Adjustment for vWf 
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and sVCAM-1 without ACR decreased the RR from 1.22 to 1.16 (Table 4, model 7). After 
addition of sICAM-1 to the three endothelial markers, the RR decreased from 1.22 to 1.13 
(Table 4, model 8). The RR for all-cause mortality associated with renal function was not 
materially affected by these markers of endothelial dysfunction (Table 5). Adjustment for 
markers of inflammatory activity did not change substantially the RR for cardiovascular 
(Table 4) or all-cause (Table 5) mortality associated with renal function. Sequential inclusion 
of smoking status, BMI (or hip-to-waist ratio), total cholesterol (or high-density lipoprotein 
cholesterol), use of lipid-lowering medication, and homocysteine as independent variables in 
model 2 of the Cox regression analysis did not materially change the effect of adjustment for 
the different markers of endothelial function and/or inflammation on the renal function-
associated cardiovascular and all-cause mortality (data not shown). 
 
Table 4. Relative risks of cardiovascular mortality associated with estimates of renal function 
Model Estimated GFR  Estimated CC Serum creatinine 
  RR (95% CI) associated 
with a decrease of 
5 ml/min per 1.73 m2 
RR (95% CI) associated 
with a decrease of 
5 ml/min per 1.73 m2 
RR (95% CI) associated 
with a increase 
of 5 µmol/l 
1 Age, gender, glucose tolerance status 1.22‡ (1.09 – 1.36) 1.10* (1.01 – 1.21) 1.11‡ (1.07 – 1.16) 
2 Model 1 + prior CVD, systolic blood pressure 1.22‡ (1.09 – 1.36) 1.12* (1.02 – 1.23) 1.11‡ (1.06 – 1.16) 
3 Model 2 + vWf 1.21† (1.08 – 1.35) 1.12* (1.02 – 1.23) 1.10‡ (1.06 – 1.15) 
4 Model 2 + sVCAM-1 1.16† (1.04 –1.30) 1.08 (0.99 – 1.19) 1.09‡ (1.04 – 1.14) 
5 Model 2 + ACR 1.17† (1.04 – 1.31) 1.09 (0.99 – 1.19) 1.09‡ (1.04 – 1.14) 
6 Model 2 + vWf, sVCAM1, ACR 1.12* (1.00 – 1.26) 1.07 (0.98 – 1.17) 1.08† (1.02 – 1.13) 
7 Model 6 – ACR  1.16* (1.04 – 1.30) 1.09 (0.99 – 1.19) 1.09‡ (1.04 – 1.14) 
8 Model 6 + sICAM-1 1.13* (1.01 – 1.27) 1.06 (0.97 – 1.17) 1.07† (1.02 – 1.13) 
9 Model 2 + CRP 1.22† (1.09 – 1.36) 1.12* (1.02 – 1.23) 1.11‡ (1.06 – 1.16) 
10 Model 2 + sICAM-1 1.20† (1.08 – 1.34) 1.10 (1.00 – 1.21) 1.10‡ (1.05 – 1.15) 
11 Model 2 + CRP, sICAM-1 1.20† (1.07 – 1.34) 1.10* (1.00 – 1.22) 1.10‡ (1.05 – 1.15) 
Von Willebrand factor, urinary albumin-creatinine ratio and C-reactive protein were transformed to natural logarithm (ln). GFR, glomerular 
filtration rate; CC, creatinine clearance; RR, relative risk; CI, confidence interval; CVD, cardiovascular disease; vWf, von Willebrand factor; 
sVCAM1, soluble vascular cell adhesion molecule-1; ACR, urinary albumin-creatinine ratio; sICAM-1, soluble intercellular adhesion 
molecule-1; CRP, C-reactive protein. *P < 0.05, †P < 0.01, ‡P < 0.001. 
 
Table 5. Relative risks of all-cause mortality associated with estimates of renal function 
Model Estimated GFR  Estimated CC Serum creatinine 
  RR (95% CI) associated 
with a decrease of 
5 ml/min per 1.73 m2 
RR (95% CI) associated 
with a decrease of 
5 ml/min per 1.73 m2 
RR (95% CI) associated 
with a increase of 
5 µmol/l 
1 Age, sex, glucose tolerance status 1.12† (1.04 – 1.19) 1.03 (0.98 – 1.09) 1.08‡ (1.04 – 1.11) 
2 Model 1 + prior CVD, systolic blood pressure 1.12† (1.05 – 1.20) 1.04 (0.98 – 1.09) 1.08‡ (1.04 – 1.11) 
3 Model 2 + vWf 1.11† (1.04 – 1.19) 1.04 (0.99 – 1.10) 1.07‡ (1.04 – 1.11) 
4 Model 2 + sVCAM-1 1.11† (1.04 – 1.19) 1.04 (0.98 – 1.10) 1.08‡ (1.04 – 1.11) 
5 Model 2 + ACR 1.10† (1.03 – 1.18) 1.04 (0.99 – 1.10) 1.07‡ (1.04 – 1.11) 
6 Model 2 + vWf, sVCAM1, ACR 1.10† (1.03 – 1.18) 1.05 (0.99 – 1.11) 1.07‡ (1.03 – 1.11) 
7 Model 6 – ACR  1.10† (1.03 – 1.18) 1.04 (0.98 – 1.10) 1.07‡ (1.04 – 1.11) 
8 Model 6 + sICAM-1 1.10† (1.03 – 1.18) 1.04 (0.98 – 1.10) 1.07‡ (1.03 – 1.10) 
9 Model 2 + CRP 1.12† (1.05 – 1.20) 1.04 (0.98 – 1.10) 1.08‡ (1.04 – 1.11) 
10 Model 2 + sICAM-1 1.11† (1.04 – 1.19) 1.03 (0.98 – 1.09) 1.07‡ (1.04 – 1.11) 
11 Model 2 + CRP, sICAM-1 1.11† (1.04 – 1.19) 1.04 (0.98 – 1.10) 1.07‡ (1.04 – 1.11) 
Von Willebrand factor, urinary albumin-creatinine ratio and C-reactive protein were transformed to natural logarithm (ln). GFR, glomerular 
filtration rate; CC, creatinine clearance; RR, relative risk; CI, confidence interval; CVD, cardiovascular disease; vWf, von Willebrand factor; 
sVCAM1, soluble vascular cell adhesion molecule-1; ACR, urinary albumin-creatinine ratio; sICAM-1, soluble intercellular adhesion 
molecule-1; CRP, C-reactive protein. *P < 0.05, †P < 0.01, ‡P < 0.001. 
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Figure 2. Proportion of subjects without cardiovascular death according to tertiles of estimated glomerular filtration rate, 
adjusted for age, sex and glucose tolerance status (Cox regression analysis). eGFR, estimated glomerular filtration rate. 
 
Additional analyses 
    Because age and gender are part of the Cockcroft-Gault formula and the MDRD equation and were 
added to the analyses with serum creatinine as key independent variable, all models were tested 
without these (stratification) variables. This did not materially influence our results (data not shown). 
    In the multivariate and Cox regression analyses, replacement of systolic blood pressure by 
diastolic blood pressure, pulse pressure, presence of hypertension, or use of blood pressure-
lowering medication did not materially change the relation between renal function and 
markers of endothelial dysfunction or inflammatory activity (data not shown). In addition, we 
repeated all analyses after exclusion of the four patients with chronic kidney disease stage 4 
(eGFR 15 to 29 ml/min per 1.73 m2) [1], which again did not materially change the results. 
    Further analyses to exclude the presence of effect modification by the presence of diabetes, 
older age (> 65 yr), male gender, or hypertension confirmed the consistency of the results, as 
the associations between renal function and biochemical markers of inflammatory activity and 
endothelial dysfunction and between eGFR and mortality were similar regardless of the 
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    This population-based study had three main findings. First, mild impairment of renal 
function was independently associated with endothelial dysfunction. Second, we confirm and 
extend our previous finding [5] of an association between mild impairment of renal function 
and cardiovascular mortality (and to a lesser extent all-cause mortality) that was independent 
of conventional risk factors and that persisted during up to 13 yr of follow-up. Third, 
endothelial dysfunction seemed to be involved in this renal function-associated cardiovascular 
mortality. 
    An increasing number of studies show that individuals with even mildly impaired renal 
function are at high risk for cardiovascular morbidity and mortality, independent of traditional 
risk factors [2]. We have proposed that endothelial dysfunction and/or inflammation may be 
(partially) responsible for this phenomenon [14]. This was based on the general view that 
changes in endothelial cell properties and increased inflammation play an important role in 
the initiation and the progression of the atherothrombotic process [6] and on observations that 
patients with renal dysfunction show evidence of endothelial dysfunction and inflammation 
[13,14]. 
    This study demonstrates that endothelial dysfunction is related to renal function in an 
elderly general population in whom renal function was only mildly impaired but cannot 
establish whether endothelial dysfunction causes impairment of GFR or vice versa or that a 
third variable causes both. Endothelial dysfunction may be an important mechanism linking 
mildly impaired renal function to cardiovascular disease, because healthy endothelium 
normally has antiatherothrombotic properties, such as promotion of vasodilatation and 
inhibition of vascular smooth muscle cell proliferation, thrombosis, and inflammatory 
activity. Many of these functions are mediated by the release of compounds with specific 
biological properties, such as nitric oxide, proteins involved in hemostasis and fibrinolysis, 
adhesion molecules, and selectins. The plasma concentrations of such substances are thought 
to reflect endothelial function status. Von Willebrand factor, which has prothrombogenic 
properties through its involvement in platelet adhesion and aggregation and in blood 
coagulation [23], has been suggested to be a marker of generalized endothelial dysfunction 
[24]. Vascular cell adhesion molecule-1 is involved in the recruitment of mononuclear blood 
cells into the vascular wall [25]. Soluble VCAM-1 in plasma is derived from shedding of 
endothelial cells, and has also been related to endothelial dysfunction [26]. In the absence of 
significant excretion of sVCAM-1 in the urine [27], plasma sVCAM-1 concentration can be 
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regarded as a reflection of endothelial release. Finally, microalbuminuria is often regarded as 
a marker of generalized endothelial dysfunction and has been shown to be independently 
associated with impaired endothelium-dependent vasodilatation [28]. In accordance with the 
concept that these markers reflect endothelial dysfunction, vWf, sVCAM-1, and 
(micro)albuminuria have all been associated with increased risk for cardiovascular and all-
cause mortality [7–9]. 
    This is the first population-based study to show that mildly impaired renal function is 
associated with endothelial dysfunction. Instead, some studies have suggested that 
microalbuminuria is associated with glomerular hyperfiltration [29,30]. For example, in the 
PREVEND study, individuals with microalbuminuria, as compared with those with 
normoalbuminuria, had a higher mean creatinine clearance (97 versus 90 ml/min per 1.73 m2) 
[29]. In contrast, we observed a linear inverse relationship between eGFR and ln ACR. This 
discrepancy may be related to the higher mean age and the lower mean eGFR in the current 
compared to these previous studies [29,30]. 
    In our study, no significant relation was found between renal function and inflammation, as 
estimated with sICAM-1 and CRP. In patients with more advanced predialysis renal 
insufficiency, plasma sICAM-1 [14,31] and CRP [14,32] have been shown to be elevated. 
The relationship between mildly impaired renal function and CRP is less clear. In another 
community-based, non-diabetic population, Stuveling et al. [33] found that CRP was related 
with both diminished and high creatinine clearance (i.e., a U-shaped relationship). As in our 
study, the positive relationship between CRP and eCC disappeared after adjustment for BMI. 
This is probably due to the strong positive relationship between CRP and BMI [34,35], which 
may be explained by the finding that interleukin-6, a regulator of the synthesis of CRP in the 
liver, has been shown to be secreted by human subcutaneous adipose tissue [36]. As neither 
serum creatinine nor eGFR was significantly related with CRP, it is unlikely that a true 
association between CRP and eCC was masked by overadjustment for BMI.  
    Mild renal function impairment was associated with cardiovascular and all-cause mortality 
during up to 13 yr of follow-up, in a way that was independent of conventional risk factors for 
cardiovascular disease. Recent studies, with a shorter follow-up, have also demonstrated that 
mildly decreased GFR is an independent risk factor for cardiovascular disease [3,4]. 
Compared to our previous study of the same cohort [5], the present study consisted of older 
individuals, had a longer follow-up and more mortality cases, and, therefore, more power to 
identify and quantify influences of individual risk factors on cardiovascular and all-cause 
mortality. A major and new finding of our study is that the association of renal function and 
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cardiovascular mortality was attenuated after adjustment for endothelial function, suggesting 
that the relationship may be partially explained by endothelial dysfunction. 
    It is likely that the change in RR for cardiovascular mortality associated with a decrease in 
eGFR of 5 ml/min per 1.73 m2 from 1.22 to 1.12, which was caused by adjustment for 
biochemical markers of endothelial dysfunction, is an underestimation of the true impact of 
endothelial dysfunction in individuals with mildly impaired renal function. The markers of 
endothelial dysfunction that we used reflect only selected aspects of a complex biological 
entity; for example, these markers contain no (or at most very indirect) information on 
endothelial nitric oxide synthesis, which is known to be impaired in individuals with impaired 
renal function [37] and which is likely to play an important role in the association between 
impaired renal function and atherothrombosis [38]. In this respect, it is noteworthy that the 
three endothelial function markers we used (vWf, sVCAM-1, and ACR) contributed mutually 
independently to the association between impaired renal function and cardiovascular 
mortality, suggesting that these various aspects of endothelial dysfunction all are relevant. 
Furthermore, misclassification of the 31 patients who had an unknown cause of death may 
have caused underestimation of the impact of endothelial dysfunction on cardiovascular 
mortality. 
    We used ACR as a marker of endothelial dysfunction. However, it has been suggested that 
microalbuminuria may sometimes reflect increased albumin excretion by the kidney without 
generalized endothelial dysfunction [21,39]. An alternative explanation of our data, therefore, 
is that decreased eGFR and increased ACR are related to cardiovascular mortality through 
similar mechanisms that (in part) have nothing to do with endothelial dysfunction. We cannot 
exclude this, but the RR of cardiovascular mortality decreased also when we adjusted for 
endothelial function assessed by vWf and sVCAM-1 without ACR, although to a lesser 
extent. 
    In this study, there was no relation between markers of inflammation and renal function or 
renal function-associated mortality. However, such relations may have been underestimated, 
because only CRP and sICAM-1 were used as parameters of inflammation. Although both are 
predictors of cardiovascular disease [8,10,11], they may only partially reflect the state of 
chronic inflammation. Whether other important markers of inflammation (e.g., tumor necrosis 
factor-α, interleukin-6, secretory phospholipase A2) explain renal insufficiency-associated 
cardiovascular mortality requires further investigation. A limitation of our data is that we 
studied a relatively healthy, elderly white population. Therefore, it remains to be investigated 
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whether the results of our study can be generalized to individuals who are younger, nonwhite, 





    In this population-based study, endothelial dysfunction, but not inflammation was related to 
renal function and seemed to contribute to cardiovascular mortality in mild renal 
insufficiency. The results of this study may be clinically relevant because endothelial 
dysfunction is potentially reversible [40]. In the prevention of cardiovascular disease in mild 
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BACKGROUND OF THE THESIS 
 
   Patients with chronic kidney disease have an elevated risk of cardiovascular morbidity and 
mortality, which cannot be totally accounted for by traditional cardiovascular risk factors, 
such as hypertension, diabetes mellitus, dyslipidaemia and smoking. Therefore, alternative 
risk factors seem to be operative and deserve attention. In this thesis, we examined the role of 
homocysteine, endothelial dysfunction, low-grade inflammation and advanced glycation end-







    Elevated plasma levels of homocysteine, a sulphur-containing amino acid, are 
independently associated with a higher risk of coronary heart disease and stroke in the general 
population. As plasma homocysteine levels are elevated in patients with renal dysfunction, it 
has been proposed that hyperhomocysteinaemia contributes to cardiovascular disease in end-
stage renal disease patients. Some prospective studies have indeed found that 
hyperhomocysteinaemia is associated with negative cardiovascular outcomes in end-stage 
renal disease, but other studies have found no significant or even an opposite effect. The 
mechanism underlying the elevated plasma homocysteine level in renal failure is 
incompletely understood. In Chapter 2, we argue that the hyperhomocysteinaemia 
encountered in end-stage renal disease is not likely to be explained by a fall in renal capacity 
to excrete or extract homocysteine, because in healthy individuals plasma homocysteine 
levels in the renal artery and vein are similar, and the urinary homocysteine excretion is 
negligible. Instead, we hypothesized that a uraemic disturbance in whole body methionine-
homocysteine metabolism could account for the increase in plasma homocysteine in renal 
failure. 
    In sulphur amino acid metabolism, the essential amino acid methionine is converted to 
homocysteine in the transmethylation pathway, with S-adenosylmethionine and S-
adenosylhomocysteine as intermediates (Chapter 1, Figure). Next, homocysteine can either 
receive a methyl group to regenerate methionine in the remethylation pathway, or be 
(irreversibly) degraded in the transsulphuration pathway. Flux rates of methionine 
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transmethylation, homocysteine remethylation and homocysteine transsulphuration may be 
influenced by plasma levels of B-vitamins, homocysteine metabolites (S-adenosylmethionine 
and S-adenosylhomocysteine) and genetic polymorphisms of enzymes involved in 
homocysteine metabolism. Homocysteine metabolism can be studied with stable-isotope 
techniques using infusions of [2H3-methyl-l-13C]methionine as tracer, which enables 
calculation of whole body flux rates of methionine transmethylation, homocysteine 
remethylation and homocysteine transsulphuration in steady state and their determinants in 
end-stage renal disease patients. Additional calculation of the metabolic homocysteine 
clearance by transsulphuration (transsulphuration rate divided by plasma total homocysteine 
concentration) gives information about the whole body homocysteine disposal capacity, 
which is not adequately reflected by the absolute transsulphuration rate. 
    In Chapter 3, we show that methionine-homocysteine metabolism in patients with end-
stage renal disease is characterized by an impaired metabolic homocysteine clearance by 
transsulphuration and remethylation. In addition, the data suggest that the absolute rates of 
remethylation and transmethylation are diminished in end-stage renal disease patients 
compared to healthy individuals and are negatively related to whole blood S-
adenosylhomocysteine levels in the whole group of patients with end-stage renal disease and 
healthy individuals. We hypothesize that the elevated intracellular concentration of S-
adenosylhomocysteine in end-stage renal disease mediates the impairment in remethylation 
and transmethylation flux rates.  
    In Chapter 4, we show that oral treatment with folic acid, a synthetic precursor of 5-
methyltetrahydrofolate, (1) lowers, but does not normalize, plasma homocysteine 
concentration, (2) increases whole body homocysteine remethylation and methionine 
transmethylation rate to normal values, and (3) does not significantly affect transsulphuration 
rate or metabolic homocysteine clearance by transsulphuration in end-stage renal disease 
patients. The resistance to folic acid of hyperhomocysteinaemia in end-stage renal disease in 
the presence of normalized remethylation and transmethylation fluxes suggests a persistent 
defect in metabolic homocysteine clearance by transsulphuration as the cause of this 
hyperhomocysteinaemia. 
    In Chapter 5, we show that, also in healthy subjects, treatment with folic acid increases (1) 
the rates of whole body homocysteine remethylation and methionine transmethylation, (2) 
decreases plasma total homocysteine concentration, and (3) does not significantly alter 
homocysteine transsulphuration or metabolic homocysteine clearance by transsulphuration. In 
addition, it was demonstrated that folic acid increased the plasma S-adenosylmethionine/S-
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adenosylhomocysteine ratio, which from in vitro studies is known to stimulate the activity of 
the methyltransferases involved in methionine transmethylation. Remarkably, the decrease in 
plasma homocysteine concentration did not correlate with the increase in remethylation 
and/or transmethylation. 
 
Endothelial dysfunction and inflammatory activity 
    The endothelium is not only a barrier to blood constituents, but is a biologically active 
interface that modulates tone, growth, haemostasis, and inflammation throughout the 
circulatory system. Endothelial dysfunction is seen in the early phases of atherosclerosis. 
Endothelial dysfunction is characterized by high plasma concentrations of endothelium-
derived proteins and impaired endothelium-dependent vasodilatation. Several studies have 
demonstrated that endothelium-dependent vasodilatation is decreased in patients with 
advanced or end-stage renal disease. On the other hand, there are relatively few studies in 
patients with renal disease that have examined blood levels of endothelium-derived proteins, 
such as von Willebrand factor, soluble vascular cell adhesion molecule-1, soluble intercellular 
adhesion molecule-1, tissue-type plasminogen activator, plasminogen activator inhibitor-1 
and E-selectin. Furthermore, it is unknown whether the relationship between endothelial 
dysfunction and renal function is linear. 
    Evidence accumulates that atherosclerosis may be an inflammatory disease. An 
inflammatory response, produced by infection, has been observed to induce endothelial 
dysfunction in healthy humans. Inflammation is characterized by increased production of 
inflammatory molecules, named cytokines (e.g. tumour necrosis factor-α and interleukin-6), 
by white blood cells. These cytokines cause a change in the production of acute phase 
proteins by the liver which can rise (e.g. C-reactive protein and fibrinogen) or fall (e.g. 
albumin). In addition, cytokines induce the production of secretory phospholipase A2 and 
stimulate the expression of soluble intercellular adhesion molecule-1 on endothelial cells. 
Thus, C-reactive protein, secretory phospholipase A2 and soluble intercellular adhesion 
molecule-1 may be used as biochemical markers of the activity of different processes of the 
inflammatory response. There are only scarce data on the relationship between renal function 
and inflammatory status. 
    To explore the association between creatinine clearance and endothelial function and 
inflammatory activity (both reflected by multiple biochemical markers), mean SD (Z-)scores 
for markers of endothelial function and inflammatory activity can be calculated. This 
approach was developed to reduce the influences of biological variability of separate 
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measurements, and to reduce the number of associations to be investigated. For calculation of 
a Z-score, for every individual, each variable has to be expressed as the standard deviation of 
the difference from the population mean. The Z-score is calculated as the mean of these 
standard deviations. 
    In Chapter 6, we show that impaired renal function is associated with endothelial 
dysfunction (as reflected by the endothelial function Z-score constructed from von Willebrand 
factor, soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1, 
type plasminogen activator, plasminogen activator inhibitor-1 and E-selectin) and 
inflammatory activity (as reflected by the inflammatory activity Z-score constructed from C-
reactive protein and secretory phospholipase A2) in 80 non-diabetic patients with a renal 
function ranging from normal to a pre-dialysis situation. These associations were linear and 
therefore present in patients with a renal function ranging from pre-dialysis to normal 
creatinine clearance. 
    In Chapter 8, as a sequel of the patient-based study of Chapters 6, we studied individuals of 
the Hoorn Study population. In this population-based study composed of 613 individuals with 
a predominantly mildly impaired renal function (mean estimated glomerular filtration rate 68 
± 12 ml/min per 1.73 m2), we showed that endothelial dysfunction (estimated by von 
Willebrand factor, soluble vascular cell adhesion molecule-1, and the urinary albumin-
creatinine ratio), but not low-grade inflammation (estimated by plasma C-reactive protein and 
soluble intercellular adhesion molecule-1), was related to renal function. Further we showed 
that renal function was an independent predictor of cardiovascular and all-cause mortality. 
Endothelial dysfunction, but not inflammatory activity, contributed to the renal function-
associated cardiovascular mortality.  
 
Advanced glycation end-products 
    Advanced glycation end-products are a heterogeneous group of compounds derived from 
the non-enzymatic reaction between glucose or other reducing sugars and proteins. Resistance 
to complete enzymatic degradation of advanced glycation end-products leads to the formation 
of advanced glycation end-product-peptides, which can be measured more easily than 
advanced glycation end-products. Advanced glycation end-products may be involved in 
atherogenesis (1) by interaction with specific advanced glycation end-product receptors, 
leading to cytokine production, and (2) by their accumulation in the vascular matrix, possibly 
interfering with endothelial function. Accumulation of advanced glycation end-products and 
advanced glycation end-product-peptides in plasma has been described in end-stage renal 
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disease and diabetes mellitus. However, little is known about the relation between advanced 
glycation end-products or advanced glycation end-product-peptides on the one hand and 
endothelial dysfunction and inflammatory activity on the other hand in pre-dialysis renal 
insufficiency. 
    In Chapter 7, we show that plasma concentrations of advanced glycation end-product-
peptides are independently related to creatinine clearance over a wide range of renal function 
in the same patient group as in Chapter 6. Advanced glycation end-product-peptides were not 
independently related to biochemical markers of endothelial dysfunction (von Willebrand 
factor, soluble vascular cell adhesion molecule-1, soluble E-selectin, tissue-type plasminogen 
activator and plasminogen activator inhibitor-1, and their compound Z-score) and 
inflammatory activity (soluble intercellular adhesion molecule-1, C-reactive protein, secretory 
phospholipase A2, and their compound Z-score). Therefore, the supposed atherogenic effect 






    The studies presented in this thesis have limitations which are discussed below. 
    In Chapter 2, considering the putative mechanisms of hyperhomocysteinaemia in chronic 
kidney disease, one has to be aware of the many uraemia-related factors that can influence 
homocysteine metabolism (e.g. protein malnutrition, vitamin deficiency, older age, drugs), of 
which probably many have not yet been identified. 
    In Chapter 3, comparing whole body homocysteine metabolism of end-stage renal disease 
patients with healthy individuals proved to be difficult, because the small number of 
individuals and the relative mismatch in age, hampered robust conclusions. In addition, the 
stable-isotope infusion technique is an elegant but costly and time-consuming method to 
quantify flux rates in homocysteine metabolism, which in itself has some limitations. First, 
because of the prerequisite of a steady state during stable-isotope measurements, individuals 
were studied during rest and in fasting condition. Therefore, generalization to the situation in 
real life, in which humans are ambulatory and postprandial most of the time is difficult. 
Second, in the stable-isotope model, samples of extracellular compartments are used to reflect 
processes that (partly) take place in the cell. Therefore, the use of samples of breath air and 
blood for calculation of whole body homocysteine metabolism, may cause underestimation of 
Summary and discussion 
 125
the contribution of intracellular homocysteine metabolism. To minimize this possible effect, 
we corrected the flux rates for a bicarbonate retention factor and checked by multiple samples 
taking that a plateau in stable-isotope enrichment was reached (and therefore an equilibrium 
between intra- and extracellular concentrations). Another limitations is that the stable-isotope 
study of the whole body homocysteine metabolism does not provide organ specific 
information. Therefore, disturbances of the homocysteine metabolism in an organ are 
underestimated when evaluating whole body metabolism. 
    In Chapter 4 and 5, studying the effect of folic acid intervention on whole body 
homocysteine metabolism in end-stage renal disease patients and healthy individuals is 
limited by the prerequisite of a steady state in the stable-isotope model. Thus, changes in flux 
rates and concentrations or tissue distributions of metabolites might have been transient and 
therefore not have been picked up. By example, a possible homocysteine lowering mechanism 
of folic acid, which cannot be detected by the stable-isotope model, could be an increase in 
homocysteine remethylation, which initially would not be accompanied by an increase in 
methionine transmethylation. The resulting rise in (re-)generated methionine could be stored 
in the cell or be used for protein synthesis. Finally, methionine transmethylation would 
increase until it is in balance with homocysteine remethylation, and homocysteine plasma 
level finds a new steady state, but, at a lower level as before folic acid treatment. The 
increased transmethylation rate induced by folic acid may be clinically relevant despite the 
fact that plasma homocysteine concentration remains elevated in end-stage renal disease 
patients. It has been shown that folic acid treatment decreases DNA hypomethylation in end-
stage renal disease patients without normalizing plasma homocysteine concentration and 
evidence is mounting that DNA hypomethylation may play an important part in the 
development of cardiovascular disease. The non-significant relation between plasma 
homocysteine and transmethylation, which seems to be present in healthy individuals as well, 
suggests that intervention trials with homocysteine-lowering treatment aimed at 
cardiovascular risk reduction should be cautious to use only plasma homocysteine as 
intermediary biochemical end-point. In addition, the relationship between the folic acid dose 
and changes in whole body homocysteine flux rates are unknown and deserve further study.  
    In Chapter 6, the study of the relation between endothelial dysfunction and inflammatory 
activity on the one hand and creatinine clearance on the other hand is hampered by the fact 
that there is no gold standard of endothelial dysfunction and inflammatory activity. We used a 
selection of biochemical markers of endothelial dysfunction which are generally accepted to 
reflect endothelial dysfunction, but we did not measure endothelium-dependent 
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vasodilatation. The markers of inflammatory activity we used are thought to reflect only a 
small part of the inflammatory process (acute phase response by C-reactive protein, leucocyte 
adhesion to the endothelium by soluble intercellular adhesion molecule-1, and synthesis of 
eicosanoids by secretory phopholipase A2). Measurement of cytokines (e.g. tumour necrosis 
factor-α and interleukin-6) that are initially produced in the inflammatory process could give 
more sensitive but perhaps less specific information about the presence of inflammation. 
Another possible limitation of this study was that the intra-individual variability of the 
markers of endothelial dysfunction and inflammatory activity was not assessed. However, the 
use of a composite Z-score of these markers should have lessened a masking effect (if any) on 
the associations that were studied. Further, the with the Cockcroft-Gault formula calculated 
creatinine clearance is a rather crude estimate of the glomerular filtration rate, even after 
correction of the body surface area.  In addition, the heterogeneity of the underlying renal 
diseases restricts interpretations of the results and the findings cannot be extrapolated to the 
general population. Finally, the cross-sectional character of the study does not allow 
conclusions regarding causality of the relations that were found.  
    In Chapter 7, in the same study population as in Chapter 6, the relation of advanced 
glycation end-product-peptides with creatinine clearance and biochemical markers of 
endothelial dysfunction and inflammatory activity was studied. Next to the same limitations 
as in Chapter 6, the use of advanced glycation end-product-peptides as reflection of advanced 
glycation end-products is arguable. However, the online spectrophotometric and 
spectrofluorometric method to detect advanced glycation end-product-peptides that was used 
in this study, has been validated with an advanced glycation end-product-Elisa, which showed 
a strong correlation between advanced glycation end-product-peptides and the major 
advanced glycation end-products Nε-(carboxymethyl)lysine and Nε-(carboxyethyl)lysine. 
    In Chapter 8, the fact that, in contrast to the patient-based study of Chapter 6, no 
significant relationship could be demonstrated between biochemical markers of inflammatory 
activity and renal function in this population-based study was remarkable. A possible 
explanation could be found in the finding that, at approximately the same creatinine clearance, 
the patients in Chapter 6 had higher blood levels of the markers of inflammatory activity (C-
reactive protein and soluble intercellular adhesion molecule-1) than the individuals from the 
general population in Chapter 8. This suggests (1) that an unknown patient-related factor 
might cause a state of (clinically unrecognized ) inflammation and (2) that a higher grade of 
inflammation is necessary to cause renal insufficiency or, again, renal function impairment 
may cause more inflammation in susceptible individuals, e.g. patients. Another explanation 
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could be that the biochemical marker of inflammatory activity that correlated most strongly 
with renal function in the patients of Chapter 6 (secretory phopholipase A2) was not measured 
in the population-based Hoorn Study described in Chapter 8.  
 
 
CONCLUSIONS AND IMPLICATIONS FOR THE FUTURE  
 
    We showed that the hyperhomocysteinaemia encountered in end-stage renal disease is 
probably caused by a disturbance in the whole body homocysteine metabolism that is 
characterized by an impaired homocysteine remethylation, methionine transmethylation and 
metabolic homocysteine clearance by transsulphuration, which is accompanied by an increase 
in S-adenosylhomocysteine and (to a lesser extent) S-adenosylmethionine. The culprit in the 
homocysteine metabolism in end-stage renal disease cannot be identified with experiments 
performed in steady state, but a defect in the transsulphuration pathway would be a plausible 
candidate and could explain our main findings. A primary decrease in homocysteine 
transsulphuration would cause accumulation of plasma homocysteine and its precursors (S-
adenosylhomocysteine more than S-adenosylmethionine) that on the one hand could stimulate 
homocysteine transsulphuration until it again equilibrates methionine intake (but at a higher 
homocysteine level) and on the other hand could inhibit methionine transmethylation and 
homocysteine remethylation. The finding that folic acid intervention was able to normalize 
homocysteine remethylation and methionine transmethylation, with a decrease (but not 
normalization) of plasma homocysteine and an unaffected metabolic homocysteine clearance 
by transsulphuration is consistent with this hypothesis. 
    Further we showed that endothelial dysfunction, inflammation and advanced glycation end-
product-peptides are related to renal function in patients with pre-dialysis chronic kidney 
disease. In a population-based study with a predominantly mildly impaired renal function, we 
showed that endothelial dysfunction, but not low-grade inflammation, is related to renal 
function and contributed to the renal function-associated cardiovascular mortality. 
    The relation between renal function and cardiovascular disease is complex. This may be 
due to renal function-associated confounders, that can affect the relation between 
cardiovascular risk factors and cardiovascular disease. By example, in chronic kidney disease, 
so far, prospective studies did not unequivocally demonstrate the predictive value for 
cardiovascular disease of high blood levels of homocysteine and advanced glycation end-
products. This does not per se reflect an altered homocysteine-mediated pathophysiology for 
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cardiovascular disease in chronic kidney disease, but more likely, reflects a confounding 
factor like malnutrition, which on the one hand has been associated with renal function 
impairment and on the other hand with low blood levels of homocysteine and advanced 
glycation end-products. Studies that investigate the relation between a cardiovascular risk 
factor or treatment in end-stage renal disease should, where possible, correct for the many 
potential confounders associated with uraemia, especially protein energy malnutrition. 
    The exact mechanism through which hyperhomocysteinaemia may lead to atherosclerosis 
is still unclear. It has been suggested that hypomethylation of DNA or other substances may 
play a role in the development of vascular disease. In fact, it has been shown that folic acid in 
end-stage renal disease not only lowers homocysteine, but also decreases DNA 
hypomethylation. When DNA hypomethylation, probably caused by the decreased 
transmethylation rate in end-stage renal disease, is the pathophysiological phenomenon 
leading to cardiovascular disease, hyperhomocysteinaemia would be an important indicator of 
this atherogenic process. We found that folic acid-induced changes in plasma homocysteine 
were not significantly related to changes in whole body transmethylation rates in healthy 
individuals. This suggests that plasma homocysteine may not be the parameter of choice for 
measuring the effect of treatments that aim for reduction of DNA hypomethylation. The latter 
may better be evaluated by recently developed methods that can measure the methylation 
status of DNA in e.g. leucocytes. 
    A problem in the studies investigating endothelial dysfunction and inflammation is that 
there is no gold standard. For example, endothelial dysfunction may not only be reflected by 
biochemical markers in plasma (from which we used a selection in the studies of this thesis), 
but also by endothelium-dependent vasodilatation. Furthermore, some markers not only 
reflect endothelial dysfunction, but also other pathophysiological processes. For example, 
albuminuria not only reflects endothelial dysfunction but also changes in renal anatomy and 
haemodynamics. Soluble intercellular adhesion molecule-1 might reflect inflammation as well 
as endothelial dysfunction. We propose the combined use of multiple markers for the analyses 
of endothelial dysfunction as well as inflammation. Analysis of individual markers will give 
specifically information about a limited aspect of endothelial dysfunction and inflammation, 
whereas combined analysis of markers with mean standard deviation (Z-)scores will give 
more sensitive information whether and to which extent endothelial dysfunction and/or 
inflammation are present. 
    The finding that the relation between inflammation and renal function was present in 
patients but could not be demonstrated in a larger group of individuals of a larger population 
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underscores the carefulness with which conclusions from a study population may be 
generalized to other populations, and the importance of the selection of the marker(s) of 
inflammatory activity. 
    Future studies that aim to explore the relation between renal function and cardiovascular 
disease should measure a broad range of markers of endothelial dysfunction and inflammatory 
activity, correct for traditional cardiovascular risk factors as well as for potential confounders 







voor degenen die niet met het onderwerp bekend zijn 
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ACHTERGROND VAN HET PROEFSCHRIFT 
 
    Patiënten met chronische nierziekten hebben een verhoogd risico op hart- en vaatziekten. 
Algemeen bekende risicofactoren voor hart- en vaatziekten, zoals hoge bloeddruk, diabetes 
mellitus, verhoogd cholesterolgehalte en roken, lijken de overmaat aan hart- en vaatziekten bij 
mensen met chronische nierziekten niet volledig te kunnen verklaren. De onderzoeken in dit 
proefschrift hebben zich gericht op homocysteïne, vaatwanddisfunctie, chronische ontsteking 
en ‘advanced glycation end-product’-peptiden als mogelijke risicofactoren voor met 






    Homocysteïne is een aminozuur. De meeste aminozuren zijn bouwstenen van eiwitten, 
maar homocysteïne niet. Homocysteïne ontstaat wanneer een ander aminozuur, methionine, 
gebruikt wordt om koolstofatomen toe te voegen aan stoffen in het lichaam. 
Hyperhomocysteïnemie (verhoogde concentratie van homocysteïne in het bloed) voorspelt het 
optreden van hart- en vaatziekten in de algemene bevolking. Omdat hyperhomocysteïnemie 
samenhangt met een gestoorde nierfunctie, wordt verondersteld dat hyperhomocysteïnemie 
bijdraagt aan de ontwikkeling van hart- en vaatziekten bij mensen met een chronische 
nierziekte. De ontstaanswijze van hyperhomocysteïnemie bij chronische nierziekten is echter 
onopgehelderd. In Hoofdstuk 2 wordt beargumenteerd dat het onwaarschijnlijk is dat 
hyperhomocysteïnemie bij chronische nierziekten wordt veroorzaakt door het verlies van het 
vermogen van de nieren om homocysteïne via de urine uit te scheiden of in de nier af te 
breken. In plaats daarvan wordt gesteld dat een gestoorde homocysteïnestofwisseling de 
oorzaak zou kunnen zijn van hyperhomocysteïnemie bij chronische nierziekten. 
    In de homocysteïnestofwisseling (Figuur 1), ontstaat homocysteïne door afsplitsing van een 
koolstofbevattende methylgroep van het essentiële aminozuur methionine (transmethylering), 
waarbij S-adenosylmethionine en S-adenosylhomocysteïne tussenproducten zijn. 
Homocysteïne kan vervolgens door toevoeging van een door folaat of betaïne gedoneerde 
methylgroep worden omgezet in methionine (remethylering) óf onomkeerbaar worden 
afgebroken (transsulfurering). Door gebruik te maken van niet-radioactief gemarkeerd 
methionine,  dat via een infuus in het  lichaam  wordt  gebracht,  kunnen  de  snelheden van de 
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        eiwit 
  foliumzuur 
               methionine 
 
           S-adenosylmethionine 
     folaat-         RE-      TRANS-        methyl- 
     cyclus          METHYLERING       METHYLERING        groep 
         S-adenosylhomocysteïne 
 
         homocysteïne 
      TRANSSULFURERING 
     afbraakproducten 
Figuur. Vereenvoudigde weergave van de homocysteïnestofwisseling. De open pijlen geven de in dit proefschrift gemeten 
omzettingsprocessen binnen de homocysteïnestofwisseling aan.  
 
methioninetransmethylering, homocysteïneremethylering en homocysteïnetranssulfurering 
worden berekend. Het vermogen van het lichaam om zich te ontdoen van homocysteïne 
(verder homocysteïneklaring genoemd) wordt weergegeven door de verhouding van de 
homocysteïnetranssulfureringssnelheid en de homocysteïneconcentratie in het bloed. 
    Hoofdstuk 3 toont dat patiënten met terminaal nierfalen (eindstadium van een nierziekte, 
waarbij nierfunctievervangende therapie noodzakelijk is geworden) een veel lagere 
homocysteïneklaring door transsulfurering hebben dan gezonde vrijwilligers. Daarnaast 
blijken de snelheden van de methioninetransmethylering en homocysteïneremethylering 
verlaagd te zijn. Er wordt gesteld dat de bij terminaal nierfalen verhoogde S-
adensylhomocysteïneconcentratie waarschijnlijk de oorzaak is van de gestoorde 
methioninetransmethylering en homocysteïneremethylering. 
    Hoofdstuk 4 laat zien dat behandeling met foliumzuur (dat in het lichaam wordt omgezet in 
folaat) bij patiënten met terminaal nierfalen de hyperhomocysteïnemie gedeeltelijk corrigeert, 
de methioninetransmethylering en homocysteïneremethylering normaliseert, maar de 
homocysteïnetranssulfurering en de homocysteïneklaring door transsulfurering niet verandert. 
Dit impliceert een foliumzuuronafhankelijk defect in de homocysteïnetranssulfurering als 
oorzaak van de resterende hyperhomocysteïnemie. 
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    Hoofdstuk 5 demonstreert dat behandeling met foliumzuur bij gezonde vrijwilligers de 
homocysteïneremethylering en methioninetransmethylering stimuleert en de homocysteïne-
concentratie verlaagt, maar de homocysteïnetranssulfurering en de homocysteïneklaring door 
transsulfurering niet significant verandert. Tevens neemt de verhouding S-
adenosylmethionine/S-adenosylhomocysteïne toe, waarvan door andere onderzoekers in 
(buiten het lichaam uitgevoerde) experimenten is aangetoond dat dit de 
methioninetransmethylering stimuleert. Opvallend is het ontbreken van een aantoonbaar 
verband tussen de mate van daling van de homocysteïneconcentratie en de toename van de 
remethylerings- en transmethyleringssnelheid. 
 
Vaatwanddisfunctie en chronische ontsteking 
    De vaatwand is niet slechts een barrière voor het bloed, maar heeft een belangrijke 
biologische functie bij de regulatie van de vaatwandspanning, vaatgroei en 
ontstekingsactiviteit in het gehele vaatstelsel. Vaatwanddisfunctie wordt gezien in de vroege 
fase van hart- en vaatziekten en wordt gekenmerkt door verhoogde concentraties in het bloed 
van bepaalde in de vaatwand geproduceerde eiwitten én door een gestoorde vaatverwijding na 
stimulatie van de vaatwand. Verschillende studies hebben deze gestoorde 
vaatwandafhankelijke vaatverwijding aangetoond bij terminaal nierfalen. Er is echter slechts 
in beperkte mate onderzoek verricht naar de relatie tussen chronische nierziekte en van de 
vaatwand afkomstige eiwitten in het bloed. 
    Steeds meer onderzoeken ondersteunen de stelling dat hart- en vaatziekten 
ontstekingsprocessen zijn. Er is aangetoond dat een door een infectie uitgelokte 
ontstekingsreactie kan leiden tot vaatwanddisfunctie. Bij een ontsteking worden cytokines 
(ontstekingsmoleculen) geproduceerd door witte bloedcellen. Deze cytokines veranderen de 
productiesnelheid van zogenaamde acute-fase-eiwitten in de lever. Daarnaast stimuleren 
cytokines de productie en expressie van sommige eiwitten in de vaatwandcel. De concentratie 
in het bloed van acute-fase-eiwitten en door de vaatwandcel geproduceerde eiwitten 
weerspiegelt dus de mate van ontsteking in het lichaam. 
    Om de relatie tussen enerzijds nierfunctie (in dit proefschrift vereenvoudigd gedefinieerd 
als de mate waarin de nieren afvalstoffen uitscheiden) en anderzijds vaatwanddisfunctie en 
ontsteking te onderzoeken (beiden weerspiegeld door bovengenoemde eiwitten), werd in dit 
proefschrift gebruik gemaakt van een scoresysteem. Met dit scoresysteem kunnen de 
concentraties van de verschillende eiwitten, die respectievelijk de vaatwanddisfunctie en de 
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ontstekingactiviteit weerspiegelen, worden samengevat in een score, waardoor met één getal 
de mate van vaatwanddisfunctie of ontstekingactiviteit kan worden weergegeven. 
    In Hoofdstuk 6 wordt bij 80 niet-diabetische patiënten (met een normale tot ernstige 
nierfunctiestoornis) aangetoond dat een verminderde nierfunctie samenhangt met zowel 
vaatwanddisfunctie als ontsteking. Dit verband is aanwezig in het gehele nierfunctiebereik. 
    In Hoofdstuk 8 wordt, als vervolg op hoofdstuk 6, bij 613 mensen uit een 
bevolkingsonderzoek in Hoorn (met een overwegend gering gestoorde nierfunctie) 
aangetoond dat vaatwanddisfunctie, maar niet ontsteking, gerelateerd is aan de nierfunctie. 
Een gestoorde nierfunctie blijkt een voorspeller te zijn van sterfte door hart- en vaatziekten, 
waarbij vaatwanddisfunctie, in tegenstelling tot ontstekingsactiviteit, bijdraagt aan de met de 
nierfunctie samenhangende oversterfte ten gevolge van hart- en vaatziekten. 
 
‘Advanced glycation end-products’ 
    ‘Advanced glycation end-products’ (AGEs) zijn stoffen die ontstaan bij niet-enzymatische 
reacties tussen suikers en eiwitten. Een onvolledige afbraak van AGEs resulteert in vorming 
van AGE-peptiden (eenvoudige verbindingen van aminozuren), die in het bloed 
gemakkelijker te bepalen zijn dan AGEs. AGEs zouden door het op gang brengen van een 
ontstekingreactie en door AGE-ophoping in de vaatwand tot vaatwanddisfunctie en mogelijk 
uiteindelijk ook hart- en vaatziekten kunnen leiden. Bij mensen met terminaal nierfalen en 
diabetes mellitus is stapeling van AGEs en AGE-peptiden in het bloed aangetoond. Bij niet-
diabetische mensen met een minder ernstige nierfunctiestoornis is echter weinig bekend over 
de relatie tussen AGEs en AGE-peptiden enerzijds en vaatwanddisfunctie en ontsteking 
anderzijds. 
    Hoofdstuk 7 laat zien dat de bloedconcentratie van AGE-peptiden gerelateerd is aan de 
nierfunctie bij de patiënten uit hoofdstuk 6. De bloedconcentratie van AGE-peptiden is echter 
niet gerelateerd aan vaatwanddisfunctie en ontsteking. Het lijkt daarom dat het veronderstelde 
schadelijke effect van AGEs niet ontstaat via vaatwanddisfunctie en ontsteking. 
 
 
CONCLUSIES EN BETEKENIS VOOR DE TOEKOMST 
 
    Concluderend lijkt hyperhomocysteïnemie bij terminaal nierfalen te worden veroorzaakt 
door een verstoring van de homocysteïnestofwisseling. Dit wordt gekenmerkt door een 
verminderde homocysteïneremethylering, methioninetransmethylering en homocysteïne-
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klaring door transsulfurering, die gepaard gaat met een toename van S-adenosylhomocysteïne 
en S-adenosylmethionine. De oorspronkelijke afwijking in de homocysteïne-stofwisseling bij 
chronische nierziekten kan met ons onderzoek niet met zekerheid worden aangetoond, maar 
een primair gestoorde homocysteïnetranssulfurering zou op theoretische gronden echter veel, 
zo niet alle, bovengeschetste afwijkingen kunnen verklaren. Het feit dat de behandeling met 
foliumzuur resulteerde in normalisatie van de homocysteïneremethylering en 
methioninetransmethylering, bij een nog steeds (zij het in mindere mate) verhoogde 
homocysteïneconcentratie en verlaagde homocysteïneklaring door transsulfurering, 
ondersteunt deze hypothese. 
    Daarnaast laat dit proefschrift zien dat homocysteïne, vaatwanddisfunctie, ontsteking en 
AGE-peptiden gerelateerd zijn aan de nierfunctie bij patiënten met een normale tot ernstig 
gestoorde nierfunctie. Bij mensen uit de algemene bevolking met een merendeels milde 
nierfunctiestoornis is vaatwanddisfunctie eveneens gerelateerd aan de nierfunctie, maar 
ontsteking niet.  In deze laatste groep blijkt vaatwanddisfunctie bij te dragen aan de met de 
nierfunctie samenhangende oversterfte ten gevolge van hart- en vaatziekten. 
    De relatie tussen nierfunctie en hart- en vaatziekten is complex. Dit wordt mede 
veroorzaakt door het gegeven dat sommige met een chronische nierziekte samenhangende 
situaties niet alleen een relatie vertonen met risicofactoren voor hart- en vaatziekten, maar ook 
met hart- en vaatziekten zelf. Zo heeft men, in tegenstelling tot bij gezonde vrijwilligers, bij 
mensen met een chronische nierziekte nog niet aan kunnen tonen dat een hoge 
bloedconcentratie van homocysteïne en AGEs het optreden van hart- en vaatziekten voorspelt. 
Dit betekent niet per se dat het ontstaan van hart- en vaatziekten bij mensen met een 
chronische nierziekte anders verloopt dan bij mensen met een normale nierfunctie, maar lijkt 
eerder te wijzen op een verstorende variabele, zoals ondervoeding, die zowel samenhangt met 
de aanwezigheid van een chronische nierziekte als een lage bloedconcentratie van 
homocysteïne en AGEs. Studies die de relatie tussen nierfunctie en hart- en vaatziekten 
onderzoeken zouden, indien mogelijk, rekening moeten houden met dergelijke verstorende 
variabelen. 
    Het exacte mechanisme waarlangs hyperhomocysteïnemie tot hart- en vaatziekten leidt is 
nog niet opgehelderd. Mogelijk speelt een gestoorde capaciteit van het lichaam om via 
methioninetransmethylering methylgroepen af te staan, hetgeen nodig is voor herstel van 
beschadigd eiwit en DNA, een rol. Inmiddels is door anderen aangetoond dat 
foliumzuurtoediening bij mensen met terminaal nierfalen niet alleen de 
hyperhomocysteïnemie doet afnemen, maar ook de DNA-methylering verbetert. Bovendien 
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zijn er aanwijzingen dat een lage DNA-methyleringsgraad de ontwikkeling van hart- en 
vaatziekten kan bevorderen. 
    Een probleem bij studies die vaatwanddisfunctie en ontsteking onderzoeken is dat er voor 
beide processen geen “gouden standaard” bestaat. Zo kan bijvoorbeeld voor meting van 
vaatwanddisfunctie, naast de in dit proefschrift gebruikte bloedconcentratie van 
vaatwandafgeleide eiwitten, ook echografisch de vaatwandafhankelijke vaatverwijding 
worden gemeten. Daarnaast geven sommige vaatwandafgeleide eiwitten niet alleen informatie 
over de vaatwandfunctie, maar ook over andere processen in het lichaam (waaronder 
ontsteking!). Het verdient daarom de voorkeur bij de bestudering van vaatwanddisfunctie en 
ontsteking gebruik te maken van een combinatie van verschillende meetinstrumenten. 
    De bevinding dat het verband tussen ontsteking en nierfunctie wel aantoonbaar was bij 
patiënten en niet bij gezonde vrijwilligers onderstreept het belang van voorzichtigheid bij 
generalisatie van conclusies die gebaseerd zijn op onderzoek van een specifieke populatie. 
    Toekomstige studies die zich richten op de relatie tussen nierfunctie en hart- en vaatziekten 
zouden vaatwanddisfunctie en ontsteking met meerdere methoden moeten meten. Verder zou 
rekening moeten worden gehouden met bekende risicofactoren voor hart- en vaatziekten en 
mogelijke verstorende variabelen die samenhangen met een gestoorde nierfunctie. Tot slot 
verdient het aanbeveling nieuwe eindpunten en pathofysiologische paden te onderzoeken, 
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